KRAS inhibitors
By developing a new compound formula I, the problem of poor inhibition of existing KRas inhibitors on KRas G12D mutants was solved, and the selective inhibition and stronger therapeutic effect on KRas G12D mutants were achieved, combined with other drugs to improve the use of Effects of cancer treatment.
Patent Information
- Application Number
- CN202380030401.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-07
- Filing Date
- 2023-03-24
- Publication Date
- 2024-12-06
AI Technical Summary
Existing KRas inhibitors are difficult to effectively inhibit KRas G12D mutants and lack small molecule inhibitors with stronger potency, selectivity and good pharmacokinetic/pharmacodynamic properties, especially in oral delivery and in KRas wild type and mutants have challenges in selective control.
A novel compound formula I is provided, whose structural characteristics include specific group combinations, for the development of compounds that have selective inhibitory effects on KRas G12D mutants, which can be used in the treatment of KRas-related cancers such as lung cancer and pancreatic cancer, and combined with Other drugs such as PD-1 inhibitors, CDK4/CDK6 inhibitors, etc. are used in combination.
Effective inhibition of KRas G12D mutants was achieved, the efficacy of treating KRas-related cancers was improved, and the pharmacokinetic characteristics and selectivity was improved, which enhanced the targeting effect on KRas mutants.
Smart Images

Figure CN119095853A_ABST
Abstract
Description
[0001] background
[0002] The MAPK / ERK signaling pathway transmits extracellular stimuli to the cell nucleus, thereby regulating a variety of cellular responses, including cell proliferation, differentiation, and apoptosis. The KRas protein is an initiator of the MAPK / ERK signaling pathway and acts as a switch responsible for inducing cell division. In its inactive state, KRas binds to guanosine diphosphate (GDP), effectively sending a negative signal to inhibit cell division. In response to extracellular signals, KRas is allosterically activated, causing GDP to exchange nucleotides with guanosine triphosphate (GTP). In its GTP-bound active state, KRas recruits and activates proteins necessary for the propagation of growth factor-induced signaling and other cell signaling receptors. Examples of proteins recruited by KRas-GTP are c-Raf and PI3-kinase. KRas, as a GTPase, converts the bound GTP back to GDP, thereby restoring itself to an inactive state and transmitting signals again to inhibit cell division. KRas gain-of-function mutations exhibit increased GTP binding and reduced ability to convert GTP to GDP. The result is increased MAPK / ERK signaling that promotes cancer cell growth. KRas missense mutations at codon 12 are the most common mutations and significantly reduce GTPase activity.
[0003] Oncogenic KRas mutations have been found in approximately 30% of human cancers and have been shown to activate multiple downstream signaling pathways. Despite the prevalence of KRas mutations, it has been a difficult therapeutic target. (Cox, ADDrugging theUndruggable RAS: Mission Possible? Nat. Rev. Drug Disc. 2014, 13, 828-851; Pylayeva-Gupta, y et al. RAS Oncogenes: Weaving a Tumorigenic Web. Nat. Rev. Cancer 2011, 11, 761-774).
[0004] To date, work has mainly focused on inhibitors of the KRas G12C mutation (e.g., WO2019 / 099524, WO2020 / 081282, WO2020 / 101736, WO2020 / 146613, and WO2021 / 118877 disclose KRas G12C inhibitors), while WO2021 / 041671 discloses small molecule inhibitors of KRas G12D, and WO2017 / 011920 discloses small molecule inhibitors of KRasG12C, G12D, and G12V.
[0005] There is still a need to provide alternative small molecule KRas inhibitors. In particular, there is a need to provide more potent, orally deliverable KRas inhibitors that can be used to treat cancer. More specifically, there is a need to provide small molecule inhibitors that specifically inhibit KRas GTP activity. There is also a need to provide small molecule KRas inhibitors that exhibit more potent efficacy at the same or reduced KRas inhibitory activity. In addition, it is desirable to provide KRas inhibitors with better pharmacokinetic / pharmacodynamic properties. There is also a need to provide more potent KRas inhibitors that exhibit increased efficacy and reduced or minimized adverse or undesirable effects. In addition, there is a need to provide more potent KRas inhibitors that exhibit selective inhibition preference for KRas G12D mutants relative to KRas wild type. In addition, there is a need to provide more potent KRas inhibitors that exhibit selective inhibition preference for KRas G12C, G12D and / or G12V mutants relative to HRAS or NRAS. The present invention solves one or more of these needs by providing novel KRas inhibitors. SUMMARY OF THE INVENTION
[0007] Provided herein are compounds of Formula I:
[0008]
[0009] Its pharmaceutically acceptable salts, and pharmaceutical compositions thereof. In Formula I,
[0010] A is -C(H)- or -N-;
[0011] B is -C(R4)- or -N-;
[0012] D1 is -CH2-, -CH2CH2- or -CH(CH2CN)-;
[0013] X is -O- or -S-;
[0014] Y is -C(CN)- or -N-;
[0015] Z is -C(R 3c )-or-N-;
[0016] G is -C(R 3b )-or-N-;
[0017] R1 is H, hydroxyl, methoxy, C 1-4 Alkyl, C 2-4 heteroalkyl, azetidine, N-linked piperazine, piperidine, morpholine, or a group selected from the following formulas:
[0018]
[0019] Wherein C1-4 Alkyl, C 2-4 The heteroalkyl, azetidine, piperidine, or N-linked piperazine is optionally substituted with one or more of the following groups: amino, hydroxy, methyl, trideuteromethyl, methoxy, oxetane, or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methyl, hydroxymethyl, methoxy, trifluoromethoxy, difluoromethoxy, -O-trideuterated methyl, cyclopropyl, oxetane, pyrazole, imidazole, amino, -CONR7R7, -O-(CH2) p -OC 1-3 Alkyl, -O-(CH2) p -OH or -O-CO-C 1-3 alkyl, wherein the piperidine or the N-linked piperazine is optionally 1-3 alkyl bridge, and wherein the cyclopropyl, imidazole or pyrazole are each optionally substituted by a hydroxyl group or a C 1-3 alkyl.
[0020] E1 is –(CR7R7–) n , E2 is -CR7R7-, -NR7- or -O-, and E3 is –(CR7R7–) m , where m+n is 1, 2, 3 or 4;
[0021] p is 1, 2, or 3;
[0022] R2 is H, halogen or methyl;
[0023] R 3a , R 3b and R 3c are each independently H, methyl or halogen;
[0024] R4 is H, methyl, -CH2-OH, -O-R5-R6, -O-R6 or azetidine optionally substituted with NR7R7, wherein R5 is -CH2-, -CH(CH3)- or -CH2-CH2-, wherein R6 is H, C 1-3 Alkyl, C 2-3 Heteroalkyl, C 3-6 Cycloalkyl, C 4-6 heterocycloalkyl, 2-oxo-1,3-dihydrobenzimidazole, imidazole or pyrazole, wherein the C 1-3 Alkyl, C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally substituted by one or more of the following groups: oxo, halogen, hydroxy, methoxy, difluoromethoxy, NR7R7, C 1-4 Alkyl, C 1-4alkenyl, -CN or -CO-CH2OH, wherein the C 1-4 The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methoxy or NR7R7, wherein the C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-4 Alkyl groups are fused to form a bicyclic ring, or the C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-3 alkyl bridge, and wherein if R4 is H, then R1 is not H; and
[0025] Each R7 is independently H or C 1-3 alkyl.
[0026] The present invention also provides a method for treating cancer, in particular lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, bile duct cancer and colorectal cancer, using a compound of Formula I-VIII (including Ia-VIIa), a pharmaceutically acceptable salt thereof and a pharmaceutical composition thereof. The method comprises administering a therapeutically effective amount of a compound of Formula I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof to a patient in need.
[0027] Also provided herein are compounds of formula I-VIII (including Ia-VIIa) for treatment and pharmaceutically acceptable salts thereof. Also provided herein are compounds of formula I-VIII (including Ia-VIIa) for treating cancer, particularly for treating lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, bile duct cancer and colorectal cancer and pharmaceutically acceptable salts thereof. In addition, also provided herein are the uses of compounds of formula I-VIII (including Ia-VIIa) or pharmaceutically acceptable salts thereof in the preparation of medicaments, which are used to treat cancer, particularly for treating lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, bile duct cancer and colorectal cancer. DETAILED DESCRIPTION OF THE INVENTION
[0029] New inhibitors of KRas gain-of-function mutation G12D are described herein. These new compounds can address the above-mentioned need for inhibitors of KRas GTP activity of gain-of-function mutants for treating cancers such as lung cancer, colorectal cancer, pancreatic cancer, bladder cancer, cervical cancer, endometrial cancer, ovarian cancer, bile duct cancer or esophageal cancer. Some of these new KRas G12D mutant inhibitor compounds are more selective for KRas G12D mutants relative to wild-type KRas (and possibly relative to other mutant types such as G12C or G12V). In addition, some of these new KRas G12D mutant inhibitor compounds are non-selective, inhibiting both wild-type KRas and KRas G12D mutants (and possibly also other mutant types such as G12C or G12V). In addition, some of these new KRas compounds are non-selective, inhibiting both wild-type KRas and Kras G12C, G12D and / or G12V mutants.
[0030] The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof:
[0031]
[0032] Among them, A, B, D1, X, Y, Z, G, R1, R2 and R 3a As defined above.
[0033] In one embodiment, a compound of Formula II or a pharmaceutically acceptable salt thereof is provided:
[0034]
[0035] Among them, R1, R2, R 3a , R4, A, D1, X, Y, Z and G are as defined above.
[0036] In one embodiment, a compound of Formula III or a pharmaceutically acceptable salt thereof is provided:
[0037]
[0038] Among them, R1, R2, R 3a , A, D1, X, Y, Z and G are as defined above.
[0039] In one embodiment, a compound of Formula IV or a pharmaceutically acceptable salt thereof is provided:
[0040]
[0041] Among them, R1, R 3a , B, D1, Z and G are as defined above.
[0042] In one embodiment, a compound of Formula V or a pharmaceutically acceptable salt thereof is provided:
[0043]
[0044] wherein R1, B, D1 and G are as defined above.
[0045] In one embodiment, a compound of Formula VI or a pharmaceutically acceptable salt thereof is provided:
[0046]
[0047] wherein R1, B, D1, Z and G are as defined above.
[0048] In one embodiment, a compound of Formula VII or a pharmaceutically acceptable salt thereof is provided:
[0049]
[0050] wherein R1, B, D1 and G are as defined above.
[0051] In one embodiment, a compound of Formula VIII or a pharmaceutically acceptable salt thereof is provided:
[0052]
[0053] wherein R1, R2, R4, A, Z and G are as defined above.
[0054] The present invention provides a compound of formula Ia or a pharmaceutically acceptable salt thereof:
[0055]
[0056] Among them, A, B, D1, X, Y, Z, R1, R2, R 3a and R 3b As defined above.
[0057] In one embodiment, a compound of Formula IIa or a pharmaceutically acceptable salt thereof is provided:
[0058]
[0059] Among them, R1, R2, R 3a , R 3b , R4, A, D1, X, Y and Z are as defined above.
[0060] In one embodiment, a compound of Formula IIIa or a pharmaceutically acceptable salt thereof is provided:
[0061]
[0062] Among them, R1, R2, R 3a , R 3b , A, D1, X, Y and Z are as defined above.
[0063] In one embodiment, a compound of Formula IVa or a pharmaceutically acceptable salt thereof is provided:
[0064]
[0065] Among them, R1, R 3a , R 3b , B, D1 and Z are as defined above.
[0066] In one embodiment, a compound of Formula Va or a pharmaceutically acceptable salt thereof is provided:
[0067]
[0068] wherein R1, B and D1 are as defined above.
[0069] In one embodiment, a compound of Formula VIa or a pharmaceutically acceptable salt thereof is provided:
[0070]
[0071] wherein R1, B, D1 and Z are as defined above.
[0072] In one embodiment, a compound of Formula VIIa or a pharmaceutically acceptable salt thereof is provided:
[0073]
[0074] wherein R1, B and D1 are as defined above.
[0075] As used herein, the term halogen means fluorine (F), chlorine (Cl), bromine (Br) or iodine (I). As used herein, the term alkyl means a saturated straight or branched monovalent hydrocarbon group having from one to a specified number of carbon atoms, for example, "C 1-4 Alkyl" or "C 1-3 Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, 1-propyl, isopropyl, butyl, and isobutyl. As used herein, the term cycloalkyl refers to a saturated, cyclic, monovalent hydrocarbon group containing a specified number of carbon atoms, such as "C 4-6 As used herein, the term heteroalkyl refers to a saturated straight or branched monovalent hydrocarbon radical containing the specified number of atoms, including both carbon atoms and one or more heteroatoms, such as "C 2-3 Heteroalkyl" and "C2-4 "heteroalkyl". For example, C4 heteroalkyl means a saturated straight or branched monovalent hydrocarbon radical containing at least one carbon atom and at least one heteroatom, wherein the total number of carbon and heteroatoms adds up to 4 atoms. As used herein, the term heterocycloalkyl means a saturated cyclic heteroalkyl radical containing the specified number of atoms, including both carbon atoms and one or more heteroatoms, such as "C 4-6 Examples of heteroatoms include, but are not limited to, nitrogen and oxygen.
[0076] For R1, the N-linked piperazine (or piperidine) is optionally connected via C 1-3 As used herein, the term "bridged" with respect to the R1 group means that the R1 group is bridged with a C 1-3 The bicyclic ring formed by the alkyl group, the C 1-3 The alkyl group is attached to two non-adjacent atoms of the N-attached piperazine ring. Examples of bridged N-attached piperazine ring groups include, but are not limited to:
[0077]
[0078] When used as a bridge, the C 1-3 Alkyl may be optionally substituted as defined, for example by halogen, for example fluorine, such as:
[0079]
[0080] In R1, the N-linked piperazinyl is not specified to be bonded through carbon or nitrogen, and may be bonded through either carbon or nitrogen. 2-4 Optional substituents on the heteroalkyl or N-linked piperazinyl may be located on carbon or heteroatoms.
[0081] For R6, the C 4-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-4 As used herein, the term "fused" with respect to the R6 group means that the R6 group is fused with a C 1-4 The bicyclic ring formed by the alkyl group, the C 1-4 The alkyl group is attached to the C 4-6 Cycloalkyl or C 4-6 Two non-adjacent atoms of the heterocycloalkyl ring. Examples of fused R6 groups include:
[0082]
[0083] In R6, the C 4-6 The heterocycloalkyl group is not specified to be bonded through carbon or nitrogen and may be bonded through either carbon or nitrogen. 4-6Substituents on heterocycloalkyl groups may be located on carbon or heteroatoms.
[0084] In an embodiment of a compound of Formula Ia or a pharmaceutically acceptable salt thereof, A is -C(H)- or -N-; B is -C(R4)- or -N-; D1 is -CH2-, -CH2CH2- or -CH(CH2CN)-; X is -O- or -S-; Y is -C(CN)- or -N-; Z is -C(R 3c )- or -N-; R1 is H, C 1-4 Alkyl, C 1-4 heteroalkyl or N-linked piperazine, wherein the C 1-4 Alkyl, C 1-4 The heteroalkyl or N-linked piperazine is optionally substituted with one or more of the following groups: amino, hydroxy, methyl, oxetane and C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methyl, hydroxymethyl, methoxy, cyclopropyl, oxetane or amino, and wherein the N-linked piperazine is optionally substituted with one or more of the following groups: 1-3 Alkyl bridge; R2 is H, halogen or methyl; R 3a , R 3b and R 3c are each independently H or halogen; and R4 is H, methyl, -CH2-OH, -O-R5-R6 or -O-R6, wherein R5 is -CH2-, -CH(CH3)- or -CH2-CH2-, wherein R6 is H, C 1-3 Alkyl, C 2-3 Heterocycloalkyl, C 4-6 Cycloalkyl or C 4-6 Heterocycloalkyl, wherein the C 1-3 Alkyl, C 4-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally substituted by one or more of the following groups: halogen, hydroxy, methoxy, C 1-4 Alkyl or C 1-4 alkenyl, wherein the C 1-4 The alkyl group is optionally substituted with one or more of the following groups: halogen or hydroxy, wherein the C 4-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-4 The alkyl groups are fused to form a bicyclic ring, and wherein if R4 is H, then R1 is not H.
[0085] In embodiments of the compound of Formula I, Ia, II, Ha, III, IIIa or VIII, or a pharmaceutically acceptable salt thereof, A is -N-.
[0086] In embodiments of the compound of Formula I, Ia, II, Ha, III, IIIa or VIII, or a pharmaceutically acceptable salt thereof, A is -C(H)-.
[0087] In embodiments of the compound of Formula I, Ia, IV, IVa, V, Va, VI, VIa, VII or VIIa, or a pharmaceutically acceptable salt thereof, B is -N-.
[0088] In embodiments of the compound of Formula I, Ia, IV, IVa, V, Va, VI, VIa, VII or Vila, or a pharmaceutically acceptable salt thereof, B is -CH-.
[0089] In an embodiment of the compound of Formula I, Ia, IV, IVa, V, Va, VI, VIa, VII or VIIa, or a pharmaceutically acceptable salt thereof, B is -C(R4)-.
[0090] In an embodiment of a compound of Formula I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI, VIa, VII or VIIa, or a pharmaceutically acceptable salt thereof, D1 is -CH2-.
[0091] In embodiments of the compound of Formula I, Ia, II, Ha, III or IIIa, or a pharmaceutically acceptable salt thereof, X is -S-.
[0092] In embodiments of the compound of Formula I, Ia, II, Ha, III or IIIa, or a pharmaceutically acceptable salt thereof, Y is -C(CN)-.
[0093] In embodiments of the compounds of any of Formula I, Ia, II, IIa, III, IIIa, IV or IVa, or pharmaceutically acceptable salts thereof, Z is -C(R 3c )-.
[0094] In embodiments of the compound of any of Formula I, Ia, II, Ha, III, IIIa, IV, or IVa, or a pharmaceutically acceptable salt thereof, Z is -N-.
[0095] In embodiments of the compounds of any one of Formulas I, II, III, IV, V or VII, or pharmaceutically acceptable salts thereof, G is -C(R 3b )-.
[0096] In embodiments of the compound of any of Formulas I, II, III, IV, V or VII, or a pharmaceutically acceptable salt thereof, G is -N-.
[0097] In embodiments of the compound of any one of Formulas I, II, III, IV or VII, or a pharmaceutically acceptable salt thereof, G is -N-, and Z is -C(R 3c )-.
[0098] In embodiments of the compounds of any one of Formulas I, II, III, IV, V or VII, or pharmaceutically acceptable salts thereof, G is -C(R 3b )-.
[0099] In embodiments of the compounds of any one of Formulas I, II, III, IV or VII, or pharmaceutically acceptable salts thereof, G is -C(R 3b )-, and Z is -N-.
[0100] In embodiments of the compound of any one of Formulas I, II, III or IV, or a pharmaceutically acceptable salt thereof, R 3b is F, or a pharmaceutically acceptable salt thereof.
[0101] In embodiments of the compound of any of Formula I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or a pharmaceutically acceptable salt thereof, R1 is H.
[0102] In an embodiment of a compound of any of Formula I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or a pharmaceutically acceptable salt thereof, R1 is an N-linked piperazine which may be optionally substituted as defined above.
[0103] In embodiments of compounds of any one of Formula I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or pharmaceutically acceptable salts thereof, R1 is optionally substituted by C 1-3 Alkyl bridged N-linked piperazine.
[0104] In embodiments of compounds of any one of Formulas I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or pharmaceutically acceptable salts thereof, R is an N-linked piperazine substituted with one or more of the following: methyl, trideuterated methyl or C 1-3 Alkyl, wherein the C 1-3The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methyl, hydroxymethyl, methoxy, trifluoromethoxy, difluoromethoxy, -O-trideuterated methyl, cyclopropyl, oxetane, pyrazole, imidazole, -CONR7R7, -O-(CH2) p -OC 1-3 Alkyl, -O-(CH2) p -OH or -O-CO-C 1-3 wherein the cyclopropyl, imidazole or pyrazole are each optionally substituted by a hydroxyl group or a C 1-3 Alkyl; and wherein the N-attached piperazine is connected via a C 1-3 Alkyl bridge, or a pharmaceutically acceptable salt thereof.
[0105] In embodiments of the compound of any one of Formula I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or a pharmaceutically acceptable salt thereof, R1 is selected from:
[0106]
[0107]
[0108] In embodiments of compounds of any one of Formulas I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or pharmaceutically acceptable salts thereof, R is H, methoxy, -CH2-CH2-NH2, or a group of the formula:
[0109]
[0110]
[0111] In embodiments of the compound of any one of Formula I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or a pharmaceutically acceptable salt thereof, R1 is
[0112]
[0113]
[0114] In embodiments of the compound of any one of Formula I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or a pharmaceutically acceptable salt thereof, R1 is
[0115]
[0116] In embodiments of compounds of any one of Formula I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or pharmaceutically acceptable salts thereof, R1 is H, methoxy, C 1-4 Alkyl, C 2-4 heteroalkyl, N-linked piperazine, piperidine or a group of the formula:
[0117]
[0118] Wherein C 1-4 Alkyl, C 2-4 The heteroalkyl, piperidine or N-linked piperazine is optionally substituted with one or more of the following groups: amino, hydroxy, methyl, trideuteromethyl, oxetane or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methyl, hydroxymethyl, methoxy, trifluoromethoxy, cyclopropyl, oxetane, pyrazole, imidazole, amino, -CONR7R7, wherein the piperidine or N-attached piperazine is optionally substituted by C 1-3 alkyl bridge, and wherein the cyclopropyl, imidazole or pyrazole are each optionally substituted by: C substituted by one or more hydroxyl groups 1-3 alkyl.
[0119] In embodiments of compounds of Formula I, Ia, II, IIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or pharmaceutically acceptable salts thereof, R4 is H, methyl, -CH2-OH, -O-R5-R6 or -O-R6, wherein R5 is -CH2-, -CH2(CH3)- or -CH2-CH2-, wherein R6 is H, C 1-3 Alkyl, C 2-3 Heterocycloalkyl, C 4-6 Cycloalkyl or C 4-6 Heterocycloalkyl, wherein the C 1-3 Alkyl, C 4-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally substituted by one or more of the following groups: halogen, hydroxy, methoxy, C 1-4 Alkyl or C 1-4 alkenyl, wherein the C 1-4 The alkyl group is optionally substituted with one or more of the following groups: halogen or hydroxy, wherein the C 4-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-4The alkyl groups are fused to form a bicyclic ring, and wherein if R4 is H, then R1 is not H.
[0120] In an embodiment of the compound of Formula Ia or a pharmaceutically acceptable salt thereof, R 3a , R 3b and R 3c are each independently H or halogen; and R1 is H, methoxy, C 1-4 Alkyl, C 2-4 heteroalkyl, N-linked piperazine, piperidine or a group of the formula:
[0121]
[0122] Wherein C 1-4 Alkyl, C 2-4 The heteroalkyl, piperidine or N-linked piperazine is optionally substituted with one or more of the following groups: amino, hydroxy, methyl, trideuteromethyl, oxetane or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methyl, hydroxymethyl, methoxy, trifluoromethoxy, cyclopropyl, oxetane, pyrazole, imidazole, amino, -CONR7R7, -O-(CH2) p -OC 1-3 Alkyl, -O-(CH2) p -OH or -O-CO-C 1-3 alkyl, wherein the piperidine or the N-linked piperazine is optionally 1-3 alkyl bridge, and wherein the cyclopropyl, imidazole or pyrazole are each optionally substituted by: C substituted by one or more hydroxyl groups 1-3 and R4 is H, methyl, -CH2-OH, -O-R5-R6, -O-R6 or an azetidine optionally substituted with NR7R7, wherein R5 is -CH2-, -CH(CH3)- or -CH2-CH2-, wherein R6 is H, C 1-3 Alkyl, C 2-3 Heteroalkyl, C 3-6 Cycloalkyl, C 4-6 Heterocycloalkyl or 2-oxo-1,3-dihydrobenzimidazole, wherein the C 1-3 Alkyl, C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally substituted by one or more of the following groups: halogen, hydroxy, methoxy, NR7R7, C 1-4 Alkyl or C 1-4 alkenyl, wherein the C 1-4 The alkyl group is optionally substituted with one or more of the following groups: halogen or hydroxy, wherein the C 3-6 Cycloalkyl or C4-6 The heterocycloalkyl group is optionally 1-4 Alkyl groups are fused to form a bicyclic ring, or the C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-3 The alkyl group is bridged, and wherein if R4 is H, then R1 is not H; or a pharmaceutically acceptable salt thereof.
[0123] In an embodiment of the compound of Formula Ia or a pharmaceutically acceptable salt thereof, R 3a , R 3b and R 3c are each independently H or halogen; and R1 is H, methoxy, C 1-4 Alkyl, C 2-4 heteroalkyl, N-linked piperazine, piperidine or a group of the formula:
[0124]
[0125] Wherein C 1-4 Alkyl, C 2-4 The heteroalkyl, piperidine or N-linked piperazine is optionally substituted with one or more of the following groups: amino, hydroxy, methyl, trideuteromethyl, oxetane or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methyl, hydroxymethyl, methoxy, trifluoromethoxy, cyclopropyl, oxetane, pyrazole, imidazole, amino or -CONR7R7, wherein the piperidine or the N-attached piperazine is optionally substituted with one or more of the following groups: 1-3 alkyl bridge, and wherein the cyclopropyl, imidazole or pyrazole are each optionally substituted by: C substituted by one or more hydroxyl groups 1-3 and R4 is H, methyl, -CH2-OH, -O-R5-R6, -O-R6 or an azetidine optionally substituted with NR7R7, wherein R5 is -CH2-, -CH(CH3)- or -CH2-CH2-, wherein R6 is H, C 1-3 Alkyl, C 2-3 Heteroalkyl, C 3-6 Cycloalkyl, C 4-6 Heterocycloalkyl or 2-oxo-1,3-dihydrobenzimidazole, wherein the C 1-3 Alkyl, C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally substituted by one or more of the following groups: halogen, hydroxy, methoxy, NR7R7, C 1-4 Alkyl or C 1-4 alkenyl, wherein the C 1-4 The alkyl group is optionally substituted with one or more of the following groups: halogen or hydroxy, wherein the C3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-4 Alkyl groups are fused to form a bicyclic ring, or the C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-3 The alkyl group is bridged, and wherein if R4 is H, then R1 is not H; or a pharmaceutically acceptable salt thereof.
[0126] In an embodiment of the compound of Formula Ia or a pharmaceutically acceptable salt thereof, R 3a , R 3b and R 3c are independently H or halogen; R1 is H, C 1-4 Alkyl, C 2-4 heteroalkyl or N-linked piperazine, wherein the C 1-4 Alkyl, C 2-4 The heteroalkyl or N-linked piperazine is optionally substituted with one or more of the following groups: amino, hydroxy, methyl, oxetane or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methyl, hydroxymethyl, methoxy, cyclopropyl, oxetane or amino, and wherein the N-linked piperazine is optionally substituted with one or more of the following groups: 1-3 and R4 is H, methyl, -CH2-OH, -O-R5-R6 or -O-R6, wherein R5 is -CH2-, -CH2(CH3)- or -CH2-CH2-, wherein R6 is H, C 1-3 Alkyl, C 2-3 Heteroalkyl, C 4-6 Cycloalkyl or C 4-6 Heterocycloalkyl, wherein the C 1-3 Alkyl, C 4-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally substituted by one or more of the following groups: halogen, hydroxy, methoxy, C 1-4 Alkyl or C 1-4 alkenyl, wherein the C 1-4 The alkyl group is optionally substituted with one or more of the following groups: halogen or hydroxy, wherein the C 4-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-4 The alkyl groups are fused to form a bicyclic ring, and wherein if R4 is H, then R1 is not H; or a pharmaceutically acceptable salt thereof.
[0127] In an embodiment of a compound of Formula I, Ia, II, IIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or a pharmaceutically acceptable salt thereof, R4 is -O-CH2-R6.
[0128] In embodiments of the compound of Formula II, Ha, IV or IVa, or a pharmaceutically acceptable salt thereof, R6 is azetidine, pyrrolidine, piperidine, oxetane, tetrahydrofuran, morpholine, cyclobutane or 1,4-dioxane.
[0129] In embodiments of compounds of Formula I, Ia, II, IIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or pharmaceutically acceptable salts thereof, R4 is methyl, methoxy, -CH2-OH, or a group of the formula:
[0130]
[0131] In embodiments of the compounds of Formula I, Ia, II, IIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or pharmaceutically acceptable salts thereof, R4 is
[0132]
[0133]
[0134] In embodiments of the compounds of Formula I, Ia, II, IIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or pharmaceutically acceptable salts thereof, R4 is
[0135]
[0136] In embodiments of the compounds of Formula I, Ia, II, IIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or pharmaceutically acceptable salts thereof, R4 is
[0137]
[0138] In embodiments of the compounds of Formula I, Ia, II, IIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or pharmaceutically acceptable salts thereof, R4 is
[0139]
[0140] In embodiments of compounds of Formula I, Ia, II, IIa, IV, IVa, V, Va, VI, VIa, VII, VIIa or VIII, or pharmaceutically acceptable salts thereof, R4 is selected from:
[0141]
[0142]
[0143] In embodiments of the compound of Formula I, Ia, II, Ha, III, IIIa or VIII, or a pharmaceutically acceptable salt thereof, R2 is F or Cl.
[0144] In embodiments of the compound of Formula I, Ia, II, IIa, III, IIIa, IV or IVa, or a pharmaceutically acceptable salt thereof, R 3b and R 3c are each independently H or F.
[0145] In embodiments of the compound of Formula I, Ia, II or IIa, or a pharmaceutically acceptable salt thereof, X is S, Y is -C(CN)-, R2 is F or Cl, R 3a Yes H, R 3b Yes H, R 3c is F, and D1 is -CH2-.
[0146] In the above embodiments of compounds of Formula I-VIII (including Ia-VIIa), the chemical diagrams are planar and have no chiral information. These compounds typically have multiple chiral centers, and various forms of various combinations of chiral centers are included. In addition, these compounds have various enantiomers, diastereomers, and atropisomers that may exist, all of which are included within the scope of this article.
[0147] Examples of compounds described herein include compounds of Table A and pharmaceutically acceptable salts thereof.
[0148] Table A: Example compounds
[0149]
[0150]
[0151]
[0152]
[0153]
[0154]
[0155]
[0156]
[0157]
[0158]
[0159]
[0160]
[0161]
[0162]
[0163]
[0164]
[0165]
[0166]
[0167]
[0168]
[0169]
[0170]
[0171]
[0172]
[0173]
[0174]
[0175]
[0176]
[0177]
[0178]
[0179]
[0180]
[0181]
[0182]
[0183]
[0184]
[0185]
[0186]
[0187]
[0188]
[0189]
[0190] The chemical diagrams in Table A contain indications of the chiral aspects of the particular compounds shown. However, the chemical diagrams in Table A do not include all possible chiral characteristics of these compounds, and the chiral indications shown are not intended to exclude variations in the chiral aspects shown. Therefore, alternative chiral forms of the compounds as well as different combinations of chiral characteristics are contemplated and included herein.
[0191] In the compound of Formula I, Ia, II, IIa, III, IIIa, IV or IVa or a pharmaceutically acceptable salt thereof, the compound is selected from:
[0192]
[0193]
[0194] or a pharmaceutically acceptable salt thereof.
[0195] Additional compounds of Formula I, Ia, II, IIa, III, IIIa, IV or IVa, or pharmaceutically acceptable salts thereof, selected from:
[0196]
[0197]
[0198]
[0199] Additional compounds of Formula I, Ia, II, IIa, III, IIIa, IV or IVa, or pharmaceutically acceptable salts thereof, selected from:
[0200]
[0201]
[0202]
[0203]
[0204]
[0205] or a pharmaceutically acceptable salt thereof.
[0206] Additional compounds of Formula I, Ia, II, IIa, III, IIIa, IV or IVa, or pharmaceutically acceptable salts thereof, selected from:
[0207]
[0208]
[0209]
[0210]
[0211]
[0212]
[0213]
[0214]
[0215]
[0216]
[0217]
[0218]
[0219]
[0220]
[0221]
[0222]
[0223]
[0224]
[0225]
[0226]
[0227]
[0228]
[0229]
[0230]
[0231]
[0232] or a pharmaceutically acceptable salt thereof.
[0233] Additional compounds of Formula I, Ia, II, IIa, III, IIIa, IV or IVa, or pharmaceutically acceptable salts thereof, selected from:
[0234]
[0235]
[0236] or a pharmaceutically acceptable salt thereof.
[0237] Also provided herein are pharmaceutical compositions comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof, examples of which include, but are not limited to, a compound in Table A and a pharmaceutically acceptable carrier, diluent or excipient.
[0238] Also provided herein is a method for treating cancer, comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof to a patient in need. In the method, the cancer may be lung cancer, colorectal cancer, pancreatic cancer, bladder cancer, cervical cancer, endometrial cancer, ovarian cancer, bile duct cancer, gastric cancer, or esophageal cancer. In the method, the cancer may more particularly be non-small cell lung cancer, pancreatic cancer, or colorectal cancer. In one embodiment, the cancer may be non-small cell lung cancer. In one embodiment, the cancer may be pancreatic cancer. In one embodiment, the cancer may be colorectal cancer.
[0239] Also provided herein is a method for treating cancer, comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof to a patient in need, wherein the cancer has one or more cells expressing mutant KRas G12D proteins. In this method, the cancer may be non-small cell lung cancer, pancreatic cancer, or colorectal cancer, wherein the cancer has one or more cells expressing KRas G12D mutant proteins. In one embodiment, the cancer is non-small cell lung cancer, wherein the cancer has one or more cells expressing KRas G12D mutant proteins. In one embodiment, the cancer is mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRasG12D mutant proteins. In one embodiment, the cancer is colorectal cancer, wherein the cancer has one or more cells expressing KRas G12D mutant proteins. The method also includes treating cancers with KRas G12D mutants in other organs.
[0240] Also provided herein is a method for treating a patient with a cancer having a KRas G12D mutant, the method comprising administering an effective amount of a compound of any one of Formulas I-VII or a pharmaceutically acceptable salt thereof to a patient in need. In the method, the cancer having a KRas G12D mutation may be a KRas G12D mutation lung cancer, a KRas G12D mutation pancreatic cancer, a KRas G12D mutation cervical cancer, a KRas G12D mutation esophageal cancer, a KRas G12D mutation endometrial cancer, a KRas G12D mutation ovarian cancer, a KRas G12D mutation bile duct cancer, and a KRas G12D mutation colorectal cancer. In one embodiment, the cancer having a KRas G12D mutation may be a KRas G12D mutation non-small cell lung cancer. In one embodiment, the cancer having a KRas G12D mutation may be a KRas G12D mutation pancreatic cancer. In one embodiment, the cancer having a KRas G12D mutation may be a KRas G12D mutation colorectal cancer.
[0241] In addition, provided herein is a method of regulating a mutant KRas G12D enzyme in a patient in need thereof by administering a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof. In one embodiment, the method comprises inhibiting a human mutant KRas G12D enzyme.
[0242] Also provided herein is a method for treating cancer in a patient in need thereof, wherein the patient suffers from a cancer determined to express a KRas G12D mutant protein. The method comprises administering to the patient an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof. The G12D mutation status of one or more cancer cells can be determined by many assays known in the art. Typically, one or more biopsies containing one or more cancer cells are obtained and sequenced and / or polymerase chain reaction (PCR) is performed on them. Circulating cell-free DNA can also be used, for example, in advanced cancers. Non-limiting examples of sequencing and PCR techniques for determining mutation status (e.g., G12D mutation status, in one or more cancer cells or in circulating free DNA) include direct sequencing, next generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), multiplex PCR, and pyrophosphate sequencing and multi-analyte profiling.
[0243] Also provided herein is a compound of any one of Formulas I-VII for treatment or a pharmaceutically acceptable salt thereof. The compound or a pharmaceutically acceptable salt thereof can be used to treat cancer. For the use of the treatment of cancer, the cancer can be lung cancer, colorectal cancer, pancreatic cancer, bladder cancer, cervical cancer, endometrial cancer, ovarian cancer, bile duct cancer or esophageal cancer. The cancer can be more particularly non-small cell lung cancer, pancreatic cancer or colorectal cancer. In one embodiment, the cancer is non-small cell lung cancer. In one embodiment, the cancer is pancreatic cancer. In one embodiment, the cancer is colorectal cancer. The cancer can have one or more cells expressing mutant KRas G12D protein, such as KRas G12D mutant lung cancer, KRas G12D mutant pancreatic cancer, KRas G12D mutant cervical cancer, KRas G12D mutant esophageal cancer, KRas G12D mutant endometrial cancer, KRas G12D mutant ovarian cancer, KRas G12D mutant bile duct cancer and KRas G12D mutant colorectal cancer. In these uses, the cancer is selected from: KRas G12D mutant non-small cell lung cancer, KRas G12D mutant colorectal cancer and KRas G12D mutant pancreatic cancer. In addition, the cancer can be non-small cell lung cancer and one or more cells express KRas G12D mutant protein. In addition, the cancer can be colorectal cancer and one or more cells express KRas G12D mutant protein. In addition, the cancer can be pancreatic cancer and one or more cells express KRas G12D mutant protein. Prior to administering the compound or a pharmaceutically acceptable salt thereof, the patient may have a cancer determined to have one or more cells expressing KRas G12D mutant protein. Prior to receiving the treatment described herein, the patient may have received a different course of treatment.
[0244] The compound of any one of Formulas I-VIII (including Ia-VIIa) provided herein or a pharmaceutically acceptable salt thereof can be used to prepare a medicament for treating cancer. When used to prepare a medicament, the cancer can be lung cancer, colorectal cancer, pancreatic cancer, bladder cancer, cervical cancer, endometrial cancer, ovarian cancer, bile duct cancer or esophageal cancer. The cancer can be more particularly non-small cell lung cancer, pancreatic cancer or colorectal cancer. In one embodiment, the cancer is non-small cell lung cancer. In one embodiment, the cancer is pancreatic cancer. In one embodiment, the cancer is colorectal cancer. The cancer has one or more cells expressing mutant KRas G12D protein. When the cancer cell expresses KRas G12D protein, the cancer can be selected from KRas G12D mutant non-small cell lung cancer, KRas G12D mutant colorectal cancer and KRas G12D mutant pancreatic cancer.
[0245] Also provided herein is a method for treating cancer, comprising administering to a patient in need thereof an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and one or more of a PD-1 inhibitor, a PD-L1 inhibitor, a CDK4 / CDK6 inhibitor, an EGFR inhibitor, an ERK inhibitor, an Aurora A inhibitor, a SHP2 inhibitor, a platinum drug, and pemetrexed or a pharmaceutically acceptable salt thereof, wherein the cancer has one or more cells expressing a mutant KRas G12D protein. Also provided herein is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof, which is used in cancer treatment for simultaneous, separate or sequential combination use with one or more of a PD-1 or PD-L1 inhibitor, a CDK4 / CDK6 inhibitor, an EGFR inhibitor, an ERK inhibitor, an Aurora A inhibitor, a SHP2 inhibitor, a platinum drug, and pemetrexed or a pharmaceutically acceptable salt thereof. In addition, a combination is provided, which comprises a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and one or more of a PD-1 or PD-L1 inhibitor, a CDK4 / CDK6 inhibitor, an EGFR inhibitor, an ERK inhibitor, an Aurora A inhibitor, a SHP2 inhibitor, a platinum drug and pemetrexed or a pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use in the treatment of cancer.
[0246] Also provided is a method for treating cancer, comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a PD-1 or PD-L1 inhibitor to a patient in need, wherein the cancer has one or more cells expressing a mutant KRas G12D protein. Also provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with a PD-1 or PD-L1 inhibitor simultaneously, separately or sequentially for use in the treatment of cancer. In addition, a combination is also provided, the combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a PD-1 or PD-L1 inhibitor, which are used for simultaneous, separate or sequential use in cancer treatment. As used herein, the PD-1 or PD-L1 inhibitor may be pembrolizumab; the PD-1 or PD-L1 inhibitor may be nivolumab; the PD-1 or PD-L1 inhibitor may be cemiplimab; the PD-1 or PD-L1 inhibitor may be sintilimab; the PD-1 or PD-L1 inhibitor may be atezolizumab; the PD-1 or PD-L1 inhibitor may be avelumab; the PD-1 or PD-L1 inhibitor may be durvalumab; or the PD-1 or PD-L1 inhibitor may be lodapilimab. As used herein, the cancer can be non-small cell lung cancer, wherein the cancer has one or more cells expressing KRas G12D mutant protein; the cancer can be colorectal cancer, wherein the cancer has one or more cells expressing KRas G12D mutant protein; or the cancer can be mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRas G12D mutant protein. The method also includes treating cancers with KRas G12D mutants in other organs.
[0247] Also provided is a method for treating cancer, comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a CDK4 / CDK6 inhibitor or a pharmaceutically acceptable salt thereof to a patient in need thereof, wherein the cancer has one or more cells expressing mutant KRas G12D protein. Also provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with a CDK4 / CDK6 inhibitor or a pharmaceutically acceptable salt thereof for treating cancer, wherein the cancer has one or more cells expressing mutant KRas G12D protein. In addition, a combination is also provided, comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a CDK4 / CDK6 inhibitor or a pharmaceutically acceptable salt thereof, for use simultaneously, separately or sequentially in the treatment of cancer, wherein the cancer has one or more cells expressing mutant KRas G12D protein. As used herein, the CDK4 / CDK6 inhibitor may be abemaciclib; the CDK4 / CDK6 inhibitor may be palbociclib; or the CDK4 / CDK6 inhibitor may be ribociclib. As used herein, the cancer may be non-small cell lung cancer, wherein the cancer has one or more cells expressing KRas G12D mutant proteins; the cancer may be colorectal cancer, wherein the cancer has one or more cells expressing KRas G12D mutant proteins; the cancer may be mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRas G12D mutant proteins. The method also includes treating cancers with KRas G12D mutants in other organs.
[0248] Also provided is a method for treating cancer, the method comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and an EGFR inhibitor or a pharmaceutically acceptable salt thereof to a patient in need, wherein the cancer has one or more cells expressing mutant KRas G12D protein. Also provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with an EGFR inhibitor or a pharmaceutically acceptable salt thereof simultaneously, separately or sequentially for the treatment of cancer. Also provided is a combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and an EGFR inhibitor or a pharmaceutically acceptable salt thereof for use simultaneously, separately or sequentially in the treatment of cancer. As used herein, the EGFR inhibitor may be erlotinib; the EGFR inhibitor may be afatinib; the EGFR inhibitor may be gefitinib; the EGFR inhibitor may be cetuximab. As used herein, the cancer can be non-small cell lung cancer, wherein the cancer has one or more cells expressing KRas G12D mutant protein; the cancer can be colorectal cancer, wherein the cancer has one or more cells expressing KRas G12D mutant protein; or the cancer can be mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRas G12D mutant protein. The method also includes treating cancers with KRas G12D mutants in other organs.
[0249] Also provided is a method for treating cancer, the method comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and an ERK inhibitor or a pharmaceutically acceptable salt thereof to a patient in need, wherein the cancer has one or more cells expressing mutant KRas G12D protein. Also provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with an ERK inhibitor or a pharmaceutically acceptable salt thereof for treating cancer, wherein the cancer has one or more cells expressing mutant KRas G12D protein. Also provided is a combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and an ERK inhibitor or a pharmaceutically acceptable salt thereof for use simultaneously, separately or sequentially in cancer treatment. As used herein, the ERK inhibitor may be LY3214996; the ERK inhibitor may be LTT462; or the ERK inhibitor may be KO-947. As used herein, the cancer can be non-small cell lung cancer, wherein the cancer has one or more cells expressing KRas G12D mutant protein; the cancer can be colorectal cancer, wherein the cancer has one or more cells expressing KRas G12D mutant protein; the cancer can be mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRas G12D mutant protein. The method also includes treating cancers with KRas G12D mutants in other organs.
[0250] Also provided is a method for treating cancer, comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and an Aurora A inhibitor to a patient in need thereof, wherein the cancer has one or more cells expressing a mutant KRas G12D protein. Also provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with an Aurora A inhibitor or a pharmaceutically acceptable salt thereof for treating cancer, wherein the cancer has one or more cells expressing a mutant KRas G12D protein. In addition, provided is a combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and an Aurora A inhibitor for use simultaneously, separately or sequentially in the treatment of cancer. As used herein, the Aurora The inhibitor A can be alisertib, tozasertib, (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridinyl]methyl]-2-methyl-piperidine-4-carboxylic acid, (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5 -methyl-1H-pyrazol-3-yl)amino]-2-pyridinyl]methyl]-2-methyl-piperidine-4-carboxylic acid: 2-methylpropane-2-amine (1:1) salt and (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridinyl]methyl]-2-methyl-piperidine-4-carboxylic acid: amine (1:1) salt, or a pharmaceutically acceptable salt thereof. In one embodiment, the Aurora A inhibitor is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridinyl]methyl]-2-methyl-piperidine-4-carboxylic acid. As used herein, the cancer can be non-small cell lung cancer, wherein the cancer has one or more cells expressing KRas G12D mutant protein; the cancer can be colorectal cancer, wherein the cancer has one or more cells expressing KRas G12D mutant protein; the cancer can be mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRasG12D mutant protein. The method also includes treating cancers with KRas G12D mutants in other organs.
[0251] Also provided is a method for treating cancer, comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a SHP2 inhibitor to a patient in need thereof, wherein the cancer has one or more cells expressing mutant KRas G12D protein. Also provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with a SHP2 inhibitor or a pharmaceutically acceptable salt thereof for treating cancer, wherein the cancer has one or more cells expressing mutant KRas G12D protein. Also provided is a combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a SHP2 inhibitor for use simultaneously, separately or sequentially in the treatment of cancer. As used herein, the SHP2 inhibitor or a pharmaceutically acceptable salt thereof may be a type I SHP2 inhibitor or a type II SHP2 inhibitor. Examples of type I SHP2 inhibitors include, but are not limited to, PHPS1, GS-493, NSC-87877, NSC-117199, and cefsulodin, and pharmaceutically acceptable salts thereof. Examples of type II SHP2 inhibitors include, but are not limited to, JAB-3068, JAB-3312, RMC-4550, RMC-4630, SHP099, SHP244, SHP389, SHP394, TNO155, RG-6433, and RLY-1971, and pharmaceutically acceptable salts thereof. Other examples of SHP2 inhibitors include, but are not limited to, BBP-398, IACS-15509, IACS-13909, X37, ERAS-601, SH3809, HBI-2376, ETS-001, and PCC0208023, and pharmaceutically acceptable salts thereof. As used herein, the cancer can be non-small cell lung cancer, wherein the cancer has one or more cells expressing KRasG12D mutant protein; the cancer can be colorectal cancer, wherein the cancer has one or more cells expressing KRasG12D mutant protein; the cancer can be mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRas G12D mutant protein. The method also includes treating cancers with KRas G12D mutants in other organs.
[0252] Also provided is a method for treating cancer, the method comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a platinum drug to a patient in need, wherein the cancer has one or more cells expressing mutant KRas G12D protein. Also provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with a platinum drug or a pharmaceutically acceptable salt thereof simultaneously, separately or sequentially for treating cancer, wherein the cancer has one or more cells expressing mutant KRas G12D protein. Also provided is a combination, the combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a platinum drug for use simultaneously, separately or sequentially in the treatment of cancer. As used herein, the platinum drug may be cisplatin; the platinum drug may be carboplatin; or the platinum drug may be oxaliplatin. As used herein, the cancer can be non-small cell lung cancer, wherein the cancer has one or more cells expressing KRas G12D mutant protein; the cancer can be colorectal cancer, wherein the cancer has one or more cells expressing KRas G12D mutant protein; the cancer can be mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRas G12D mutant protein. The method also includes treating cancers with KRas G12D mutants in other organs.
[0253] Also provided is a method for treating cancer, the method comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and pemetrexed to a patient in need, wherein the cancer has one or more cells expressing mutant KRas G12D protein. Also provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with pemetrexed simultaneously, separately or sequentially for treating cancer, wherein the cancer has one or more cells expressing mutant KRas G12D protein. Also provided is a combination, the combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and pemetrexed, for use simultaneously, separately or sequentially in cancer treatment, wherein the cancer has one or more cells expressing mutant KRas G12D protein. As used herein, the cancer has one or more cells expressing KRas G12D mutant protein. In addition, a platinum drug (and the platinum drug may be cisplatin, carboplatin or oxaliplatin) may also be administered to the patient. As described herein, the cancer can be colorectal cancer, wherein the cancer has one or more cells expressing a KRas G12D mutant protein, or the cancer can be a mutant pancreatic cancer, wherein the cancer has one or more cells expressing a KRas G12D mutant protein. The method also includes treating cancers of other organs with KRas G12D mutants.
[0254] Also provided herein is a method for treating cancer, comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof to a patient in need, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. In this method, the cancer may be non-small cell lung cancer, pancreatic cancer, or colorectal cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins. In one embodiment, the cancer is non-small cell lung cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins. In one embodiment, the cancer is mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins. In one embodiment, the cancer is colorectal cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins. The method also includes treating cancers of other organs harboring KRas G12C, G12D and / or G12V mutants.
[0255] Also provided herein are methods of treating a patient having a cancer having a KRas G12C, G12D and / or G12V mutation, comprising administering to a patient in need thereof an effective amount of a compound of any one of Formulae I-VII, or a pharmaceutically acceptable salt thereof. In this method, the cancer having KRas G12C, G12D and / or G12V mutations can be KRas G12C, G12D and / or G12V mutation lung cancer, KRas G12C, G12D and / or G12V mutation pancreatic cancer, KRas G12C, G12D and / or G12V mutation cervical cancer, KRas G12C, G12D and / or G12V mutation esophageal cancer, KRas G12C, G12D and / or G12V mutation endometrial cancer, KRas G12C, G12D and / or G12V mutation ovarian cancer, KRas G12C, G12D and / or G12V mutation bile duct cancer and KRas G12C, G12D and / or G12V mutation colorectal cancer. In one embodiment, the cancer having KRas G12C, G12D and / or G12V mutations may be KRas G12C, G12D and / or G12V mutations in non-small cell lung cancer. In one embodiment, the cancer having KRas G12C, G12D and / or G12V mutations may be KRas G12C, G12D and / or G12V mutations in pancreatic cancer. In one embodiment, the cancer having KRas G12C, G12D and / or G12V mutations may be KRas G12C, G12D and / or G12V mutations in colorectal cancer.
[0256] In addition, provided herein is a method of regulating mutant KRas G12C, G12D and / or G12V enzymes in patients in need thereof by administering a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof. In one embodiment, the method comprises inhibiting human mutant KRas G12C, G12D and / or G12V enzymes.
[0257] Also provided herein is a method for treating cancer in a patient in need thereof, wherein the patient suffers from a cancer determined to express KRas G12C, G12D and / or G12V mutant proteins. The method comprises administering to the patient an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof. The G12D mutation status of one or more cancer cells can be determined by many assays known in the art. Typically, one or more biopsies containing one or more cancer cells are obtained and sequenced and / or polymerase chain reaction (PCR) is performed on them. Circulating free DNA can also be used, for example, in advanced cancers. Non-limiting examples of sequencing and PCR techniques for determining mutation status (e.g., G12D mutation status, in one or more cancer cells or in circulating free DNA) include direct sequencing, next generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), multiplex PCR, and pyrophosphate sequencing and multi-analyte analysis.
[0258] Also provided herein is a compound of any one of Formulas I-VII for treatment or a pharmaceutically acceptable salt thereof. The compound or a pharmaceutically acceptable salt thereof can be used to treat cancer. For the use of the treatment of cancer, the cancer can be lung cancer, colorectal cancer, pancreatic cancer, bladder cancer, cervical cancer, endometrial cancer, ovarian cancer, bile duct cancer or esophageal cancer. The cancer can be more particularly non-small cell lung cancer, pancreatic cancer or colorectal cancer. In one embodiment, the cancer is non-small cell lung cancer. In one embodiment, the cancer is pancreatic cancer. In one embodiment, the cancer is colorectal cancer. The cancer can have one or more cells expressing a mutant KRas G12C, G12D and / or G12V protein, such as KRas G12C, G12D and / or G12V mutant lung cancer, KRas G12C, G12D and / or G12V mutant pancreatic cancer, KRas G12C, G12D and / or G12V mutant cervical cancer, KRas G12C, G12D and / or G12V mutant esophageal cancer, KRas G12C, G12D and / or G12V mutant endometrial cancer, KRas G12C, G12D and / or G12V mutant ovarian cancer, KRas G12C, G12D and / or G12V mutant cholangiocarcinoma, and KRas G12C, G12D and / or G12V mutant colorectal cancer. In these uses, the cancer is selected from: KRasG12C, G12D and / or G12V mutant non-small cell lung cancer, KRas G12C, G12D and / or G12V mutant colorectal cancer and KRas G12C, G12D and / or G12V mutant pancreatic cancer. In addition, the cancer can be non-small cell lung cancer and one or more cells express KRas G12C, G12D and / or G12V mutant proteins. In addition, the cancer can be colorectal cancer and one or more cells express KRas G12C, G12D and / or G12V mutant proteins. In addition, the cancer can be pancreatic cancer and one or more cells express KRas G12C, G12D and / or G12V mutant proteins. Prior to administering the compound or a pharmaceutically acceptable salt thereof, the patient may have a cancer determined to have one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins. The patient may have received different courses of treatment prior to receiving the treatment described herein.
[0259] The compound of any one of Formulas I-VIII (including Ia-VIIa) provided herein or a pharmaceutically acceptable salt thereof can be used to prepare a medicament for treating cancer. When used to prepare a medicament, the cancer can be lung cancer, colorectal cancer, pancreatic cancer, bladder cancer, cervical cancer, endometrial cancer, ovarian cancer, bile duct cancer or esophageal cancer. The cancer can be more particularly non-small cell lung cancer, pancreatic cancer or colorectal cancer. In one embodiment, the cancer is non-small cell lung cancer. In one embodiment, the cancer is pancreatic cancer. In one embodiment, the cancer is colorectal cancer. The cancer may have one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. When the cancer cells express KRas G12C, G12D and / or G12V protein, the cancer can be selected from KRas G12C, G12D and / or G12V mutant non-small cell lung cancer, KRas G12C, G12D and / or G12V mutant colorectal cancer, and KRas G12C, G12D and / or G12V mutant pancreatic cancer.
[0260] Also provided herein is a method for treating cancer, comprising administering to a patient in need thereof an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and one or more of a PD-1 inhibitor, a PD-L1 inhibitor, a CDK4 / CDK6 inhibitor, an EGFR inhibitor, an ERK inhibitor, an Aurora A inhibitor, a SHP2 inhibitor, a platinum drug, and pemetrexed, or a pharmaceutically acceptable salt thereof, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D, and / or G12V proteins. Also provided herein is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof, which is used in cancer treatment for simultaneous, separate, or sequential combination use with one or more of a PD-1 or PD-L1 inhibitor, a CDK4 / CDK6 inhibitor, an EGFR inhibitor, an ERK inhibitor, an Aurora A inhibitor, a SHP2 inhibitor, a platinum drug, and pemetrexed, or a pharmaceutically acceptable salt thereof. Also provided is a combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and one or more of a PD-1 or PD-L1 inhibitor, a CDK4 / CDK6 inhibitor, an EGFR inhibitor, an ERK inhibitor, an Aurora A inhibitor, a SHP2 inhibitor, a platinum drug and pemetrexed or a pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential use in the treatment of cancer.
[0261] Also provided is a method for treating cancer, the method comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a PD-1 or PD-L1 inhibitor to a patient in need, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. Also provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with a PD-1 or PD-L1 inhibitor simultaneously, separately or sequentially for use in the treatment of cancer. Also provided is a combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a PD-1 or PD-L1 inhibitor for simultaneous, separate or sequential use in cancer treatment. As used herein, the PD-1 or PD-L1 inhibitor may be pembrolizumab; the PD-1 or PD-L1 inhibitor may be nivolumab; the PD-1 or PD-L1 inhibitor may be cemiplizumab; the PD-1 or PD-L1 inhibitor may be sintilimab; the PD-1 or PD-L1 inhibitor may be atuzumab; the PD-1 or PD-L1 inhibitor may be oveltumab; the PD-1 or PD-L1 inhibitor may be duruvalumab; or the PD-1 or PD-L1 inhibitor may be lodalimab. As used herein, the cancer can be non-small cell lung cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins; the cancer can be colorectal cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins; or the cancer can be mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins. The method also includes treating cancers with KRasG12C, G12D and / or G12V mutants in other organs.
[0262] Also provided is a method for treating cancer, comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a CDK4 / CDK6 inhibitor or a pharmaceutically acceptable salt thereof to a patient in need thereof, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. In addition, provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with a CDK4 / CDK6 inhibitor or a pharmaceutically acceptable salt thereof for treating cancer, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. Also provided is a combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a CDK4 / CDK6 inhibitor or a pharmaceutically acceptable salt thereof for simultaneous, separate or sequential use in the treatment of cancer, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. As used herein, the CDK4 / CDK6 inhibitor may be abemaciclib; the CDK4 / CDK6 inhibitor may be palbociclib; or the CDK4 / CDK6 inhibitor may be riboxiclib. As used herein, the cancer can be non-small cell lung cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins; the cancer can be colorectal cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins; the cancer can be mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins. The method also includes treating cancers with KRas G12C, G12D and / or G12V mutants in other organs.
[0263] Also provided is a method for treating cancer, the method comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and an EGFR inhibitor or a pharmaceutically acceptable salt thereof to a patient in need, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. Also provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with an EGFR inhibitor or a pharmaceutically acceptable salt thereof simultaneously, separately or sequentially for the treatment of cancer. Also provided is a combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and an EGFR inhibitor or a pharmaceutically acceptable salt thereof for use simultaneously, separately or sequentially in the treatment of cancer. As used herein, the EGFR inhibitor may be erlotinib; the EGFR inhibitor may be afatinib; the EGFR inhibitor may be gefitinib; the EGFR inhibitor may be cetuximab. As used herein, the cancer can be non-small cell lung cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins; the cancer can be colorectal cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins; or the cancer can be mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRasG12C, G12D and / or G12V mutant proteins. The method also includes treating cancers with KRas G12C, G12D and / or G12V mutants in other organs.
[0264] Also provided is a method for treating cancer, the method comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and an ERK inhibitor or a pharmaceutically acceptable salt thereof to a patient in need thereof, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. Also provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with an ERK inhibitor or a pharmaceutically acceptable salt thereof for treating cancer, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. Also provided is a combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and an ERK inhibitor or a pharmaceutically acceptable salt thereof for use simultaneously, separately or sequentially in cancer treatment. As used herein, the ERK inhibitor may be LY3214996; the ERK inhibitor may be LTT462; or the ERK inhibitor may be KO-947. As used herein, the cancer may be non-small cell lung cancer, wherein the cancer has one or more cells expressing KRasG12C, G12D and / or G12V mutant proteins; the cancer may be colorectal cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins; the cancer may be mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins. The method also includes treating cancers with KRas G12C, G12D and / or G12V mutants in other organs.
[0265] Also provided is a method for treating cancer, comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and an Aurora A inhibitor to a patient in need thereof, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. Also provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with an Aurora A inhibitor or a pharmaceutically acceptable salt thereof for treating cancer, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. Also provided is a combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and an Aurora A inhibitor for use simultaneously, separately or sequentially in the treatment of cancer. As used herein, the Aurora The inhibitor A can be aliserti, tauzerti, (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridinyl]methyl]-2-methyl-piperidine-4-carboxylic acid, (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridinyl]methyl]-2-methyl-piperidine-4-carboxylic acid, -yl)amino]-2-pyridinyl]methyl]-2-methyl-piperidine-4-carboxylic acid: 2-methylpropane-2-amine (1:1) salt and (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridinyl]methyl]-2-methyl-piperidine-4-carboxylic acid: amine (1:1) salt, or pharmaceutically acceptable salts thereof. In one embodiment, the Aurora A inhibitor is (2R,4R)-1-[(3-chloro-2-fluoro-phenyl)methyl]-4-[[3-fluoro-6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyridinyl]methyl]-2-methyl-piperidine-4-carboxylic acid. As used herein, the cancer can be non-small cell lung cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins; the cancer can be colorectal cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins; the cancer can be mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins. The method also includes treating cancers with KRas G12C, G12D and / or G12V mutants in other organs.
[0266] Also provided is a method for treating cancer, comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a SHP2 inhibitor to a patient in need thereof, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. Also provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with a SHP2 inhibitor or a pharmaceutically acceptable salt thereof for treating cancer, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. Also provided is a combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a SHP2 inhibitor for use simultaneously, separately or sequentially in the treatment of cancer. As used herein, the SHP2 inhibitor or a pharmaceutically acceptable salt thereof may be a type I SHP2 inhibitor or a type II SHP2 inhibitor. Examples of type I SHP2 inhibitors include, but are not limited to, PHPS1, GS-493, NSC-87877, NSC-117199, and cefsulodin, and pharmaceutically acceptable salts thereof. Examples of type II SHP2 inhibitors include, but are not limited to, JAB-3068, JAB-3312, RMC-4550, RMC-4630, SHP099, SHP244, SHP389, SHP394, TNO155, RG-6433, and RLY-1971, and pharmaceutically acceptable salts thereof. Other examples of SHP2 inhibitors include, but are not limited to, BBP-398, IACS-15509, IACS-13909, X37, ERAS-601, SH3809, HBI-2376, ETS-001, and PCC0208023, and pharmaceutically acceptable salts thereof. As used herein, the cancer can be non-small cell lung cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins; the cancer can be colorectal cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins; the cancer can be mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins. The method also includes treating cancers with KRas G12C, G12D and / or G12V mutants in other organs.
[0267] Also provided is a method for treating cancer, the method comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a platinum drug to a patient in need, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. Also provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with a platinum drug or a pharmaceutically acceptable salt thereof simultaneously, separately or sequentially for treating cancer, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. Also provided is a combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and a platinum drug for use simultaneously, separately or sequentially in the treatment of cancer. As used herein, the platinum drug may be cisplatin; the platinum drug may be carboplatin; or the platinum drug may be oxaliplatin. As used herein, the cancer can be non-small cell lung cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins; the cancer can be colorectal cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins; the cancer can be mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins. The method also includes treating cancers with KRas G12C, G12D and / or G12V mutants in other organs.
[0268] Also provided is a method for treating cancer, the method comprising administering an effective amount of a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and pemetrexed to a patient in need thereof, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. Also provided is a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof for use in combination with pemetrexed simultaneously, separately or sequentially for treating cancer, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. Also provided is a combination comprising a compound of any one of Formulas I-VIII (including Ia-VIIa) or a pharmaceutically acceptable salt thereof and pemetrexed for use simultaneously, separately or sequentially in the treatment of cancer, wherein the cancer has one or more cells expressing mutant KRas G12C, G12D and / or G12V proteins. As used herein, the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins. In addition, a platinum drug (and the platinum drug can be cisplatin, carboplatin or oxaliplatin) can also be administered to the patient. As described herein, the cancer can be colorectal cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins, or the cancer can be mutant pancreatic cancer, wherein the cancer has one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins. The method also includes treating cancers with KRas G12C, G12D and / or G12V mutants in other organs.
[0269] The term "pharmaceutically acceptable salt" as used herein refers to salts of compounds that are considered acceptable for clinical and / or veterinary use. Examples of pharmaceutically acceptable salts and common methods for preparing them can be found in "Handbook of Pharmaceutical Salts: Properties, Selection and Use" P. Stahl et al., Second Revised Edition, Wiley-VCH, 2011 and SM Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, 1977, 66 (1), 1-19.
[0270] Pharmaceutical compositions containing compounds of Formula I-VII as described herein can be prepared using pharmaceutically acceptable additives. The term "pharmaceutically acceptable additive" used in pharmaceutical compositions as used herein refers to one or more carriers, diluents and excipients that are compatible with other additives of the composition or formulation and harmless to the patient. Examples of pharmaceutical compositions and their preparation methods can be found in "Remington: The Science and Practice of Pharmacy", edited by Loyd, V. et al., 22nd edition, Mack Publishing Co., 2012. Non-limiting examples of pharmaceutically acceptable carriers, diluents and excipients include the following: saline, water, starch, sugars, mannitol and silica derivatives; adhesives such as carboxymethyl cellulose, alginate, gelatin and polyvinyl pyrrolidone; kaolin and bentonite; and polyethylene glycol.
[0271] The term "effective amount" as used herein refers to an amount that is effective to achieve the desired therapeutic effect, such as an amount that is effective in treating a disorder or disease such as a cancerous lesion or the progression of abnormal cell growth and / or cell division. Factors considered when determining the effective amount or dosage of a compound include: whether the compound or its salt is administered; co-administration of other active agents (if used); the species of the patient being treated; the size, age, sex and general health of the patient; the extent or stage and / or severity of the disorder; the response of individual patients; the mode of administration; the bioavailability characteristics of the administered formulation; the selected dosage regimen; and the use of other concomitant drugs.
[0272] The treating physician, veterinarian or other medical personnel will be able to determine the effective amount of the compound for treating a patient in need. The pharmaceutical composition can be formulated into a tablet or capsule for oral administration, a solution for oral administration or an injectable solution. The tablet, capsule or solution may contain a compound of the present invention in an amount effective to treat a patient in need of treating cancer.
[0273] The term "treat" as used herein includes slowing, controlling, delaying, reducing, stopping, reversing, preventing or ameliorating the progression or severity of existing symptoms, disorders, conditions, which may specifically include slowing the growth of cancerous lesions or the progression of abnormal cell growth and / or cell division. Treatment does not necessarily mean the complete elimination of all disorders or disease symptoms.
[0274] As used herein, the term "patient" refers to a mammal in need of treatment. In particular, the patient can be a human in need of treatment for cancer, such as a cancer harboring a KRas G12D mutant.
[0275] Certain abbreviations are defined as follows: “ACN” means acetonitrile; “AcOH” or “HOAc” means acetic acid; “AIBN” means azobisisobutyronitrile; “Alloc” means allyloxycarbonyl; “aq.” means aqueous or containing water; “atm” means atmospheric pressure; “Boc-Gly-OH” means N-(tert-butyloxycarbonyl)glycine; “BrettPhos” means 2-dicyclohexylphosphino-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl; “BroP” means bromotris(dimethylamino)phosphonium hexafluorophosphate; “Cbz” means benzyloxycarbonyl; “Cbz-Cl” means benzyl chloroformate; “conc "." means concentrated; "CSI" means chlorosulfonyl isocyanate; "CV" means column capacity; "DCM" means dichloromethane; "DIAD" means diisopropyl azodicarboxylate; "DIBAL-H" means diisobutylaluminum hydride; "DIEA" and "DIPEA" mean N,N-diisopropylethylamine; "(dippf)Rh(cod)BF4" means [1,4-bis(diphenylphosphino)butane](1,5-cyclooctadiene)rhodium(I) tetrafluoroborate; "DMAP" means 4-dimethylaminopyridine; "DMEA" means N,N-dimethylethylamine; "DMEM" means Dulbecco's modified Eagle's medium. medium); “DMF” refers to N,N-dimethylformamide; “DMSO” refers to dimethyl sulfoxide; “DNA” refers to deoxynucleotide; “DPEPhosPdCl2” refers to dichlorobis(diphenylphosphinophenyl) ether palladium(II); “DTT” refers to dithiothreitol; “EDTA” refers to ethylenediaminetetraacetic acid; “EGTA” refers to ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid; “ELISA” refers to enzyme-linked immunosorbent assay; “ERK” refers to extracellular signal-regulated kinase; “EtOAc” refers to ethyl acetate; “Et2O” refers to ethyl ether; “EtOH” refers to ethanol; “FA” refers to formic acid; “FBS” refers to fetal bovine serum; “Fmoc” refers to refers to fluorenylmethoxycarbonyl; “GDP” refers to guanosine diphosphate; “GTP” refers to guanosine triphosphate; “h” refers to hour; “HATU” refers to 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium-3-oxide hexafluorophosphate; “Hex” or “hex” refers to hexane; “HPLC” refers to high performance liquid chromatography; “HRP” refers to horseradish peroxidase; “IPA” refers to isopropyl alcohol; “IPAm” refers to isopropylamine; “KOAc” refers to potassium acetate; “LC-ES / MS” refers to liquid chromatography-electrospray mass spectrometry; “LC-MS” refers to liquid chromatography-mass spectrometry; “LiHMDS” refers to lithium bis(trimethylsilyl)amide;“L-prolinol” refers to [(2S)-pyrrolidin-2-yl]methanol; “MAPK” refers to mitogen-activated protein kinase; “mCPBA” refers to 3-chloro-peroxybenzoic acid; “Me” refers to methyl; “MeOH” refers to methanol; “min” refers to minutes; “MTBE” refers to tert-butyl methyl ether; “NaBH(OAc)3” refers to sodium triacetoxyborohydride; “NaOMe” refers to sodium methoxide; “NBS” refers to N-bromosuccinimide; “NCS” refers to N-chlorosuccinimide; “N-methyl-L-prolinol” refers to [(2S)-1-methylpyrrolidin-2-yl]methanol; “NMM” refers to N-methylmorpholine; “NMP” refers to 1-methylpyrrolidin-2-one; “NIS” refers to N-iodosuccinimide; “PCR” refers to polymerase chain reaction reaction; "Pd-117" refers to dichloro[bis(2-(diphenylphosphino)phenyl)ether]palladium(II), CAS 205319-06-8; "Pd-118" refers to 1,1'-bis(di-tert-butylphosphino)ferrocenepalladium dichloride, CAS 95408-45-0; "Pd2(dba)3" refers to tris(dibenzylideneacetone)dipalladium(0); "Pd(dppf)Cl2" refers to [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride; "Pd(OAc)2" refers to palladium(II) acetate; Pd(PPh3)4 refers to tetrakis(triphenylphosphine)palladium(0); "PE" refers to petroleum ether or ether; "Ph" refers to phenyl; "RBF" refers to round-bottom flask; "RPMI" refers to Roswell Park Memorial Institute (Roswell Park Memorial Institute); "RT" means room temperature; "RuPhos" means 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl, CAS 787618-22-8; "sat." means saturated; "SCX" means strong cation exchange; "Selectfluor; TM " refers to 1-chloromethyl-4-fluoro-1,4-diazabicyclo[2.2.2]octanebis(tetrafluoroborate), "SPE" refers to solid phase extraction; "SPhos" refers to 2-dicyclohexylphosphino-2',6'-dimethoxy-1,1'-biphenyl; "TBAF" refers to tetrabutylammonium fluoride; "TBDMSCl" refers to tert-butyldimethylchlorosilane; "TBDMS" refers to tert-butyldimethylsilyl; "tBu" refers to tert-butyl; "t-BuOH" refers to tert-butyl alcohol or tert-butyl alcohol; "TEA" refers to triethylamine; "TES" refers to triethylsilane; "Tf2O" refers to trifluoromethanesulfonic anhydride; "TFA" refers to trifluoroacetic acid; "THF" refers to tetrahydrofuran; "TMEDA" refers to tetramethylethylenediamine; "t R” refers to retention time; “XantPhos” refers to 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene; “XPhos” refers to 2-(dicyclohexylphosphino)-2',4',6'-tri-isopropyl-1,1'-biphenyl; “XPhos Palladacycle G2” refers to chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II), CAS 1310584-14-5; “XPhos Palladacycle Gen.4” or “XPhos Pd G4" is (2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl) (2'-methylamino-1,1'-biphenyl-2-yl) palladium(II) methanesulfonate, CAS 1599466-81-5.
[0276] Individual isomers, enantiomers, diastereomers and atropisomers can be separated or resolved at any convenient point in the synthesis of the compounds listed below by, for example, selective crystallization techniques or chiral chromatography (see, for example, J. Jacques et al., "Enantiomers, Racemates, and Resolutions", John Wiley and Sons, Inc., 1981, and EL Eliel and SH Wilen, "Stereochemistry of Organic Compounds", Wiley-Interscience, 1994). The molecules described herein include compounds that are atropisomers and compounds that can exist in different conformations or different rotational isomers. Atropisomers are compounds that exist in different conformations that result from restricted rotation around a single bond. If the energy barrier for rotation around a single bond is high enough that the rate of interconversion is slow enough so that the individual rotational isomers can be separated from each other, multiple atropisomers can be separated into separate chemical species. This specification is intended to include all possible isomers, enantiomers, diastereomers, and atropisomers of the compounds disclosed herein or that can be prepared using the compounds disclosed herein. Among the molecules described herein, only those in which the absolute conformation (or atropisomer conformation) of a chiral center is known use nomenclature or chemical formula indicating chirality or atropisomerism. Those skilled in the art will readily understand when additional chiral centers are present in the molecules described herein and when these chiral centers can be identified.
[0277] Compounds of any of Formulas I-VII that are chemically capable of forming salts are readily converted to pharmaceutically acceptable salts and can be isolated as pharmaceutically acceptable salts. Salt formation can occur via the addition of a pharmaceutically acceptable acid to form an acid addition salt. Salts can be formed while deprotecting nitrogen or oxygen, i.e., removing protecting groups. Examples, reactions, and conditions for salt formation can be found in Gould, PL, "Salt selection for basic drugs," International Journal of Pharmaceutics, 33 :201-217(1986);Bastin, RJ et al. "SaltSelection and Optimization Procedures for Pharmaceutical New ChemicalEntities," Organic Process Research and Development, 4 :427-435 (2000); and Berge, SM et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, 66 :1-19,(1977).
[0278] Compound of the present invention or its salt can be prepared by various operations, some of which are described in the schemes, preparation examples and embodiments below. The specific synthesis steps of each described route can be combined in different ways, or combined with the steps from different routes, to prepare compound of the present invention or salt. The product of each step in the preparation examples below can be reclaimed by conventional methods, including extraction, evaporation, precipitation, chromatography, filtration, grinding and crystallization.
[0279] Option 1a
[0280]
[0281] Scheme 1a describes the preparation of dihydroisobenzofuran (5). Commercially available 4-chlorophthalic anhydride (1) can be subjected to reductive ring opening using LiAlH in THF to obtain diol (2). Subsequently, dialkyl carbonates such as dimethyl carbonate and strong bases such as NaOMe are used for cyclization to obtain heterocycle (3). Subsequently, KNO or HNO together with strong acids such as HSO are used for electrophilic aromatic substitution to obtain nitroaryl compounds (4). Heterocycle (4) can be brominated with various suitable reagents (such as but not limited to NBS, POBr, Br and 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione) to obtain 4-bromo-5-chloro-6-nitro-1,3-dihydroisobenzofuran (5).
[0282] Option 1b
[0283]
[0284] Scheme 1b describes the preparation of dihydroisobenzofuran (9). Using commercially available (2-bromo-5-fluorophenyl)methanol (6), a palladium-catalyzed carbonylation can be accomplished using a ligand such as XantPhos and a palladium source such as Pd(OAc)2, using a suitable base such as triethylamine and a polar aprotic solvent such as acetonitrile to afford the lactone (7). One skilled in the art will appreciate that a variety of bidentate phosphine ligands can be used. Subsequent nitration and bromination using the conditions previously mentioned can afford the functionalized isobenzofuranone (8). Reduction of compound (8) can be accomplished using a hydride reagent such as DIBAL-H to afford an intermediate internal hemiacetal compound, which is further reduced with triethylsilane and TFA to afford 4-bromo-5-fluoro-6-nitro-1,3-dihydroisobenzofuran (9).
[0285] Solution 2
[0286]
[0287] Scheme 2 describes the preparation of cyanomethyl-substituted heterocyclic compounds of (15). The nitroaryl compound of (10) can be reduced to the corresponding aniline compound of (11) using a sulfur-doped Pt / C catalyst under hydrogenation conditions. Alternatively, it will be appreciated by those skilled in the art that the reduction can also be achieved using iron or zinc powder and NH4Cl in a polar solvent such as THF, EtOH or MeOH. Protection of the amino moiety can be accomplished using catalytic amounts of DMAP, di-tert-butyl dicarbonate or a Boc group in acetonitrile under reflux conditions. It will be appreciated by those skilled in the art that other suitable carbamate protecting groups such as Alloc, Fmoc and Cbz can also be used to replace the Boc protecting group. Reduction of the lactone moiety of compound (12) using a suitable hydride reagent such as DIBAL-H at low temperatures (e.g., low temperatures obtained using a dry ice / acetone bath) can yield the hydroxy compound of (13). The cyanomethyl compound of (14) can be obtained by using diethyl cyanomethylphosphonate in a miscible solvent such as THF under Horner-Emmons reaction conditions. Deprotection of the amino group on the cyanomethyl-substituted heterocycle (14) can be achieved by using HCl in 1,4-dioxane to afford the aniline compound (15) after basic workup.
[0288] Solution 3
[0289]
[0290] Scheme 3 describes the preparation of the isochromanol compound of (20). Starting from the benzoic acid compound of (16), cyclization is achieved by palladium-catalyzed CH insertion reaction followed by subsequent oxidative addition to ethylene oxide dissolved in THF to obtain the isochromanol compound of (17). Those skilled in the art will appreciate that various N-acyl amino acids can be used as ligands for palladium. For example, N-acetyl valine can be used. Polar acidic solvents such as trifluoroethanol, TFA or hexafluoroisopropanol can be used as solvents. Trifluoroethanol and hexafluoroisopropanol are preferred. Reduction of the carbonyl moiety can be achieved by using a two-step process. In the first step, LiBH4 in THF can be used to obtain the isochromanol intermediate, which is then reacted with p-toluenesulfonic acid in toluene under reflux conditions in the second step to obtain the isochromanol compound of (18). Subsequent bromination using the conditions mentioned above, such as NBS, can obtain the aryl bromide compound of (19). The nitro moiety can be reduced using iron powder and NH4Cl in a mixed solvent system (eg THF and water) to afford the aniline compound (20).
[0291] Option 4a
[0292]
[0293] Scheme 4a describes the preparation of the quinoline compound (25). The nitroaryl compound (21) can be reduced to the corresponding aniline compound (22) using iron or zinc powder by the reaction conditions mentioned previously. Acylation of the amine compound (22) using 3-ethoxyprop-2-enoyl chloride in THF and a suitable base such as pyridine can provide the enamide compound (23). Cyclization using H2SO4 as solvent followed by trituration in ice water provides the quinolinone compound (24). Subsequent chlorination can be achieved using a suitable reagent such as (chloromethylene)dimethyliminium chloride or POCl3 to provide the chloroquinoline compound (25).
[0294] Option 4b
[0295]
[0296] Scheme 4b describes the preparation of the methylthioquinoline compound (29). Commercially available Meldrum acid can be converted to the sulfanyl compound (27) using CS2 and a polar aprotic solvent such as DMSO followed by alkylation with iodomethane. N-alkylation of the aniline compound (22) with the methylthio compound (27) affords the functionalized compound (28) by heating in a nonpolar solvent such as toluene followed by trituration in a suitable solvent system such as Et2O / EtOAc. Cyclization can occur by refluxing at about 180°C in a suitable high boiling point solvent such as diphenyl ether to afford the quinolinol compound (29).
[0297] Solution 5
[0298]
[0299] Scheme 5 shows the preparation of the cinnoline compound (34). The dihydroisobenzofuran compound (22) can be iodinated by various reagents known to those skilled in the art, such as NIS, I2 and pyridinium iodo-chloride, to give the iodo-aniline compound (30). 0Stille coupling of iodide (30) with a source such as Pd(PPh3)4 and a suitable tributyltin alkane such as tributyl(1-ethoxyvinyl)tin alkane can give the vinyl compound (31). Acid hydrolysis using aqueous HCl can give the acetophenone compound (32). Those skilled in the art are familiar with the conditions for diazotization of the amine moiety using sodium nitrite TFA followed by cyclization to give the hydroxycinnoline compound (33). Standard chlorination conditions such as oxalyl chloride and DMF in DCM can be used to give the chlorocinnoline compound (34).
[0300] Solution 6
[0301]
[0302] Scheme 6 describes the preparation of quinazolinyl compounds (39). Thioacylation of aniline compounds (35) can be achieved using a suitable isothiocyanate such as ethoxycarbonyl isothiocyanate to give carbamothioyl compounds (36). S-alkylation can be achieved using a weak base such as K2CO3 in a polar solvent such as acetone followed by the slow addition of iodoethane to give sulfanyl compounds (37). Cyclization at 175°C in a solvent such as anhydrous NMP or diphenyl ether can give hydroxyquinazoline compounds (38), which can then be chlorinated using, for example, oxalyl chloride, thionyl sulfide, (chloromethylene)dimethylammonium chloride or POCl3 and adjusting the solvent as needed to obtain chloroquinazoline compounds (39).
[0303] Solution 7
[0304]
[0305] Scheme 7 describes the preparation of bicyclic substituted quinolinyl compounds (43). Suzuki coupling of the boronate compounds (40) with the bromoquinoline compounds (25) using a base such as Cs2CO3 in THF, using a suitable palladium complex known to those skilled in the art such as [bis(2-(diphenylphosphino)phenyl)ether]palladium(II) dichloride, can afford the biaryl compounds (41). Nucleophilic aromatic substitution of the chloro-moiety ortho to the quinoline nitrogen using a strong base such as LiHMDS in THF and a suitable nucleophile such as a primary or secondary alcohol (commonly known as S N AR), can produce substituted quinolinyl compounds of (42). By removing the protecting group on the amine moiety using a suitable acid such as DCM in TFA, functionalized quinolinyl compounds of (43) can be obtained.
[0306] Solution 8
[0307]
[0308] Scheme 8 depicts two routes for the preparation of bicyclic substituted quinazoline compounds (48). Chloroquinazoline compounds (39) can be subjected to S-reaction using a suitable nucleophile such as a substituted piperazine. N AR. One skilled in the art will appreciate that various non-nucleophilic bases such as, but not limited to, DIPEA, TEA, or NMM and polar aprotic solvents such as acetonitrile or DMF may be used in the reaction to afford substituted quinazolinyl compounds of (44). In one route, the compound of (44) may first undergo desulfurization using triethylsilane and PdCl2 to afford the quinazolinyl compound of (45). An alternative method of desulfurization involves oxidation of the thioether compound of (44) using mCPBA to afford the intermediate sulfone moiety, which may then be removed using conditions known to one skilled in the art such as NaBH4 in DCM / MeOH to afford the quinazolinyl compound of (45). This is then reacted with the bicyclic boronate of (40) using the Suzuki coupling conditions mentioned previously to afford the bicyclic substituted quinazolinyl compound of (47). Another route is to first use Suzuki coupling to obtain a bicyclic substituted quinazolinyl compound (46), followed by a desulfurization reaction to obtain a quinazolinyl compound (47). The amine moiety on the compound (47) can then be appropriately deprotected using methods known to those skilled in the art, such as using TFA to remove the Boc-protecting group, to obtain a substituted quinazolinyl compound (48).
[0309] Solution 9
[0310]
[0311] Scheme 9 describes the preparation of dihydrofuranoquinoline compounds (56), also prepared via two routes. One skilled in the art can select a route depending on the order in which they wish to functionalize the dihydrofuranoquinoline core. In one route, the hydroxy moiety of the quinoline compound (29) can be converted to a leaving group (LG) such as chloro. Chlorination can be accomplished using oxalyl chloride and DMF in DCM to afford the quinoline compound (49). Subsequent nucleophilic displacement with a substituted piperazine using a suitable hindered base such as DIPEA in an aprotic solvent such as DMSO at elevated temperatures ~130°C can afford the substituted quinoline compound (50). Aryl coupling of the bromo-quinoline compound (50) using the bicyclic boronate ester of (40) under Suzuki conditions can afford the biaryl compound (53). Alternatively, to first introduce the bicyclic aromatic group, Suzuki coupling of bromide (29) and boronate (40) can be accomplished using conditions well known to those skilled in the art, such as using K3PO4 as a base and the palladium complex 1,1'-bis(di-tert-butylphosphino)ferrocenepalladium dichloride and refluxing in dioxane / water to give the biaryl compound (51). The hydroxyl moiety of the quinolinyl compound (51) can then be converted to a leaving group (LG), such as chloro, bromo or triflate, by standard methods known to those skilled in the art. For example, the triflate ester can be obtained from the hydroxy-quinolinyl compound (51) by using trifluoromethanesulfonic anhydride and DMAP in DCM at 0°C, which can then be used for S-terminal reaction with substituted piperazine as described above. N AR to give the dihydrofuranoquinolyl compound (53). The compound (53) can then be oxidized using mCPBA or other suitable oxidizing agents known to those skilled in the art and using a suitable solvent if necessary to give the sulfone compound (54). The sulfone moiety can be subjected to nucleophilic displacement using a suitable nucleophile such as a primary or secondary alcohol using a strong base such as LiHMDS in THF to give the substituted quinolyl compound (55). Subsequently, removal of the protecting group can be achieved by a method appropriate to the protecting group used, such as removal of Boc using TFA in DCM to give the dihydrofuranoquinoline compound (56).
[0312] Solution 10
[0313]
[0314] Scheme 10 describes the preparation of dihydrofuranoquinazoline compounds (61) with route options to functionalize the quinazoline core in two different ways. One route to the intermediate compound (60) is to start with oxidation of the thioether compound (44) using mCPBA as mentioned above to give the sulfone compound (57). Then, nucleophilic displacement of the sulfone moiety can give the difunctionalized quinazoline compound (58). Suzuki coupling of the bromide compound (58) and the boronate compound (40) (e.g., substituted benzothiophenes, benzothiazoles, and benzofurans) can then produce the biaryl compound (60). Suzuki coupling can also be achieved in reverse by reacting the bromide of (58) with bis(neopentyl glycolato)diboron in the presence of a weak base such as KOAc and a palladium complex such as [bis(2-(diphenylphosphino)phenyl)ether]dichloropalladium(II) to form a boronate ester on the quinazoline core, which is then coupled to a Boc-protected chlorothienopyridine (e.g., tert-butyl N-(4-chlorothieno[3,2-c]pyridin-2-yl)carbamate) to afford the biaryl compound (60). Another route to the intermediate compound of (60) involves first initiating a Suzuki coupling, whereupon the bromide of (44) can be arylated with the boronate of (40) to afford the biaryl compound (46). Oxidation of the sulfide moiety on compound (46) using standard conditions as mentioned above can provide the sulfone compound (59), which can be reacted by S-reaction with a nucleophile such as a primary or secondary alcohol. N AR, the functionalized compound (60) can be obtained. Removal of the protecting group is then accomplished by methods appropriate to the protecting group employed, such as removal of Boc with TFA in DCM, to afford the dihydrofuranoquinazoline compound (61).
[0315] Preparation Example 1
[0316] 5-Fluoro-3H-isobenzofuran-1-one
[0317]
[0318] To a stirred mixture of (2-bromo-5-fluorophenyl)methanol (500 g, 2.44 mol) and TEA (474.6 mL, 3.41 mol, 1.4 eq.) in ACN (2500 mL) was added Pd(OAc)2 (10.95 g, 48.77 mmol, 0.02 eq.) and XantPhos (42.33 g, 73.16 mmol, 0.03 equiv.) at RT, then stirred at 120 °C under 10 atm of carbon monoxide for 3 days. The reaction was cooled to RT and concentrated. The residue was diluted with H2O (1,000 mL) and then extracted with EtOAc (2×1000 mL). The combined organic layers were washed with brine (2×1000 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was triturated with 10:1 hexanes / EtOAc (1,100 mL) and then filtered. The filter cake was dried at 50°C for 18 h to obtain the title compound as a yellow solid (300 g, 81%). MS (ES) m / z = 153 (M+1).
[0319] Preparation Example 2
[0320] 4-Bromo-5-fluoro-6-nitro-3H-isobenzofuran-1-one
[0321]
[0322] To a stirred mixture of 5-fluoro-3H-isobenzofuran-1-one (300 g, 1.97 mol) in H2SO4 (1,500 mL) at 65°C was added HNO3 (273.38 g, 4.348 mol, 2.2 eq.) dropwise. The reaction was stirred for 1 h and then cooled to RT. 1,3-Dibromo-5,5-dimethylimidazolidine-2,4-dione (2,255.43 g, 7.88 mol, 4 eq.) was added portionwise over 20 min and stirred at RT for ~18 h. The mixture was poured into ice / water (pretreated with 3 kg Na2SO3) and filtered. The filter cake was dissolved in EtOAc (3,000 mL), washed with saturated aqueous Na2CO3 (2×1000 mL) and brine (2×1000 mL), dried over anhydrous Na2SO4 and concentrated. The residue was triturated with 10:1 hexanes / EtOAc (660 mL), filtered and dried at 50 °C for -18 h to afford the title compound as a yellow solid (270 g, 49%) which was used in the subsequent step without further purification. 1 H NMR (400MHz, DMSO-d6) δ8.58 (s, 1H), 5.51 (s, 2H).
[0323] Preparation Example 3
[0324] 5-Chloro-6-nitro-3H-isobenzofuran-1-one
[0325]
[0326] In a 1L 3-necked round-bottom flask, a solution of 5-chloro-3H-isobenzofuran-1-one (60 g, 355.91 mmol) in HNO3 (46 mL) and H2SO4 (277 mL) was heated at 100°C for 4 h under N2. The mixture was slowly added to ice water (1 L) and stirred for 30 min. The resulting precipitate was filtered and rinsed with H2O (2×300 mL) and dried under vacuum at 45°C to give the title compound (57 g, 70%) as a yellow solid. MS (ES) m / z=214 (M+1).
[0327] Preparation Example 4
[0328] 4-Bromo-5-chloro-6-nitro-3H-isobenzofuran-1-one
[0329]
[0330] In a 1L 3-necked round-bottom flask, a solution of 5-chloro-6-nitro-3H-isobenzofuran-1-one (65 g, 283 mmol) was dissolved in H2SO4 (600 mL) and cooled to 0°C. Under N2, NBS (60 g, 337 mmol) was added in portions at a rate such that the temperature was maintained at 0°C. The reaction was then stirred at 50°C for ~18 h. The mixture was slowly added to ice water (1 L) and stirred for 30 min. The resulting precipitate was filtered and rinsed with H2O (2×300 mL) and dried in vacuo at 45°C to give the title compound (65 g, 72%) as a yellow solid. MS (ES) m / z=292 (M+1).
[0331] Preparation Example 5
[0332] 4-Bromo-5-fluoro-6-nitro-1,3-dihydroisobenzofuran
[0333]
[0334] To a stirred mixture of 4-bromo-5-fluoro-6-nitro-3H-isobenzofuran-1-one (270 g, 978 mmol) in DCM (2,500 mL) was added DIBAL-H (1 M in THF, 1,467 mL, 1.467 mol, 1.5 eq.) at -78 °C under N2. The reaction was stirred at -78 °C for 5 h and then quenched with 5N NaOH (300 mL) at -78 °C. The resulting mixture was allowed to warm to RT and then concentrated. The residue was diluted with EtOAc (2,500 mL), washed with brine (2×1000 mL), dried over anhydrous Na2SO4 and concentrated. The residue was triturated with 10:1 hexane / EtOAc (550 mL) and filtered. The solid was dried (190 g, 683.4 mmol) and then dissolved in DCM (1,500 mL) and treated with Et3SiH (662 mL, 4.10 mol, 6 eq.) dropwise at 0°C. The reaction was stirred at 0°C for 20 min. TFA (152 mL, 2.05 mol, 3 eq.) was added dropwise at 0°C. The ice bath was removed and the reaction was stirred at RT for ~18 h. The reaction was concentrated to give an oil which was diluted with EtOAc (2,000 mL), washed with saturated aqueous Na2CO3 (2×500 mL) and brine (2×500 mL), dried over anhydrous Na2SO4 and concentrated to give the title compound (110 g, 42%) which was used in the subsequent step without further purification. 1 H NMR (400MHz, DMSO-d6) δ8.16 (d, J = 6.2Hz, 1H), 5.18–5.15 (m, 2H), 5.11–5.06 (m, 2H).
[0335] Preparation Example 6
[0336] 7-Bromo-6-fluoro-1,3-dihydroisobenzofuran-5-amine
[0337]
[0338] To a stirred mixture of 4-bromo-5-fluoro-6-nitro-1,3-dihydroisobenzofuran (110 g, 420 mmol) and NH4Cl (112.3 g, 2.10 mol, 5 eq.) in EtOH (1,000 mL) and H2O (200 mL) was added Fe (117.22 g, 2.09 mol, 5 eq.) in portions at RT, followed by stirring at 80°C for ~18 h. The mixture was filtered and concentrated. The mixture was diluted with H2O (500 mL) and extracted with EtOAc (2×1000 mL). The combined organic layers were washed with brine (2×500 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified with silica gel (25% to 50% EtOAc / Hex) to give the title compound (70 g, 72%) as a yellow solid. MS (ES) m / z=231 (M+1).
[0339] Preparation Example 7
[0340] [4-Chloro-2-(hydroxymethyl)phenyl]methanol
[0341]
[0342] To a stirred mixture of LiAlH4 (1.9 L, 2.74 mol, 2 eq., 2.5 M in THF) in THF (1 L) was added dropwise 4-chlorophthalic anhydride (250 g, 1.34 mol, 1.00 eq.) in THF (500 mL) at -20 °C under N2. The resulting mixture was stirred at 45 °C under N2 for 30 min. The reaction was quenched by adding H2O (1.5 L) and 15% NaOH (500 mL) at RT. The mixture was filtered and the filter cake was washed with MTBE (3×250 mL). The filtrate was extracted with MTBE (3×1.5 L). The combined organic layers were washed with brine (2×2 L) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give the title compound (219.5 g, 93%) as an off-white solid. 1 H NMR (300MHz, DMSO-d6) δ7.45–7.36(m,2H),7.28(dd,J=8.2Hz,1H),5.40–5.13(m,2H),4.54(s,2H),4.49(s,2H).
[0343] Preparation Example 8
[0344] 5-Chloro-1,3-dihydroisobenzofuran
[0345]
[0346] To a stirred mixture of [4-chloro-2-(hydroxymethyl)phenyl]methanol (219.5 g, 1.271 mol) and dimethyl carbonate (458.2 g, 5.082 mol, 4 eq.) in ACN (3 L) was added NaOMe (137.4 g, 2.544 mol, 2 eq.) in portions at RT. The resulting mixture was stirred at 80 °C under N2 for ~18 h. The mixture was concentrated under reduced pressure, diluted with H2O (2 L) and extracted with EtOAc (3×2 L). The combined organic layers were washed with brine (2×2 L) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified with silica gel (10:1 to 8:1 hex / EtOAc) to give the title compound (165 g, 82%) as a light brown solid. 1 H NMR (300MHz, DMSO-d6) δ7.42–7.37 (m, 1H), 7.33 (d, J = 1.4Hz, 2H), 4.99 (s, 4H).
[0347] Preparation Example 9
[0348] 5-Chloro-6-nitro-1,3-dihydroisobenzofuran
[0349]
[0350] To a solution of 5-chloro-1,3-dihydroisobenzofuran (110 g, 712 mmol) in H2SO4 (700 mL) at -10°C was added a solution of KNO3 (64.74 g, 640 mmol, 0.9 eq.) in H2SO4 (200 mL) at -5°C–0°C. The resulting mixture was stirred at 0°C for another 30 min and then slowly added to stirred ice-cold H2O. The precipitated solid was collected by filtration and washed with H2O (3×1 L). The filter cake was dried in vacuo to give the title compound (110 g, 77%) as a light brown solid, which was used in the subsequent step without further purification. 1 H NMR (400MHz, DMSO-d6) δ8.05(s,1H),7.75(s,1H),5.07–5.02(m,4H).
[0351] Preparation Example 10
[0352] 4-Bromo-5-chloro-6-nitro-1,3-dihydroisobenzofuran
[0353]
[0354] To a stirred solution of 5-chloro-6-nitro-1,3-dihydroisobenzofuran (125 g, 626 mmol) in H2SO4 (700 mL) at -10°C was added 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione (179.1 g, 626.3 mmol, 1 eq.) in portions. The mixture was stirred at -10°C for 1 h and then slowly added to stirred ice-cold H2O. The precipitated solid was collected by filtration and washed with H2O (3 x 0.5 L). The filter cake was dried in vacuo and purified on silica gel (10:1 to 5:1 Hex / EtOAc) to give the title compound (83.5 g, 47.9%) as a white solid. 1 H NMR (300MHz, DMSO-d6) δ8.07 (d, J = 1.1 Hz, 1H), 5.19 (dt, J = 2.3, 1.1 Hz, 2H), 5.08 (t, 2H).
[0355] Preparation Example 11
[0356] 7-Bromo-6-chloro-1,3-dihydroisobenzofuran-5-amine
[0357]
[0358] To a stirred mixture of 4-bromo-5-chloro-6-nitro-1,3-dihydroisobenzofuran (37.0 g, 133 mmol) and NH4Cl (42.64 g, 797.2 mmol, 6 eq.) in EtOH (200 mL) and H2O (40 mL) was added Fe (44.52 g, 797.2 mmol, 6 equiv.) in portions at RT. The resulting mixture was stirred at 80 °C for ~18 h. The resulting mixture was filtered hot and the filter cake was washed with EtOAc (3 x 500 mL). The filtrate was concentrated under reduced pressure and purified with silica gel (15:1 to 10:1 Hex / EtOAc) to give the title compound (25 g, 76%) as a light yellow solid. MS (ES) m / z = 248 (M+1).
[0359] Preparation Example 12
[0360] N-(7-Bromo-6-chloro-1,3-dihydroisobenzofuran-5-yl)-3-ethoxy-prop-2-enamide
[0361]
[0362] To a stirred solution of 7-bromo-6-chloro-1,3-dihydroisobenzofuran-5-amine (6.00 g, 24.1 mmol) and 3-ethoxyprop-2-enoyl chloride (4.06 g, 30.2 mmol) in THF (50 mL) was added pyridine (3.82 g, 48.3 mmol) dropwise at 0°C. The resulting mixture was stirred at RT for 2 h. The resulting mixture was concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (5:1) to give the product (6.00 g, 66.0%) as a yellow solid. MS (ES) m / z = 346 (M+1).
[0363] Preparation Example 13
[0364] N-(7-Bromo-6-fluoro-1,3-dihydroisobenzofuran-5-yl)-3-ethoxy-prop-2-enamide
[0365]
[0366] In a manner similar to the method of Preparation Example 12, the title compound (1.4 g, 89%) was obtained as a light yellow solid using 7-bromo-6-fluoro-1,3-dihydroisobenzofuran-5-amine. MS (ES) m / z = 332 (M+1).
[0367] Preparation Example 14
[0368] 4-Bromo-5-chloro-3,6-dihydro-1H-furo[3,4-f]quinolin-7-one
[0369]
[0370] To a stirred solution of H2SO4 (20 mL) at 0°C was added N-(7-bromo-6-chloro-1,3-dihydroisobenzofuran-5-yl)-3-ethoxy-prop-2-enamide (6.10 g, 17.6 mmol) in portions. The resulting mixture was stirred at RT for ~18 h. The mixture was slowly added to stirred ice-cold water (200 mL). The precipitated solid was collected by filtration and washed with H2O (3×100 mL). The filter cake was dried in vacuo to give the product (5.00 g, 87.0%) as a yellow solid. MS (ES) m / z=300 (M+1).
[0371] Preparation Example 15
[0372] 4-Bromo-5-fluoro-3,6-dihydro-1H-furo[3,4-f]quinolin-7-one
[0373]
[0374] In a manner similar to the method described in Preparation 14, the title compound (1.2 g, quantitative) was obtained as a brown solid using N-(7-bromo-6-fluoro-1,3-dihydroisobenzofuran-5-yl)-3-ethoxy-prop-2-enamide. MS (ES) m / z = 284 (M+1).
[0375] Preparation Example 16
[0376] 4-Bromo-5,7-dichloro-1,3-dihydrofuro[3,4-f]quinoline
[0377]
[0378] To a stirred solution of 4-bromo-5-chloro-3,6-dihydro-1H-furo[3,4-f]quinolin-7-one (5.00 g, 16.6 mmol) in DMF (20 mL) was added POCl3 (9.30 mL, 99.8 mmol) dropwise at 0°C. The resulting mixture was stirred at 90°C for 2 h. The mixture was slowly added to stirred ice-cold water (200 mL). The precipitated solid was collected by filtration and washed with H2O (3×100 mL). The filter cake was dried in vacuo to give the product (3.50 g, 62.7%) as a yellow solid. MS (ES) m / z=318 (M+1).
[0379] Preparation Example 17
[0380] 4-Bromo-7-chloro-5-fluoro-1,3-dihydrofuro[3,4-f]quinoline
[0381]
[0382] To a stirred suspension of 6-bromo-5-chloro-3-ethylthio-7,9-dihydrofuro[3,4-f]quinazolin-1-ol (1.2 g, 4.2 mmol) in DCM (40 mL) was added (chloromethylene)dimethylammonium chloride (2.2 g, 17 mmol, 4 eq.) and stirred at RT for ~18 h. The reaction was diluted with DCM and washed with H2O and brine. The organic layer was dried over Na2SO4, filtered and concentrated to a solid which was triturated with a small amount of DCM. The solid was filtered, washed with a small amount of DCM and air dried to give Batch 1. The filtrate was concentrated and purified on silica gel eluting with EtOAc / hexanes (0% to 80%) to give Batch 2. The two batches were combined to give the title compound (1.0 g, 78%) as a brown solid. MS (ES) m / z = 304 (M+1).
[0383] Preparation Example 18
[0384] 6-Amino-4-bromo-5-fluoro-3H-isobenzofuran-1-one
[0385]
[0386] To a suspension of 4-bromo-5-fluoro-6-nitro-3H-isobenzofuran-1-one (1.11 g, 4.02 mmol) in AcOH (4 mL), H2O (2 mL) and EtOH (20 mL) was added iron (1.0 g, 18 mmol) and heated at 70°C for 2 h. The reaction was cooled to RT, partitioned between DCM and saturated aqueous NaHCO3, and filtered through a pad of celite. The pad was rinsed with DCM, the filtrate was partitioned, the organic layer was dried over MgSO4 and concentrated to give the title compound (0.90 g, 91%) as a white solid. MS (ES) m / z = 246 (M-1).
[0387] Preparation Example 19
[0388] 6-Amino-4-bromo-5-chloro-3H-isobenzofuran-1-one
[0389]
[0390] To a mixture of 4-bromo-5-chloro-6-nitro-3H-isobenzofuran-1-one (7.98 g, 27.3 mmol) in EtOH (200 mL) and H2O (40 mL) was added NH4Cl (5.84 g, 109 mmol) followed by iron powder (6.09 g, 109 mmol). The mixture was stirred in an oil bath at 80 °C for 20 h. The mixture was filtered through a pad of celite and washed with acetone. The filtrate was concentrated to ~50 mL. The resulting precipitate was collected by filtration and dried in vacuo overnight to give the first batch of product (2.57 g) as a beige solid. The celite mixture was stirred in acetone / MeOH (2 / 1) and filtered. The process was repeated twice. The combined filtrate was concentrated and dried in a vacuum oven at 60 °C overnight to give the second batch of product (3.70 g). The batches were combined to give the title compound (6.27 g, 87.5%). MS (ES) m / z = 279 (M + H2O + 1).
[0391] Preparation Example 20
[0392] N-(7-Bromo-6-fluoro-3-oxo-1H-isobenzofuran-5-yl)-N-tert-butoxycarbonyl-carbamic acid tert-butyl ester
[0393]
[0394] A mixture of 6-amino-4-bromo-5-fluoro-3H-isobenzofuran-1-one (36.0 g, 146 mmol), di-tert-butyl dicarbonate (100 g, 444 mmol) and DMAP (4.50 g, 37.0 mmol) in ACN (1,000 mL) was heated to reflux. After reflux for 30 min, the reaction mixture was cooled to RT. The solvent was removed under reduced pressure and the residue was dissolved in DCM (1,000 mL), washed with ice-cold 10% citric acid, saturated aqueous NaHCO3, brine, then dried over MgSO4, filtered and concentrated. The crude material was purified by silica gel column chromatography (100% A to 100% B; A = 4% MTBE and 20% DCM in Hex, B = 10% MTBE and 20% DCM in Hex) to give the title compound (36.0 g, 55%). 1 H NMR (300MHz, DMSO-d6) δ8,11(s,1H),5.49(s,2H),1.40(s,18H).
[0395] Preparation Example 21
[0396] N-(7-Bromo-6-chloro-3-oxo-1H-isobenzofuran-5-yl)-N-tert-butoxycarbonyl-carbamic acid tert-butyl ester
[0397]
[0398] In a similar manner to the method of Preparation 20, 6-amino-4-bromo-5-chloro-3H-isobenzofuran-1-one was used to obtain the title compound (34.6 g, 61%) as an off-white solid. 1 H NMR (300MHz, DMSO-d6) δ8.10(s,1H),5.48(s,2H),1.40(s,18H).
[0399] Preparation Example 22
[0400] tert-Butyl N-(7-bromo-6-fluoro-3-hydroxy-1,3-dihydroisobenzofuran-5-yl)carbamate
[0401]
[0402] To a solution of N-(7-bromo-6-fluoro-3-oxo-1H-isobenzofuran-5-yl)-N-tert-butyloxycarbonyl-carbamate (36.0 g, 80.7 mmol) in DCM (1,600 mL) at -70°C was added DIBAL-H (1 M in DCM, 245 mL, 245 mmol) over 2 h. After addition, the reaction mixture was stirred at -70°C for 1 h. The reaction was quenched by the addition of NaOH solution (1 M in H2O, 164 mL, 164 mmol) at -70°C. The mixture was diluted with DCM (1,000 mL) and stirred to RT. After the addition of MgSO4 (200 g), the mixture was stirred for 10 min and then left to stand overnight at RT with MgSO4. The mixture was filtered through celite and washed with a 10% solution of MeOH in DCM (1,000 mL). The filtrate was concentrated and purified by silica gel column chromatography (5-40% EtOAc / Hex) to give the title compound (25.0 g, 89%) as a white solid. MS (ES) m / z = 346 (M-1).
[0403] Preparation Example 23
[0404] tert-Butyl N-(7-bromo-6-chloro-3-hydroxy-1,3-dihydroisobenzofuran-5-yl)carbamate
[0405]
[0406] In a manner similar to the method of Preparation Example 22, the title compound (5.10 g, 65.4%) was obtained as a white solid using N-(7-bromo-6-chloro-3-oxo-1H-isobenzofuran-5-yl)-N-tert-butoxycarbonyl-carbamic acid tert-butyl ester. MS (ES) m / z = 346 (M-H2O+1).
[0407] Preparation Example 24
[0408] tert-Butyl N-[7-bromo-3-(cyanomethyl)-6-fluoro-1,3-dihydroisobenzofuran-5-yl]carbamate
[0409]
[0410] To the flask, tert-butyl N-(7-bromo-6-fluoro-3-hydroxy-1,3-dihydroisobenzofuran-5-yl)carbamate (9.70 g, 27.9 mmol), THF (200 mL), diethyl cyanomethylphosphonate (7.00 mL, 42.3 mmol) and Cs2CO3 (10.0 g, 30.7 mmol) were added. The flask was equipped with a condenser and the mixture was heated to reflux. After 3 h, the mixture was cooled and filtered through diatomaceous earth and rinsed with EtOAc. The combined filtrate and washings were concentrated. The crude oil was diluted with EtOAc (500 mL) and H2O (500 mL) was added. The mixture was transferred to a separatory funnel and the layers were separated. The aqueous layer was extracted with EtOAc (500 mL), and the combined organic layer was washed with brine, dried with MgSO4, filtered and concentrated. The crude material was purified by flash column chromatography on silica gel eluting with 5-40% EtOAc / Hex to afford the title compound (9.15 g, 89%) as a white solid. 1 H NMR (300MHz, DMSO-d6) δ9.28(s,1H),7.68(s,1H),5.52(s,H),5.02(m,2H),3.18(m,2H),1.49(s,9H).
[0411] Preparation Example 25
[0412] tert-Butyl N-[7-bromo-6-chloro-3-(cyanomethyl)-1,3-dihydroisobenzofuran-5-yl]carbamate
[0413]
[0414] In a manner similar to the method of Preparation Example 24, the title compound (3.92 g, 72%) was obtained as a white solid using tert-butyl N-(7-bromo-6-chloro-3-hydroxy-1,3-dihydroisobenzofuran-5-yl)carbamate. MS (ES) m / z = 385 (M-1).
[0415] Preparation Example 26
[0416] 2-(6-Amino-4-bromo-5-fluoro-1,3-dihydroisobenzofuran-1-yl)acetonitrile
[0417]
[0418] To a suspension of tert-butyl N-[7-bromo-3-(cyanomethyl)-6-fluoro-1,3-dihydroisobenzofuran-5-yl]carbamate (9.10 g, 24.5 mmol) in MeOH (150 mL) cooled in an ice bath was added HCl solution (4 M in 1,4-dioxane, 64.0 mL, 256 mmol). The reaction was stirred at RT for 6 h. The mixture was cooled in an ice bath and neutralized first with 2N NaOH solution and then with saturated aqueous NaHCO3. The mixture was concentrated and the resulting solid was collected and dried in vacuo at 60°C overnight to give the title compound as a white solid (6.10 g, 92%). MS (ES) m / z = 269 (M-1).
[0419] Preparation Example 27
[0420] 2-(6-Amino-4-bromo-5-chloro-1,3-dihydroisobenzofuran-1-yl)acetonitrile
[0421]
[0422] In a manner similar to the method of Preparation Example 26, the title compound (2.64 g, 99%) was obtained as an off-white solid using tert-butyl N-[7-bromo-6-chloro-3-(cyanomethyl)-1,3-dihydroisobenzofuran-5-yl]carbamate. MS (ES) m / z = 287 (M+1).
[0423] Preparation Example 28
[0424] 7-Methyl-6-nitro-isochroman-1-one
[0425]
[0426] To a stirred mixture of 3-methyl-4-nitrobenzoic acid (70.0 g, 386 mmol) and N-acetyl-L-leucine (13.4 g, 77.3 mmol) in hexafluoroisopropanol (750 mL) was added KOAc (37.9 g, 386 mmol) and Pd(OAc)2 (8.68 g, 38.6 mmol) followed by ethylene oxide (155 mL, 386 mmol, 1 eq., 2.5 M in THF) at RT. The reaction mixture was stirred at 80 °C under N2 for 8 h. The mixture was diluted with EtOAc (1,000 mL). The organic layer was washed with brine (500 mL), dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE:EtOAc (3:1 to 1:1) to give the product (56.0 g, 52.4%) as a yellow solid. MS (ES) m / z = 249 (M + 1).
[0427] Preparation Example 29
[0428] 7-Methyl-6-nitro-isochroman
[0429]
[0430] To a stirred mixture of 7-methyl-6-nitro-isochroman-1-one (66.0 g, 319 mmol) in THF (800 mL) at -78 °C under N2 was added LiBH4 (2M in THF, 400 mL, 800 mmol) dropwise. The reaction mixture was warmed to RT and stirred for 3 h. The reaction was diluted with saturated aqueous NH4Cl (300 mL) and extracted with EtOAc (2×600 mL). The combined organic layers were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. To the crude 2-[2-(hydroxymethyl)-4-methyl-5-nitrophenyl]ethanol (50.0 g, 237 mmol) was added 4-methylbenzene-1-sulfonic acid (44.8 g, 260 mmol) and toluene (500 mL). The resulting reaction mixture was heated at 115 °C for ~18 h. The reaction was cooled to RT. The mixture was diluted with EtOAc (1,000 mL) and washed with brine (500 mL), then dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE:EtOAc (3:1 to 1:1) to give the product (30.0 g, 36.3%) as a yellow solid. 1 H NMR (300MHz, CDCl3) δ7.81(s,1H),6.96(s,1H),4.82–4.74(m,2H),4.02–3.96(m,2H),2.96–2.82(m,2H),2.5(s,3H).
[0431] Preparation Example 30
[0432] 8-Bromo-7-methyl-6-nitro-isochroman
[0433]
[0434] To a mixture of 7-methyl-6-nitro-isochroman (30 g, 150 mmol) in concentrated H2SO4 (300 mL) was added NBS (32.1 g, 180 mmol) in portions at RT. The reaction was stirred at RT for ~18 h. The reaction mixture was poured into ice water (500 mL) and filtered. The filter cake was washed with a saturated aqueous solution of Na2CO3 (2×50 mL), then dissolved in EtOAc (500 mL), washed with brine (2×50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE:EtOAc (3:1 to 1:1) to give the product (23.0 g, 56.5%) as a yellow solid. 1 H NMR (300MHz, CDCl3) δ7.58(s,1H),4.78–4.68(m,2H),4.02–3.92(m,2H),2.98–2.86(m,2H),2.57(s,3H).
[0435] Preparation Example 31
[0436] 8-Bromo-7-methyl-isochroman-6-amine
[0437]
[0438] To a mixture of 8-bromo-7-methyl-6-nitro-isochroman (23.0 g, 84.5 mmol) and NH4Cl (22.6 g, 423 mmol) in EtOH (250 mL) and H2O (50 mL) was added iron powder (23.6 g, 423 mmol) at RT. The resulting reaction mixture was heated at 80°C for 6 h. The mixture was filtered and the filter cake was washed with EtOAc (2×200 mL). The filtrate was diluted with EtOAc (100 mL), washed with brine (500 mL), dried over anhydrous Na2SO4, concentrated and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE:EtOAc (2:1 to 1:2) to give the product (17.0 g, 83%) as a yellow solid. MS (ES) m / z=242 (M+1).
[0439] Preparation Example 32
[0440] Ethyl N-[(7-bromo-6-fluoro-1,3-dihydroisobenzofuran-5-yl)carbamothioyl]carbamate
[0441]
[0442] To a solution of 7-bromo-6-fluoro-1,3-dihydroisobenzofuran-5-amine (20.4 g, 87.9 mmol) in DCM (550 mL) was slowly added ethoxycarbonyl isothiocyanate (9.7 mL, 82 mmol, 0.93 eq.) via an addition funnel followed by stirring at RT for ~4 h. The solid was filtered. The filtrate was concentrated, suspended in DCM (100 mL) and hexane (350 mL) and stirred at RT. The resulting filtered solid and the previous filtered solid were dried under vacuum at 50 °C for 2 h. The batches were combined to give the title compound (32.6 g, quantitative yield) as a white solid. MS (ES) m / z = 363 (M+1).
[0443] The following compounds in Table 1 were prepared in a manner similar to that described in Preparation 32. The compounds were purified by a variety of methods that would be apparent to those skilled in the art.
[0444] Table 1:
[0445]
[0446] Preparation Example 37
[0447] (NZ)-N-[[(7-Bromo-6-fluoro-1,3-dihydroisobenzofuran-5-yl)amino]-ethylthio-methylene]carbamic acid ethyl ester
[0448]
[0449] A suspension of ethyl N-[(7-bromo-6-fluoro-1,3-dihydroisobenzofuran-5-yl)carbamothioyl]carbamate (32.6 g, 89.8 mmol) and acetone (450 mL) was added to a 2 L 3-neck round bottom flask equipped with an overhead stirrer, a dropping funnel, and a thermocouple. Solid K2CO3 (37.2 g, 269 mmol, 3.00 eq.) was added thereto in several portions, and then EtI (7.2 mL, 90 mmol, 1.0 eq.) was added dropwise over 20 min. The mixture was stirred at RT for ~18 h. The solid was filtered, and the filtrate was concentrated and partitioned between DCM (500 mL) and H2O (500 mL). The organic layer was further washed with brine and dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified by silica gel (0 to 30% EtOAc / Hex) to give the title compound (30.9 g, 85.6%) as a white solid. MS (ES) m / z = 391 (M+1).
[0450] The following compounds in Table 2 were prepared in a manner similar to that described in Preparation 37. A variety of methods were used to purify the compounds, which methods would be apparent to those skilled in the art.
[0451] Table 2:
[0452]
[0453] Preparation Example 42
[0454] 6-Bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-ol
[0455]
[0456] A 2L 4-necked round bottom flask was equipped with an overhead stirrer, a dropping funnel, a N2 inlet tube, and a thermocouple and purged with N2. NMP (anhydrous, 300 mL) was added. The mixture was heated to 175°C. In a second flask, (NZ)-N-[[(7-bromo-6-fluoro-1,3-dihydroisobenzofuran-5-yl)amino]-ethylthio-methylene]carbamic acid ethyl ester (22.63 g, 57.83 mmol) and NMP (anhydrous, 100 mL) were combined under N2 and stirred until a homogeneous solution was obtained. When the first flask reached 175°C, the contents of the second flask were poured into the dropping funnel and quickly added dropwise to the hot NMP. After 30 min, the heat was turned off and the reaction was cooled to 45°C. H2O (500 mL) was slowly added and the mixture was stirred at RT for 1 h. The solid was filtered, rinsed with H2O (300 mL) and dried under vacuum at 50°C for ~18 h to give the title compound (15.2 g, 73%) as an off-white solid. MS (ES) m / z = 363 (M+1).
[0457] The following compounds in Table 3 were prepared in a manner similar to that described in Preparation 42. A variety of methods were used to purify the compounds, which methods would be apparent to those skilled in the art.
[0458] Table 3:
[0459]
[0460]
[0461] Preparation Example 47
[0462] 7-Bromo-6-fluoro-4-iodo-1,3-dihydroisobenzofuran-5-amine
[0463]
[0464] A mixture of 7-bromo-6-fluoro-1,3-dihydroisobenzofuran-5-amine (15.0 g, 64.6 mmol) and NIS (16.0 g, 71.1 mmol) in CHCl3 (400 mL) was stirred at 50°C under N2 for ~18 h. The resulting mixture was concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluting with PE / EtOAc (10:1-5:1) to give the product (16.0 g, 69.2%) as an orange solid. MS (ES) m / z = 358 (M+1).
[0465] Preparation Example 48
[0466] 7-Bromo-6-chloro-4-iodo-1,3-dihydroisobenzofuran-5-amine
[0467]
[0468] In a manner similar to the method of Preparation Example 47, the title compound (0.19 g, 60%) was obtained as a white solid using 7-bromo-6-chloro-1,3-dihydroisobenzofuran-5-amine. MS (ES) m / z = 372 (M+1).
[0469] Preparation Example 49
[0470] 5-Amino-7-bromo-6-fluoro-1,3-dihydroisobenzofuran-4-carboxylic acid methyl ester
[0471]
[0472] To a stirred solution of 7-bromo-6-fluoro-4-iodo-1,3-dihydroisobenzofuran-5-amine (1.62 g, 4.53 mmol) in MeOH (20 mL) and DMF (20 mL) was added TEA (1.89 mL, 13.6 mmol) and Pd(dppf)Cl2 (331 mg, 0.45 mmol) at RT under CO atmosphere. The mixture was stirred at 60 °C under CO atmosphere for ~18 h using a CO balloon. The resulting mixture was concentrated under reduced pressure and diluted with EtOAc (300 mL). The mixture was washed with H2O (3×200 mL), brine (200 mL), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc in PE (20% to 40%, gradient over 30 min) to give the product (1.00 g, 76.1%) as a yellow solid. MS (ES) m / z = 290 (M + 1).
[0473] Preparation Example 50
[0474] 5-Amino-7-bromo-6-chloro-1,3-dihydroisobenzofuran-4-carboxylic acid methyl ester
[0475]
[0476] In a manner similar to the method of Preparation Example 49, the title compound (6.2 g, 58%) was obtained as a pale yellow solid using 7-bromo-6-chloro-4-iodo-1,3-dihydroisobenzofuran-5-amine. MS (ES) m / z = 306 (M+1).
[0477] Preparation Example 51
[0478] 7-Bromo-4-(1-ethoxyvinyl)-6-fluoro-1,3-dihydroisobenzofuran-5-amine
[0479]
[0480] To a stirred mixture of 7-bromo-6-fluoro-4-iodo-1,3-dihydroisobenzofuran-5-amine (6.00 g, 16.8 mmol) and tributyl(1-ethoxyvinyl)stannane (22.7 g, 62.9 mmol) in DMF (60 mL) was added Pd(PPh3)4 (3.88 g, 3.34 mmol) in portions at RT. The reaction was then stirred at 80 °C for ~18 h. The mixture was cooled to RT and extracted with EtOAc (200 mL). The organic layer was washed with H2O (3×50 mL), brine (50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give the product (5.07 g, quantitative yield), which was used in the subsequent step without further purification. MS (ES) m / z=301 (M+1).
[0481] Preparation Example 52
[0482] 1-(5-Amino-7-bromo-6-fluoro-1,3-dihydroisobenzofuran-4-yl)ethanone
[0483]
[0484] To a stirred mixture of 7-bromo-4-(1-ethoxyvinyl)-6-fluoro-1,3-dihydroisobenzofuran-5-amine (5.00 g, 16.6 mmol) in THF (50 mL) at 0°C was added 1 M HCl (50 mL) in water, followed by stirring at RT for 3 h. The resulting mixture was extracted with EtOAc (100 mL), i.e., the organic layer was washed with 1 M aqueous Na2CO3 solution (100 mL), brine (50 mL), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE:EtOAc (3:1 to 1:1) to give the product (2.00 g, 44.1%) as a yellow solid. MS (ES) m / z = 274 (M+1).
[0485] Preparation Example 53
[0486] 6-Bromo-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-ol
[0487]
[0488] A mixture of methyl 5-amino-7-bromo-6-fluoro-1,3-dihydroisobenzofuran-4-carboxylate (6.00 g, 20.7 mmol) and formamide (48.0 mL, 1,200 mmol) was stirred at 160 °C under N2 for 12 h. The mixture was cooled to RT and diluted with H2O (300 mL) at 0 °C. The precipitated solid was collected by filtration and washed with H2O (3×50 mL). The solid was dried under vacuum to give the product (5.2 g, 88.1%) as a brown solid. MS (ES) m / z=285 (M+1).
[0489] Preparation Example 54
[0490] 6-Bromo-5-chloro-7,9-dihydrofuro[3,4-f]quinazolin-1-ol
[0491]
[0492] In a manner similar to the method of Preparation Example 53, the title compound (3.5 g, 58%) was obtained as a black solid using 5-amino-7-bromo-6-chloro-1,3-dihydroisobenzofuran-4-carboxylic acid methyl ester. MS (ES) m / z = 301 (M+1).
[0493] Preparation Example 55
[0494] 4-Bromo-5-fluoro-1,3-dihydrofuro[3,4-f]cinnolin-9-ol
[0495]
[0496] To a stirred mixture of 1-(5-amino-7-bromo-6-fluoro-1,3-dihydroisobenzofuran-4-yl)ethanone (2.00 g, 7.30 mmol) in TFA (40 mL) was added NaNO2 (0.600 g, 8.76 mmol) at RT and stirred at 70°C for 2 h. The reaction was cooled to RT and then concentrated under reduced pressure, H2O (100 mL) was added, the resulting mixture was extracted with EtOAc (2×100 mL), and the combined organic layers were washed with brine (50 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluting with DCM:MeOH (10:1) to give the product (1.20 g, 57.7%) as a yellow solid. MS (ES) m / z=285 (M+1).
[0497] Preparation Example 56
[0498] 6-Bromo-5-fluoro-3-methyl-7,9-dihydrofuro[3,4-f]quinazolin-1-ol
[0499]
[0500] A stirred mixture of methyl 5-amino-7-bromo-6-fluoro-1,3-dihydro-2-benzofuran-4-carboxylate (350 mg, 1.21 mmol) and ACN (594 mg, 14.5 mmol) in 4M HCl (10 mL) in 1,4-dioxane was heated at 100°C under N2. The resulting mixture was stirred at 100°C under N2 for ~18 h. The mixture was diluted with H2O (100 mL) and extracted with EtOAc (2×50 mL). The organic layer was concentrated under reduced pressure to give the product (290 mg, 80.4%) as a yellow solid. MS (ES) m / z=299 (M+1).
[0501] Preparation Example 57
[0502] 5-[Bis(methylthio)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione
[0503]
[0504] To a stirred mixture of Meldrum acid (20 g, 138.76 mmol) and TEA (42.13 g, 416.30 mmol, 3 eq.) in DMSO (100 mL) was added CS2 (15.85 g, 208.15 mmol, 1.5 eq.). The resulting mixture was stirred at RT under N2 for 3 h. CH3I (59.09 g, 416.30 mmol, 3 eq.) was added dropwise at 0°C. The temperature was allowed to warm to RT and the reaction was stirred for ~18 h. The resulting mixture was diluted with EtOAc (1,000 mL), washed with H2O (2 x 200 mL), then with brine (200 mL), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified on silica gel eluting with PE:EtOAc (4:1 to 2:1) to give the title compound (23 g, 67%) as a yellow solid. 1 H NMR(400MHz,DMSO-d6)δ2.64(s,6H),1.68(s,6H).
[0505] Preparation Example 58
[0506] 5-[[(7-Bromo-6-chloro-1,3-dihydroisobenzofuran-5-yl)amino]-methylthio-methylene]-2,2-dimethyl-1,3-dioxane-4,6-dihydro-
[0507] ketone
[0508]
[0509] A stirred mixture of 5-[bis(methylthio)methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione (16.49 g, 66.40 mmol, 1.1 eq.) and 7-bromo-6-chloro-1,3-dihydroisobenzofuran-5-amine (15 g, 60 mmol, 1 eq.) in toluene (150 mL) was heated at 80 ° C for 2 days. The reaction mixture was concentrated under reduced pressure and the residue was purified by trituration with 10:1 PE:EtOAc (250 mL). The solid was collected by filtration and dried in vacuo to give the title compound (20 g, 73%) as a brown solid. 1 H NMR (400MHz, DMSO-d6) δ11.97(s,1H),7.52(s,1H),5.14(s,2H),5.03(s,2H),2.37(s,3H),1.67(s,6H).
[0510] Preparation Example 59
[0511] 4-Bromo-5-chloro-7-methylthio-1,3-dihydrofuro[3,4-f]quinolin-9-ol
[0512]
[0513] A solution of 5-[[(7-bromo-6-chloro-1,3-dihydroisobenzofuran-5-yl)amino]-methylthio-methylene]-2,2-dimethyl-1,3-dioxane-4,6-dione (18 g, 40 mmol, 1 eq.) in diphenyl ether (200 mL) was stirred at 180°C for 1 h. The reaction was allowed to cool to RT, then diluted with PE (500 mL) and stirred at RT for 20 min. After filtration, the filter cake was washed with PE (2×50 mL) and dried under reduced pressure to give the title compound (11.3 g, 81%) as a yellow solid, which was used in the next step without further purification. MS (ES) m / z=346 (M+1).
[0514] Preparation Example 60
[0515] 6-Bromo-1-chloro-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline
[0516]
[0517] To a 5 L 3-neck round bottom flask equipped with a dropping funnel, thermocouple, and overhead stirrer was added a solution of DMF (50 mL, 646 mmol, 4 eq.) in DCM (1,000 mL) and placed in an ice / water bath and cooled to ~4 °C. Oxalyl chloride (50.0 mL, 576 mmol, 4 eq.) was added dropwise via an addition funnel over ~40 min. Upon completion of the addition, the reaction was stirred at ~4 °C for 15 min. Solid 6-bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-ol (50.4 g, 140 mmol) was added to the reaction mixture in multiple portions and the resulting suspension was stirred at ~4 °C for 30 min. The ice bath was removed and the reaction was warmed to RT and stirred for 1 h. H2O (1 L) was then added and the mixture was stirred for 15 min. The mixture was partitioned, and the organic layer was washed with brine (1 L), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified on silica gel using DCM / Hex (60% to 90%) to give the title compound (45.1 g, 89%) as a white solid. MS (ES) m / z = 363 (M+1).
[0518] The following compounds in Table 4 were prepared in a manner similar to that described in Preparation 60. A variety of methods were used to purify the compounds, which methods would be apparent to those skilled in the art.
[0519] Table 4:
[0520]
[0521]
[0522] a After removing the ice bath, the reaction was heated at 37 °C for -24 h.
[0523] Preparation Example 66
[0524] 2-(6-Bromo-1-chloro-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-9-yl)acetonitrile
[0525]
[0526] 2-(6-bromo-3-ethylthio-5-fluoro-1-hydroxy-7,9-dihydrofurano[3,4-f]quinazolin-9-yl)acetonitrile (4.6 g, 12 mmol) was added in portions to a solution of DMF (60 mL) and POCl3 (50.00 mL, 538 mmol). The mixture was heated at 90°C in an oil bath for 1 h. The reaction mixture was cooled to RT and then slowly added to an ice-water mixture with stirring. The resulting solid was collected by filtration, washed with cold water, and dried overnight in a vacuum oven at 55°C to give the title compound (4.5 g, 75%) as a light brown solid. MS (ES) m / z = 402 (M+1).
[0527] Preparation Example 67
[0528] 2-(6-Bromo-1,5-dichloro-3-ethylthio-7,9-dihydrofuro[3,4-f]quinazolin-9-yl)acetonitrile
[0529]
[0530] In a manner similar to the method of Preparation Example 66, the title compound (0.9 g, 81%) was obtained as an off-white solid using 2-(6-bromo-5-chloro-3-ethylthio-1-hydroxy-7,9-dihydrofuro[3,4-f]quinazolin-9-yl)acetonitrile. MS (ES) m / z = 418 (M+1).
[0531] Preparation Example 68
[0532] 6-Bromo-3-ethylthio-5-methyl-9,10-dihydro-7H-pyrano[4,3-f]quinazoline
[0533]
[0534] A mixture of 6-bromo-1-chloro-3-ethylthio-5-methyl-9,10-dihydro-7H-pyrano[4,3-f]quinazoline (1.10 g, 2.94 mmol) and TMEDA (500 mg, 4.30 mmol) in THF (20 mL) was purged with argon. Pd(ddpf)Cl2·DCM complex (120 mg, 0.144 mmol) and NaBH3CN (280 mg, 4.46 mmol) were added. The reaction mixture was purged with argon again and heated to 45 ° C. After 2 h, the reaction mixture was cooled to RT and diluted with EtOAc, washed with saturated aqueous NH4Cl solution and brine, and dried over anhydrous Na2SO4. The mixture was dried, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc (0 to 40%) in hexane to give the product (998 mg, quantitative yield) as a yellow solid. MS (ES) m / z = 339 (M + 1).
[0535] Preparation Example 300
[0536] 6-Bromo-5-chloro-3-ethylthio-7,9-dihydrofuro[3,4-f]quinazoline
[0537]
[0538] In a manner similar to the method of Preparation Example 68, 6-bromo-1,5-dichloro-3-ethylthio-7,9-dihydrofuro[3,4-f]quinazoline was used to obtain the title compound (0.38 g, 51%) as a white solid. MS (ES) m / z = 345, 347 (M+1, Br).
[0539] Preparation Example 301
[0540] 6-Bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline
[0541]
[0542] In a manner similar to that of Preparation Example 68, the title compound (1.00 g, 92%) was obtained using 6-bromo-1-chloro-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline. MS (ES) m / z = 329, 331 (M+1, Br).
[0543] Preparation Example 69
[0544] 4-Bromo-5-fluoro-benzothiophene-2-carboxylic acid methyl ester
[0545]
[0546] A solution of methyl thioglycolate (0.18 mL, 2.0 mmol, 1 eq.) in THF (5 mL) was purged with N2, to which NaH (60 mass %) (0.101 g, 2.53 mmol, 1.24 eq.) in mineral oil was added at RT. Gas evolution was observed and a precipitate formed in the flask. The reaction was stirred at RT for 20 min. A solution of 2-bromo-3,6-difluorobenzaldehyde (0.475 g, 2.04 mmol) in THF (5 mL) was slowly added via a syringe over ~2 min. The reaction was stirred at RT for 9 h. Additional methyl thioglycolate (0.1 mL, 1 mmol, 0.5 eq.) and sodium hydride (60 mass %) (0.050 g, 1.3 mmol, 0.6 eq.) in mineral oil were added and stirring was continued at RT for ~18 h. The mixture was diluted with EtOAc and washed with saturated aqueous NH4Cl and brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified on silica gel using 2% MTBE / Hex to give the title compound (0.346 g, 59%) as a white solid. 1 H NMR (400MHz, DMSO-d6) δ8.23–8.19(dd,J=4.49,8.9Hz,1H),8.05(s,1H),7.62(t,J=9.0Hz,1H),3.93(s,3H).
[0547] Preparation Example 70
[0548] 4-Bromo-5-fluoro-benzothiophene-2-carboxylic acid
[0549]
[0550] To a solution of 4-bromo-5-fluoro-benzothiophene-2-carboxylic acid methyl ester (19.2 g, 66.4 mmol, 1 eq.) in MeOH (130 mL) and THF (130 mL) was added 5N NaOH (66 mL, 330 mmol, 5 eq.) and stirred at RT for 40 min. The mixture was concentrated and H2O (500 mL) was added. The pH was adjusted to ~2 using 5N HCl. The mixture was extracted with EtOAc (2×500 mL) and the combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated. The solid was dried under vacuum at 50°C to give the title compound (17.6 g, 96%) as a white solid. MS (ES) m / z=229 (M-1-CO2).
[0551] Preparation Example 71
[0552] N-(4-Bromo-5-fluoro-benzothiophen-2-yl)carbamic acid tert-butyl ester
[0553]
[0554] To a solution of 4-bromo-5-fluoro-benzothiophene-2-carboxylic acid (1.5 g, 5.5 mmol) in tert-butanol (30 mL) was added TEA (1.5 mL, 11 mmol, 2.0 eq.) and diphenylphosphoryl azide (1.5 mL, 6.9 mmol, 1.3 eq.) and heated at 95°C for 1 h. The mixture was cooled and concentrated. The residue was purified on silica gel using MTBE / Hex (4% to 20%) to give the title compound (0.987 g, 52%) as a white solid. MS (ES) m / z = 290 (M+1).
[0555] Preparation Example 72
[0556] tert-Butyl N-[4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5-fluoro-benzothiophen-2-yl]carbamate
[0557]
[0558] A mixture of tert-butyl N-(4-bromo-5-fluoro-benzothiophen-2-yl)carbamate (3.08 g, 8.90 mmol) and bis(neopentyl glycolate)diboron (4.02 g, 17.8 mmol, 2 eq.) and KOAc (2.62 g, 26.7 mmol, 3 eq.) in 1,4-dioxane (70 mL, 819.9 mmol) was bubbled with N2 for 20 min. Pd(ddpf)Cl2 (0.69 g, 0.90 mmol, 0.1 eq.) was added to the mixture. The reaction was sonicated for 3 min, followed by a vacuum / N2 refill cycle (3×) and heated at 100° C. for 3 h. The mixture was cooled to RT, filtered through celite and rinsed with 1:4 EtOAc / Hex. The filtrate was concentrated and the residue was purified on silica gel (0-40% MTBE / Hex) to give the title compound (2.95 g, 87%) as a white solid. 1 H NMR(400MHz,DMSO-d6)δ10.81–10.79(bs,1H),7.84–7.74(dd,J=5.07,8.59,1 H),7.14(s,1H),6.94–6.88(m,1H),3.89(bs,4H),1.49(s,10H),1.03(s,6H).
[0559] Preparation Example 73
[0560] 2-Bromo-3-fluoro-6-methoxy-benzaldehyde
[0561]
[0562] In a 2L 3-necked round bottom flask equipped with a thermocouple, dropping funnel and condenser, NaOMe (30 mass %) (95 mL, 475 mmol, 1.1 eq.) in MeOH was added dropwise to a solution of 2-bromo-3,6-difluoro-benzaldehyde (95.0 g, 430 mmol) in MeOH (850 mL) over ~15 min and stirred at 60°C for 5 h. The reaction was cooled to RT. The reaction mixture was slowly poured into H2O (2 L) while stirring. A viscous precipitate formed in the flask. The mixture was stirred at RT for 15 min and filtered. The filter cake was dried under vacuum at 50°C for ~18 h to give the title compound (75.4 g, 75%) as a white solid. MS (ES) m / z = 232 (M+1).
[0563] Preparation Example 74
[0564] 2-Bromo-3-fluoro-6-hydroxy-benzaldehyde
[0565]
[0566] To a 3-neck 2L round bottom flask equipped with a thermometer, overhead stirrer and dropping funnel, a solution of 2-bromo-3-fluoro-6-methoxy-benzaldehyde (79.2g, 340mmol) in DCM (700ml) was added. The flask was placed in a dry ice / acetone bath and cooled to -76°C. BBr3 (1.0M in DCM, 340mL, 340mmol, 1eq.) was added dropwise at a rate that kept the internal temperature below -70°C. The reaction was stirred in a dry ice / acetone bath for 15min, then the ice bath was removed and the reaction was stirred at RT for ~18h. The reaction was placed in an ice / water bath. After the internal temperature stabilized at ~2.5°C, H2O (250mL) was added dropwise via an addition funnel. The ice bath was removed, the reaction was allowed to warm to RT and stirred for an additional 15min. The reaction mixture was partitioned, the aqueous phase was treated with DCM (200mL) and brine (100mL), and partitioned again. The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated to give a brown solid. Hexane (250 mL) was added and the slurry was stirred for 30 min. The solid was filtered and the filtrate precipitated additional solids upon standing, which were filtered and combined with the previously filtered solids (Batch 1). The combined batches were dried under vacuum at 50°C overnight. The filtrate was concentrated and purified with silica gel (5% to 30% DCM / Hex) to give more product (Batch 2). The two batches were combined to give the title compound (66.7 g, 90%) as a white solid. GCMS (EI) m / z = 219 (M) + .
[0567] Preparation Example 75
[0568] 4-Bromo-5-fluoro-benzofuran-2-carboxylic acid
[0569]
[0570] In a 2 L 3-neck round bottom flask equipped with an overhead stirrer, thermocouple, to a solution of 2-bromo-3-fluoro-6-hydroxy-benzaldehyde (64.45 g, 294.3 mmol) in DMF (600 mL, 7,760 mmol) was added K2CO3 (89.5 g, 648 mmol, 2.2 eq.), NaI (8.83 g, 58.9 mmol, 0.2 eq.) and ethyl bromoacetate (36 mL, 324.2 mmol, 1.1 eq.) and heated at 70 °C for ~18 h. The temperature was raised to 120 °C for 4 h. The reaction was cooled to ~45 °C and then the heat was removed and the reaction was allowed to cool. When the internal temperature reached ~45 °C, a viscous precipitate formed in the flask. H2O (1 L) was added via an addition funnel in a slow stream of water to give a nearly homogeneous mixture. The pH was adjusted to ~3 with concentrated HCl and the mixture was stirred at RT for 30 min. The solid was filtered, rinsed with H2O (500 mL), and dried under vacuum at 50°C to give the title compound (52.4 g, 69%) as a white solid. MS (ES), m / z = 212 (M-1-CO2).
[0571] Preparation Example 76
[0572] N-(4-Bromo-5-fluoro-benzofuran-2-yl)carbamic acid tert-butyl ester
[0573]
[0574] In a manner similar to the method of Preparation Example 71, 4-bromo-5-fluoro-benzofuran-2-carboxylic acid was used, and the product was purified on silica gel, eluting with MTBE / Hex (5% to 30%) to give the title compound (29.1 g, 35%) as a yellow solid, MS (ES), m / z = 274 (M+1-tBu).
[0575] Preparation Example 77
[0576] tert-Butyl N-[4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5-fluoro-benzofuran-2-yl]carbamate
[0577]
[0578] In a manner similar to the method of Preparation Example 72, the title compound (21.3 g, 71%) was obtained as a light brown solid using tert-butyl N-(4-bromo-5-fluoro-benzofuran-2-yl)carbamate. MS (ES), m / z = 240 (M+1, mass of boronic acid observed). 1 H NMR(400MHz,DMSO-d6)δ10.74(bs,1H),8.43(s,1H),7.82(dd,J=5.1,8.8Hz,1H), 6.91(dd,J=8.8,9.5Hz,1H),7.15(s,1H),3.81(s,4H),1.50(s,9H),1.03(s,6H).
[0579] Preparation Example 78
[0580] tert-Butyl N-[3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzothiophen-2-yl]carbamate
[0581]
[0582] A mixture of tert-butyl N-(4-bromo-3-cyano-benzothiophene-2-yl)carbamate (U.S. Patent Application Publication US2021 / 0179633A1, Preparation Example 7) (19.0 g, 53.8 mmol), bis(neopentyl glycol)diboron (18.2 g, 80.6 mmol) and KOAc (15.8 g, 161 mmol) in 1,4-dioxane (350 mL) was passed through N2 for 40 min. Pd-117 (3.93 g, 5.38 mmol) was added, and the resulting mixture was heated at 95 ° C for 1.5 h. The reaction was cooled, filtered through diatomaceous earth and rinsed with DCM. The filtrate was concentrated and the residue was purified on silica gel, eluted with EtOAc / Hex (10-50%) to give the title compound (11.7 g, 56%) as an off-white solid. MS (ES), m / z = 317 (M-1, mass of boronic acid observed). 1 H NMR (400MHz, DMSO-d6) δ11.28 (s, 1H), 7.95 (dd, J=1.0, 8.0Hz, 1H), 7.54 (dd, J= 1.0,7.2Hz,1H),7.31(t,J=7.6Hz,1H),3.78(s,4H),1.53(s,9H),1.04(s,6H).
[0583] Preparation Example 79
[0584] tert-Butyl N-(4-chlorothieno[3,2-c]pyridin-2-yl)carbamate
[0585]
[0586] To a suspension of 4-chlorothieno[3,2-c]pyridine-2-carboxylic acid (78 g, 365.1 mmol) in t-BuOH (1,500 mL) was added TEA (155 mL, 1,110 mmol) and diphenylphosphoryl azide (100 g, 356.1 mmol). The mixture was stirred and heated to ~80 °C. After 14 h, the reaction was cooled to RT and the solids were allowed to settle. The liquid above the solids was decanted, and the solids were filtered and rinsed with DCM. The filtrate and decanted solution were combined and concentrated. The crude material was purified on silica gel eluting with MTBE / Hex (10-50%) to give the title compound (65 g, 58.3%) as a white solid. MS (ES) m / z = 285 (M+1).
[0587] Preparation Example 80
[0588] N-(4-Chloro-3-cyano-thieno[3,2-c]pyridin-2-yl)carbamic acid tert-butyl ester
[0589]
[0590] Tert-butyl N-(4-chlorothieno[3,2-c]pyridin-2-yl)carbamate (5.0 g, 18 mmol) in THF (120 mL) was cooled using an ice / water bath. CSI (4.7 mL, 53 mmol) was added dropwise at a steady rate in one portion under N2 with stirring. After 1.5 h, the cold reaction mixture was transferred to an addition funnel and added dropwise to DMF (125 mL) cooled in an ice bath over 14 min. After addition, the ice bath was removed and the reaction was stirred at RT for 1 h. The reaction was diluted with EtOAc and washed with brine and saturated aqueous NaHCO3. The aqueous layer was extracted with EtOAc (2×) and the combined organic layers were dried over Na2SO4. The solvent was evaporated and the oil containing DMF was evaporated using a stream of N2 to give a brown solid. EtOH (25 mL) was added to the solid, which was sonicated, filtered, the solid was rinsed with DCM and air-dried to give the product (2.2 g, 37%) as a white solid. MS (ES) m / z = 310 (M+1).
[0591] Preparation Example 227
[0592] N-(4-Bromo-7-fluoro-benzofuran-2-yl)carbamic acid tert-butyl ester
[0593]
[0594] 4-Bromo-7-fluoro-benzofuran-2-carboxylic acid ethyl ester. Combine 6-bromo-3-fluoro-2-hydroxy-benzaldehyde (2.9 g, 13 mmol) with potassium carbonate (2.0 g, 14 mmol) and sodium iodide (0.40 g, 2.7 mmol) in DMF (45 mL). Add ethyl bromoacetate (1.6 mL, 14 mmol) and stir the reaction mixture at room temperature overnight. Add potassium carbonate (2.0 g, 14 mmol). Stir the reaction mixture at 120 ° C for 3 h and cool to room temperature. Dilute the reaction mixture with water (60 mL), stir for 30 min, and filter the resulting solid. Wash the solid with water and dry it in a vacuum oven (40 ° C) to give 4-bromo-7-fluoro-benzofuran-2-carboxylic acid ethyl ester (1.2 g, 32%) as a light brown solid. MS (ES) m / z = 287, 289 (M+1, Br).
[0595] 4-Bromo-7-fluoro-benzofuran-2-carboxylic acid. In a manner similar to the method of Preparation Example 79, 4-bromo-7-fluoro-benzofuran-2-carboxylic acid ethyl ester was used to obtain 4-bromo-7-fluoro-benzofuran-2-carboxylic acid (0.97 g, 90%) as a white solid. MS (ES) m / z = 256, 258 (M-1, Br).
[0596] N-(4-bromo-7-fluoro-benzofuran-2-yl)carbamic acid tert-butyl ester. In a manner similar to that of Preparation Example 79, 4-bromo-7-fluoro-benzofuran-2-carboxylic acid was used to obtain the title compound (0.42 g, 66%). MS (ES) m / z = 328, 330 (M-1, Br).
[0597] Preparation Example 228
[0598] tert-Butyl N-(4-bromo-3-cyano-7-fluoro-benzofuran-2-yl)carbamate
[0599]
[0600] In a manner similar to the method of Preparation Example 80, the title compound (1.75 g, 63%) was obtained using tert-butyl N-(4-bromo-7-fluoro-benzofuran-2-yl)carbamate. MS (ES) m / z = 354, 356 (M+1, Br).
[0601] Preparation Example 229
[0602] tert-Butyl N-(4-chloro-7-methyl-thieno[3,2-c]pyridin-2-yl)carbamate
[0603]
[0604] 4-Chloro-7-methyl-thieno[3,2-c]pyridine-2-carboxylic acid methyl ester. Combine 2,4-dichloro-5-methyl-pyridine-3-carbaldehyde (7.25 g, 38.2 mmol), potassium carbonate (10.5 g, 76.0 mmol) and DMF (127 mL), heat at 70 °C overnight, and cool to room temperature. Add the reaction mixture to water (500 mL) and filter. Rinse the solid with water and dry to give 4-chloro-7-methyl-thieno[3,2-c]pyridine-2-carboxylic acid methyl ester (8.30 g, 90%) as a white solid. MS (ES) m / z = 242 (M+1).
[0605] 4-Chloro-7-methyl-thieno[3,2-c]pyridine-2-carboxylic acid. In a manner similar to that of Preparation Example 70, 4-chloro-7-methyl-thieno[3,2-c]pyridine-2-carboxylic acid methyl ester was used to obtain 4-chloro-7-methyl-thieno[3,2-c]pyridine-2-carboxylic acid (6.5 g, 84%) as a white solid. MS (ES) m / z = 228 (M+1).
[0606] N-(4-chloro-7-methyl-thieno[3,2-c]pyridin-2-yl)carbamic acid tert-butyl ester. In a manner similar to that of Preparation Example 79, 4-chloro-7-methyl-thieno[3,2-c]pyridine-2-carboxylic acid was used to obtain the title compound (0.83 g, 63%). MS (ES) m / z = 299 (M+1).
[0607] Preparation Example 230
[0608] tert-Butyl N-(4-chloro-3-cyano-7-methyl-thieno[3,2-c]pyridin-2-yl)carbamate
[0609]
[0610] In a manner similar to the method of Preparation Example 80, the title compound (0.542 g, 31%) was obtained using tert-butyl N-(4-chloro-7-methyl-thieno[3,2-c]pyridin-2-yl)carbamate. MS (ES) m / z = 324 (M+1).
[0611] Preparation Example 231
[0612] tert-Butyl N-(4-chloro-3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamate
[0613]
[0614] N-(3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamic acid ethyl ester. A solution of 2-(4-chloro-5-fluoropyridin-3-yl)acetonitrile (11.8 g, 56.1 mmol) in DMF (112 mL) was cooled to 0°C. Potassium tert-butoxide (7.00 g, 61.1 mmol) was added. After 15 min, ethoxycarbonyl isothiocyanate (7.45 mL, 61.8 mmol) was added dropwise. The reaction mixture was allowed to slowly warm to room temperature overnight. The reaction mixture was poured into a mixture of ice / water (1.5 L), stirred until all ice melted, and filtered through celite. The solid was dried in a vacuum oven (60°C) overnight and separated from the celite to give N-(3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamic acid ethyl ester (11.9 g, 79%) as a solid. MS (ES) m / z = 266 (M + 1).
[0615] 2-Amino-7-fluoro-thieno[3,2-c]pyridine-3-carbonitrile. A suspension of ethyl N-(3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamate (11.9 g, 44.4 mmol) in DMSO (90 mL) was cooled to 0°C. NaOH (5M in water, 90 mL) was added dropwise over 15 min. The reaction mixture was heated to 105°C for 1 h and then cooled to room temperature. The reaction mixture was poured into a mixture of ice / water (1.8 L), stirred until all ice melted, and filtered through celite. The solid was dried in a vacuum oven (50°C) overnight and separated from the celite to give the crude 2-amino-7-fluoro-thieno[3,2-c]pyridine-3-carbonitrile.
[0616] Tert-butyl N-(3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamate. A mixture of crude 2-amino-7-fluoro-thieno[3,2-c]pyridine-3-carbonitrile (8.6 g, 44.4 mmol), DCM (90 mL), DMF (90 mL) and N,N-diisopropylethylamine (15.5 mL, 88.9 mmol) was cooled to 0°C. 4-Dimethylaminopyridine (0.54 g, 4.42 mmol) and di-tert-butyl dicarbonate (14.6 g, 66.7 mmol) were added. The reaction mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure and the remaining material was diluted with DCM (400 mL) and 5% aqueous citric acid solution (250 mL). The aqueous phase was washed twice with DCM. The combined organic phases were washed with saturated aqueous NaHCO3, dried over MgSO4, filtered and concentrated to give tert-butyl N-(3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamate (7.5 g, 58%) as a brown solid. MS (ES) m / z = 294 (M+1).
[0617] N-(3-cyano-7-fluoro-5-oxido-thieno[3,2-c]pyridin-5-ium-2-yl)carbamic acid tert-butyl ester. 3-Chloroperoxybenzoic acid (9.00 g, 40.2 mmol) was added to a solution of N-(3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamic acid tert-butyl ester (7.85 g, 26.8 mmol) in DCM (180 mL). The reaction mixture was stirred at room temperature overnight and then cooled to 0°C for ~15 min. The solid was collected by filtration and dried in a vacuum oven (60°C). The filtrate was diluted with MeOH and silica gel, concentrated, and the residue was purified on silica gel eluting with 0-6% MeOH in DCM. The fractions containing the desired substance were combined with the filtered solid and concentrated to give tert-butyl N-(3-cyano-7-fluoro-5-oxo-thieno[3,2-c]pyridin-5-ium-2-yl)carbamate (7.26 g, 88%) as an off-white solid. MS (ES) m / z = 310 (M+1).
[0618] Tert-butyl N-(4-chloro-3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamate. A suspension of tert-butyl N-(3-cyano-7-fluoro-5-oxo-thieno[3,2-c]pyridin-5-ium-2-yl)carbamate (5.27 g, 17.0 mmol) in 1,2-dichloroethane (34 mL) was cooled to 0°C. A solution of phosphoryl chloride (32 mL, 344 mmol) in 1,2-dichloroethane (34 mL) was added dropwise. The reaction mixture was stirred at room temperature for 30 min, at 45°C for 90 min, and cooled to room temperature. The reaction mixture was diluted with 1,2-dichloroethane (100 mL) and added to a mixture of saturated aqueous NaHCO3 solution (500 mL), NaOH (5 M in water, 40 mL), and ice. Solid NaHCO3 was added to the stirred mixture to maintain pH ~6-7. After bubbling ceased, the phases were separated. The aqueous phase was extracted three times with DCM. The combined organic phases were dried over MgSO4 and filtered. The filtrate was diluted with MeOH and silica gel, concentrated, and the residue was purified on silica gel, eluting with 50-100% DCM in hexanes, and the fractions containing the desired material were concentrated to give the title compound (3.87 g, 69%) as a white solid. MS (ES) m / z = 328 (M+1).
[0619] Preparation Example 81
[0620] tert-Butyl N-(4-bromobenzofuran-2-yl)carbamate
[0621]
[0622] In a manner similar to the method of Preparation Example 71, the title compound (6.48 g, 50%) was obtained using 4-bromobenzofuran-2-carboxylic acid. MS (ES) m / z = 310 (M-1).
[0623] Preparation Example 82
[0624] N'-(4-Bromo-3-cyano-benzofuran-2-yl)-N,N-dimethyl-formamidine
[0625]
[0626] To a round-bottom flask was added tert-butyl N-(4-bromobenzofuran-2-yl)carbamate (6.48 g, 20.8 mmol) and THF (0.3 M, 69.2 mL). The solution was cooled to -78 °C under N2, and CSI (6.0 mL, 68.5 mmol, 3.3 eq.) was slowly added over 5 min. The reaction was stirred for 30 min, then transferred via cannula to stirred DMF (100 mL) at RT and rinsed with THF. The reaction mixture was stirred at RT for 16 h. The reaction was then cooled in an ice bath, saturated aqueous NaHCO3 solution (~160 mL) was slowly added until bubbling disappeared, and the mixture was then diluted with EtOAc. The organic phase was washed with saturated aqueous NaHCO3 solution (2×) and brine (3×), dried with MgSO4, filtered and concentrated. The resulting material was mixed with EtOAc to loosen the solid. Hexane was added and the mixture was sonicated to break up larger pieces. The solid was filtered, rinsed with 20% EtOAc / hexanes and dried in vacuo to give the title compound (3.39 g, 55.9%) as a light green solid, MS (ES) m / z = 292 (M+1).
[0627] Preparation Example 83
[0628] N'-[3-Cyano-4-(5,5-dimethyl-1,3,2-dioxaborin-2-yl)benzofuran-2-yl]-N,N-dimethyl-formamidine
[0629]
[0630] To a round bottom flask was added N'-(4-bromo-3-cyano-benzofuran-2-yl)-N,N-dimethyl-formamidine (3.38 g, 11.6 mmol), bis(neopentyl glycol)diboron (7.84 g, 34.7 mmol, 3.0 eq.), KOAc (3.75 g, 38.2 mmol, 3.3 eq.) and 1,4-dioxane (96 mL). The mixture was bubbled with N2 and Pd-117 (0.83 g, 1.16 mmol, 0.1 eq.) was added and the reaction was stirred at 100°C for 2.5 h. The reaction mixture was cooled and filtered through celite, rinsing with 20% EtOAc / hexane. The filtrate was concentrated and the residue was purified on silica gel, eluting with EtOAc / Hex (0-100%). The fractions containing the desired material were concentrated and EtOAc was added to the resulting solid. The solid was filtered and rinsed with EtOAc and hexanes, dried in vacuo at RT to give the title compound (2.64 g, 70%) as a brown solid. MS (ES) m / z = 258 (M+1), corresponding to the boronic acid. 1 H NMR (400MHz, DMSO-d6) δ8.52(s,1H),7.48–7.44(m,2H),7.17(dd,J=7.4,8.0Hz,1H),3.78(s,4H),3.2(s,3H),3.1(s,3H)1.00(s,6H).
[0631] Preparation Example 232
[0632] tert-Butyl N-[3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-7-fluoro-benzofuran-2-yl]carbamate
[0633]
[0634] In a manner similar to the method of Preparation Example 83, the title compound (0.75 g, 73%) was obtained using tert-butyl N-(4-bromo-3-cyano-7-fluoro-benzofuran-2-yl)carbamate. MS (ES) m / z = 321 (M+1, corresponding boronic acid).
[0635] Preparation Example 84
[0636] (2R,4R)-4-Hydroxy-1-(9-phenylfluoren-9-yl)pyrrolidine-2-carboxylic acid methyl ester
[0637]
[0638] To a stirred mixture of (2R,4R)-4-hydroxypyrrolidine-2-carboxylic acid methyl ester hydrochloride (20.0 g, 138 mmol) and 9-bromo-9-phenylfluorene (53.1 g, 165 mmol) in DCM (400 mL) were added trimethylsilyl chloride (37.4 g, 344 mmol), TEA (13.9 g, 138 mmol) and Pb(NO3)2 (41.1 g, 124 mmol) in portions at RT. The resulting mixture was stirred at 70°C under N2 for ~18 h. The reaction was cooled to RT and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give the product (42 g, 79.2%) as a white solid. MS (ES) m / z = 386 (M+1).
[0639] Preparation Example 85
[0640] (2R)-4-oxo-1-(9-phenylfluoren-9-yl)pyrrolidine-2-carboxylic acid methyl ester
[0641]
[0642] To a stirred solution of (2R,4R)-4-hydroxy-1-(9-phenylfluorene-9-yl)pyrrolidine-2-carboxylic acid methyl ester (30.0 g, 77.8 mmol) and oxalyl chloride (83.0 g, 654 mmol) in DCM (1,000 mL) was added TEA (243 g, 2397 mmol) and DMSO (85.1 g, 1090 mmol) at -40 °C. The resulting mixture was stirred at -40 °C under N2 for 8 h. The mixture was allowed to warm to RT and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE / EtOAc (2:1) to give the product (25.7 g, 85.6%) as a yellow solid. 1 H NMR(400MHz,DMSO-d6)δ7.87(dd,J=14.0Hz,2H),7.51–7.23(m,11H),3.76–3.59( m,2H),3.36(s,1H),3.04(s,3H),2.66(dd,J=17.9,8.5Hz,1H),2.28–2.16(m,1H).
[0643] Preparation Example 86
[0644] (2S,3R)-3-Fluoro-4-oxo-1-(9-phenylfluoren-9-yl)pyrrolidine-2-carboxylic acid methyl ester
[0645]
[0646] To a stirred solution of (2R)-4-oxo-1-(9-phenylfluoren-9-yl)pyrrolidine-2-carboxylic acid methyl ester (40.0 g, 104 mmol) and TEA (31.7 g, 312 mmol) in DCM (1000 mL) was added trimethylsilyl trifluoromethanesulfonate (119 g, 208 mmol) dropwise at -40 °C. The resulting mixture was stirred at -40 °C under N2 for 2 h. Concentrated under reduced pressure, diluted with pentane (1,000 mL), washed with saturated aqueous NaHCO3 solution (2×500 mL) and brine, and the organic layer was dried over anhydrous Na2SO4. The solution was concentrated in vacuo to give the crude silyl enol ether (47.3 g, quantitative). To a solution of crude silyl enol ether (13.0 g, 28.5 mmol) in DCM (200 mL) was added Selectfluor (131 g, 37.0 mmol) in portions at RT. The resulting mixture was stirred at RT for ~18 h. The mixture was then concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluting with PE / EtOAc (1:1) to give the title compound (3.96 g, 34.4%) as a light yellow solid. 1 H NMR (300MHz, CDCl3) δ7.83–7.70(m,2H),7.51–7.28(m,11H),5.10(dd,J=50.9,7.9Hz,1H),4.10–3.96(m,2H),3.74–3.61(m,1H),3.25(s,3H).
[0647] Preparation Example 87
[0648] Methyl (2S,3R,4S)-3-fluoro-4-hydroxy-1-(9-phenylfluoren-9-yl)pyrrolidine-2-carboxylate
[0649]
[0650] To a stirred solution of (2S,3R)-3-fluoro-4-oxo-1-(9-phenylfluoren-9-yl)pyrrolidine-2-carboxylic acid methyl ester (8.00 g, 19.93 mmol) in THF (60 mL) and EtOH (60 mL) was added NaBH4 (0.83 g, 21.9 mmol) in portions at 0°C under N2. The resulting mixture was stirred at 0°C under N2 for 1 h. The mixture was extracted with EtOAc (3×100 mL). The combined organic layers were washed with H2O (2×10 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified on silica gel using PE:EtOAc (4:1 to 2:1) as eluent to give the title compound (6.66 g, 83%) as a light yellow solid. MS (ES) m / z=426 (M+Na).
[0651] Preparation Example 88
[0652] Methyl (2S,3R,4R)-3-fluoro-4-(4-nitrobenzoyloxy)-1-(9-phenylfluoren-9-yl)pyrrolidine-2-carboxylate
[0653]
[0654] To a stirred mixture of PPh3 (3.25 g, 12.4 mmol) and DIAD (2.41 g, 11.9 mmol) in THF (100 mL) at 0°C under N2 was added dropwise (2S, 3R, 4S)-3-fluoro-4-hydroxy-1-(9-phenylfluoren-9-yl)pyrrolidine-2-carboxylic acid methyl ester (1.00 g, 2.48 mmol) and 4-nitrobenzoic acid (0.41 g, 2.48 mmol). The reaction was stirred at 0°C for 1 h, then diluted with H2O and extracted with EtOAc (3×200 mL). The combined organic layers were washed with H2O (2×50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified on silica gel, eluting with PE:EtOAc (4:1 to 2:1) to give the title compound (450 mg, 38.6%) as a yellow solid. 1 H NMR (400MHz, CDCl3) δ8.30–8.26(m,2H),8.16–8.10(m,2H),7.76–7.72(m,1H),7.70–7.66(m,1H),7.53–7.49(m,2H),7.41–7.35(m,4H),7.28 –7.24(m,4H),7.22–7.18(m,1H),5.74–5.70(m,1H),5.15–5.09(m,1H) ,4.06–4.02(m,1H),3.68–3.64(m,1H),3.35(s,3H),3.10–3.06(m,1H).
[0655] Preparation Example 89
[0656] Methyl (2S,3R,4R)-3-fluoro-4-hydroxy-1-(9-phenylfluoren-9-yl)pyrrolidine-2-carboxylate
[0657]
[0658] To a stirred mixture of (2S,3R,4R)-3-fluoro-4-(4-nitrobenzoyloxy)-1-(9-phenylfluoren-9-yl)pyrrolidine-2-carboxylic acid methyl ester (3.00 g, 5.43 mmol) in THF (100 mL) and H2O (25 mL) was added dropwise a solution of LiOH·H2O (255 mg, 6.08 mmol) dissolved in H2O (25 mL) at 0°C. After stirring at 0°C for 2 h, the reaction mixture was adjusted to pH 7 with formic acid and extracted with EtOAc (3×200 mL). The combined organic layers were washed with brine (2×50 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. Purification on silica gel residue eluting with PE:EtOAc (1:1) gave the title compound (1.76 g, 80.7%) as a yellow solid. MS (ES) m / z = 426 (M + Na).
[0659] Preparation Example 90
[0660] (3R,4R,5S)-4-Fluoro-5-(hydroxymethyl)-1-(9-phenylfluoren-9-yl)pyrrolidin-3-ol
[0661]
[0662] To a stirred mixture of (2S,3R,4R)-3-fluoro-4-hydroxy-1-(9-phenylfluoren-9-yl)pyrrolidine-2-carboxylic acid methyl ester (3.00 g, 7.44 mmol) in THF (100 mL) was added dropwise 1M LiAlH4 in THF (15.0 mL, 15.0 mmol) at -60 °C under N2. The reaction was stirred at -60 °C for 2 h. The reaction mixture was diluted with EtOAc (200 mL), washed with aqueous potassium sodium tartrate solution (100 mL), brine, and dried over Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified on silica gel using PE:EtOAc (1:1) as eluent to give the title compound (1.85 g, 66.3%) as a light yellow solid. 1 H NMR(400MHz, CDCl3)δ7.78(dt,J=7.6,0.9Hz,1H),7.74–7.63(m,2H),7.61–7.43(m,4H),7.37–7.20( m,6H),4.61–4.43(m,2H),3.54(d,J=10.0Hz,1H),3.25–3.22(m,1H),2.89–2.63(m,3H),2.25(s,1H).
[0663] Preparation Example 91
[0664] Methanesulfonic acid ((2S,3R,4R)-3-fluoro-4-((methylsulfonyl)oxy)-1-(9-phenyl-9H-fluoren-9-yl)pyrrolidin-2-yl)methyl ester
[0665]
[0666] To a stirred mixture of (3R,4R,5S)-4-fluoro-5-(hydroxymethyl)-1-(9-phenylfluoren-9-yl)pyrrolidin-3-ol (1.00 g, 2.66 mmol) in THF (50 mL) at 0°C under N2 was added TEA (1.62 g, 16.0 mmol) and methanesulfonyl chloride (1.22 g, 10.7 mmol) dropwise. When LC-MS showed the reaction was complete, the resulting mixture was diluted with H2O (150 mL) and extracted with EtOAc (3×100 mL). The combined organic layers were washed with H2O (2×30 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified on silica gel eluting with PE:EtOAc (4:1 to 2:1) to give the title compound (1.32 g, 93.4%) as a white solid. MS (ES) m / z = 532 (M + 1).
[0667] Preparation Example 92
[0668] (1S,4S,7S)-7-Fluoro-2-(9-phenyl-9H-fluoren-9-yl)-2,5-diazabicyclo[2.2.1]heptane
[0669]
[0670] A mixture of [(2S,3R,4R)-3-fluoro-4-(methylsulfonyloxy)-1-(9-phenylfluoren-9-yl)pyrrolidin-2-yl]methyl methanesulfonate (4.00 g, 7.52 mmol) in 2.0 M NH3 in IPA (210 mL, 420 mmol) was heated at 100 °C overnight. The mixture was cooled to RT and concentrated under reduced pressure. The residue was purified on silica gel using DCM:MeOH (12:1 to 10:1) as eluent to give the title compound (1.00 g, 37.3%) as a light yellow solid. MS (ES) m / z = 357 (M+1).
[0671] Preparation Example 93
[0672] Benzyl (1S, 4S, 7S)-7-fluoro-2-(9-phenyl-9H-fluoren-9-yl)-2,5-diazabicyclo[2.2.1]heptane
[0673]
[0674] To a stirred mixture of (1S,4S,7S)-7-fluoro-2-(9-phenylfluoren-9-yl)-2,5-diazabicyclo[2.2.1]heptane (1.20 g, 3.37 mmol) and DIEA (1.31 g, 10.1 mmol) in DCM (100 mL) was added Cbz-Cl (0.86 g, 5.05 mmol) in portions at 0°C. The resulting mixture was stirred at RT for 2 h and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EtOAc (9:1 to 5:1) as eluent to give the product (1.41 g, 85.4%) as a white solid. MS (ES) m / z = 491 (M+1).
[0675] Preparation Example 94
[0676] (1S,4S,7R)-7-Fluoro-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid benzyl ester
[0677]
[0678] To a stirred solution of (1S,4S,7R)-7-fluoro-5-(9-phenylfluoren-9-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid benzyl ester (1.41 g, 2.88 mmol) in DCM (16 mL) was added TFA (8.00 mL, 106 mmol) at RT. The resulting mixture was stirred for 1 h and then concentrated under reduced pressure. The residue was dissolved in EtOAc (300 mL) and washed with saturated aqueous NaHCO3 solution (3×100 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give the product as a white solid (1.3 g, crude), which was used in the subsequent step without further purification. MS (ES) m / z=251 (M+1).
[0679] Preparation Example 95
[0680] ((2S,4R)-4-Fluoro-1-methylpyrrolidin-2-yl)methanol
[0681]
[0682] To a stirred solution of (2S,4R)-4-fluoropyrrolidine-1,2-dicarboxylic acid 1-tert-butyl 2-methyl ester (20.0 g, 80.9 mmol, 1.0 eq.) in THF (200 mL) was added dropwise LiAlH4 (485.3 mL, 485.3 mmol, 6.0 eq., 1 M in THF) at -50 °C under N2. The resulting mixture was stirred at -50 °C under N2 for 1 h. The mixture was then stirred at 70 °C under N2 for 2 h. The mixture was cooled to 0 °C and quenched by adding H2O. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with saturated aqueous NaCl solution and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with DCM / MeOH (5:1) to give the product (2.94 g, 27.3%) as a yellow oil. 1 HNMR (400MHz, CDCl3) δ5.13 (dm, J=55.7Hz, 1H), 3.74 (dd, J=3.3, 11.4Hz, 1H), 3.54 (ddd, J=26.4, 11.9, 5.1Hz, 1H), 3.48 (dd ,J=2.0,11.2Hz,1H),2.89(s,1H),2.82(m,1H),2.67(ddd,J=32.4,11.9,2.5Hz,1H),2.43(s,3H),2.13(m,1H),2.06(m,1H).
[0683] Preparation Example 96
[0684] [2-(Hydroxymethyl)-1-methylpyrrolidin-2-yl]methanol
[0685]
[0686] [2-(Hydroxymethyl)pyrrolidin-2-yl]methanol (500 mg, 3.81 mmol, 1.0 eq.) and HCHO (343 mg, 11.4 mmol, 3.0 eq.) in MeOH (10.00 mL) were stirred at RT for 0.5 h. Then, NaBH3CN (479 mg, 7.62 mmol, 2.00 eq.) was slowly added at 0°C. The resulting mixture was stirred at RT for 4 h. The reaction was quenched with H2O (5 mL) at 0°C and then diluted with H2O. The mixture was extracted with EtOAc (3×200 mL). The combined organic layers were washed with brine (3×100 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified on silica gel using DCM / MeOH / NH4OH (100:10:1 to 100:20:1) to give the product (400 mg, 72.3%) as a yellow oil. (M+1).1 H NMR (300MHz, DMSO-d6+D2O) δ4.31–4.08(m,2H),3.38–3.23(m,4H),2.72(t,J=6.3Hz,2H),2.33s,3H),1.76–1.50(m,4H).
[0687] Preparation Example 97
[0688] 1-[tert-Butyl(dimethyl)silyl]oxypropan-2-one
[0689]
[0690] A solution of 1-hydroxypropane-2-one (25.00 g, 337.48 mmol, 1.0 eq.), tert-butyldimethylsilyl chloride (76.30 g, 506.22 mmol, 1.50 eq.) and imidazole (50.54 g, 742.45 mmol, 2.20 eq.) in DCM (100 mL) was stirred at RT under N2 for 4 h. The resulting mixture was diluted with EtOAc (400 mL), washed with H2O (3×500 mL) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using EtOAc / PE (0-5%) as eluent to give the product (56.00 g, 88.10%) as a colorless oil. 1 H NMR (400MHz, CDCl3) δ4.15(s,2H),2.17(s,3H),0.93(s,9H),0.09(s,6H).
[0691] Preparation Example 98
[0692] 1-Benzyl-4-[[tert-butyl(dimethyl)silyl]oxymethyl]-3-methoxy-4-methyl-azetidin-2-one
[0693]
[0694] 1-[tert-butyl(dimethyl)silyl]oxypropane-2-one (30.00 g, 159.28 mmol, 1.00 eq.), benzylamine (17.07 g, 159.30 mmol, 1.00 eq.) and A mixture of molecular sieves (30 g) in DCM (300 mL) was stirred at 45 °C under N2 for 12 h. TEA (37.23 g, 367.92 mmol, 2.31 eq.) was added to the mixture, followed by dropwise addition of methoxyacetyl chloride (22.47 g, 207.06 mmol, 1.30 eq.) at -78 °C over 30 min. The reaction was warmed to RT and stirred for 12 h. The mixture was filtered and the filter cake was washed with DCM (200 mL). The filtrate was diluted with H2O (300 mL) and extracted with DCM (3×300 mL). The combined organic layers were washed with saturated aqueous NaCl solution (200 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (10%) to give the product (9.00 g, 12.12%) as a light yellow oil. 1 HNMR(400MHz, CDCl3)δ7.37–7.18(m,5H),4.45–4.27(m,2H),4.10(s,1H),3. 71–3.56(m,2H),3.50(s,3H),1.22(s,3H),0.86(s,9H),0.05–-0.09(m,6H).
[0695] Preparation Example 99
[0696] (1-Benzyl-3-methoxy-2-methyl-azetidin-2-yl)methoxy-tert-butyl-dimethyl-silane
[0697]
[0698] To a stirred mixture of AlCl3 (1.85 g, 13.85 mmol, 1.21 eq.) in THF (20 mL) at -10°C under N2 was added a solution of LiAlH4 (0.64 g, 16.82 mmol, 1.47 eq.) in THF (10 mL). The resulting mixture was warmed to RT and stirred for 3 h. After cooling to -10°C, a solution of 1-benzyl-4-[[tert-butyl(dimethyl)silyl]oxymethyl]-3-methoxy-4-methyl-azetidin-2-one (4.00 g, 11.4 mmol, 1.0 eq.) in THF (10 mL) was added dropwise. The mixture was warmed to RT and stirred for another 1 h. H2O (0.64 mL) was then added, followed by 15% NaOH (0.64 mL) and additional H2O (1.92 mL). The mixture was filtered and the filter cake was washed with THF (100 mL). The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using EtOAc / PE (0-10%) to give the product (1.56 g, 40.63%) as a colorless oil. 1HNMR (400MHz, CDCl3) δ7.27–7.10(m,5H),3.80–3.65(m,3H),3.61(dd,J=6.4,4.7Hz 1H),3.53(d,J=13.2Hz,1H),3.23(d,J=4.9Hz,4H),2.98(dd,J=7.7,4.7Hz,1H),1.22(s,3H),0.83(s,9H),0.00(d,6H).
[0699] Preparation Example 100
[0700] tert-Butyl-[(3-methoxy-1,2-dimethyl-azetidin-2-yl)methoxy]-dimethyl-silane
[0701]
[0702] To a solution of (1-benzyl-3-methoxy-2-methyl-azetidin-2-yl)methoxy-tert-butyl-dimethyl-silane (1.1 g, 3.28 mmol, 1.00 eq.) in MeOH (10 mL) was added Pd / C (110 mg, 10% wt) under N2. The mixture was hydrogenated at RT under H2 atmosphere using a hydrogen balloon for 24 h. To the above mixture was added (HCHO) at RT n The resulting mixture was placed under H2 atmosphere (balloon) and stirred for another 10 h at RT. The mixture was filtered and the filter cake was washed with MeOH (50 mL). The filtrate was concentrated under reduced pressure to give the product (0.8 g, crude product) as a colorless oil, which was used in subsequent steps without further purification.
[0703] Preparation Example 101
[0704] (3-Methoxy-1,2-dimethyl-azetidin-2-yl)methanol
[0705]
[0706] A solution of tert-butyl-[(3-methoxy-1,2-dimethyl-azetidin-2-yl)methoxy]-dimethyl-silane (800 mg, 3.08 mmol, 1 eq.) in 4M HCl / MeOH (10.00 mL) was stirred at RT under N2 for 10 h. The resulting mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography using DCM / MeOH / NH3H2O (15:3:0.2) to give the product (250 mg, 55.84%) as a light yellow solid. 1H NMR (400MHz, CDCl3) δ3.84(dd,J=6.3,4.8Hz,1H),3.78–3.66(m,2H),3.46(dd,J=8.0,6.3Hz,1H),3.36–3.28(m,4H),2.35(s,3H),1.18(s,3H).
[0707] Preparation Example 102
[0708] 8-(6-Bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-
[0709] Butyl Ester
[0710]
[0711] To a suspension of 6-bromo-1-chloro-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline (21.0 g, 57.8 mmol) in ACN (580 mL) was added tert-butyl 3,8-diazabicyclo[3.2.1]octane-3-carboxylate (15.2 g, 69.5 mmol, 1.20 eq.) and DIPEA (40 mL, 229 mmol, 4 eq.) and stirred at RT for 90 min. H2O (1 L) was added slowly via an addition funnel and the mixture was stirred at RT for 1 h. The solid was filtered, rinsed with H2O (500 mL) and dried under vacuum at 50 °C to give the title compound (31 g, quantitative yield) as a white solid, MS (ES) m / z = 539 (M+1).
[0712] The following compounds in Table 5 were prepared in a manner similar to that described in Preparation 102. A variety of methods were used to purify the compounds, which methods would be apparent to those skilled in the art.
[0713] Table 5:
[0714]
[0715]
[0716] Preparation Example 108
[0717] tert-(1R,4R)-5-(6-bromo-5-chloro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid
[0718] Butyl Ester
[0719]
[0720] To a stirred mixture of 6-bromo-5-chloro-7H,9H-furo[3,4-f]quinazolin-1-ol (3 g, 9.95 mmol) and BrOP (5.79 g, 14.92 mmol) in 1,4-dioxane (30 mL) was added TEA (6.92 mL, 49.75 mmol) dropwise at RT. The resulting mixture was stirred at 80 °C under N2 for 4 h. Cooled to RT and (1R,4R)-tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (3.95 g, 19.90 mmol) was added. Reheated at 80 °C under N2. After 2 h, the mixture was cooled to RT, diluted with H2O (200 mL) and extracted with EtOAc (3×500 mL). The combined organic layers were washed with brine (3×200 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EtOAc (3:1 to 2:1) as eluent to give the title compound (780 mg, 14.6%) as a yellow solid. MS (ES) m / z=481 (M+1).
[0721] Preparation Example 109
[0722] (1R,4R)-tert-butyl 5-[6-bromo-9-(cyanomethyl)-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate
[0723]
[0724] To a suspension of 2-(6-bromo-1-chloro-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-9-yl)acetonitrile (4.40 g, 8.85 mmol) in DMF (80 mL) cooled in an ice bath was added tert-butyl (1R,4R)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (2.00 g, 9.78 mmol) and DIPEA (3.10 mL, 17.8 mmol). The reaction was stirred at RT for 2 h. DMF was removed under reduced pressure. The residue was dissolved in EtOAc (500 mL), washed with saturated aqueous NaHCO3 and brine, dried over anhydrous MgSO4, filtered and concentrated. The residue was purified by silica gel column chromatography eluting with EtOAc / Hex (10-100%) to give the title compound (4.00 g, 80%) as a light brown solid. MS (ES) m / z = 564 (M+1).
[0725] Preparation Example 110
[0726] (1R,4R)-tert-butyl 5-[6-bromo-5-chloro-9-(cyanomethyl)-3-ethylthio-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate
[0727]
[0728] In a manner similar to the method of Preparation Example 108, the title compound (0.53 g, 76%) was obtained as a yellow solid using 2-(6-bromo-1,5-dichloro-3-ethylthio-7,9-dihydrofuro[3,4-f]quinazolin-9-yl)acetonitrile. MS (ES) m / z = 580 (M+1).
[0729] Preparation Example 111
[0730] 8-(4-bromo-5-chloro-7-methylthio-1,3-dihydrofuro[3,4-f]quinolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl
[0731] ester
[0732]
[0733] In a dry reaction vessel, DMSO (198 mL) was purged with N2 for 5 min using a gas dispersion tube. DIPEA (3.9 mL, 22 mmol) was added and purged for an additional 3 min. Solid 4-bromo-5,9-dichloro-7-methylthio-1,3-dihydrofuro[3,4-f]quinoline (8.1 g, 22 mmol) and tert-butyl 3,8-diazabicyclo[3.2.1]octane-3-carboxylate (19 g, 89 mmol, 4 eq.) were added, the reaction vessel was sealed, and heated to 130 °C for 48 h. After cooling to RT, the reaction was poured into a separatory funnel, diluted with DCM (1.5 L), washed with H2O (3 x 500 mL), separated, and concentrated. The residue was purified on silica gel (100% DCM to 5% EtOAc / DCM) to give the title compound (5.36 g. 45%) as a white solid. MS (ES) m / z = 540 (M + 1).
[0734] Preparation Example 112
[0735] (1R,4R)-5-(6-bromo-5-fluoro-3-methyl-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-2,5-diazabicyclo[2.2.1]heptane-2-yl
[0736] Tert-Butyl Formate
[0737]
[0738] A mixture of 6-bromo-5-fluoro-3-methyl-7,9-dihydrofuro[3,4-f]quinazolin-1-ol (280 mg, 0.936 mmol), phosphonitrilic chloride trimer (423 mg, 1.22 mmol) and DIEA (605 mg, 4.68 mmol) in ACN was stirred at 50 °C under N2 for 5 h. After cooling to RT, (1R,4R)-tert-butyl 2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (119 mg, 0.602 mmol) and DIEA (605 mg, 4.68 mmol) were added and the resulting mixture was stirred for another 2 h. The reaction was stirred at RT for another 2 h. The mixture was diluted with H2O (150 mL), extracted with EtOAc (3×50 mL) and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EtOAc (3:1 to 1:1) as eluent to give the title compound (280 mg, 62.3%) as a yellow solid. MS (ES) m / z = 479 (M+1).
[0739] Preparation Example 113
[0740] 6-Bromo-1-[(1R,4R)-2,5-diazabicyclo[2.2.1]heptane-2-yl]-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline
[0741]
[0742] (1R,4R)-tert-butyl 5-(6-bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (500 mg, 0.951 mmol) was stirred in DCM (5 mL, 78.00 mmol). TFA (2 mL, 26.45 mmol) was added. The reaction vessel was capped and stirred at RT for ~18 h. The reaction solution was placed on a 10 g SCX column and washed with 3 column volumes of MeOH and then eluted with 3 column volumes of 2N NH3 in MeOH. The basic fraction was concentrated to give the title compound (426 mg, quantitative yield) as a viscous oil. MS (ES) m / z = 426 (M+1).
[0743] Preparation Example 114
[0744] 8-(6-Bromo-3-ethylsulfonyl-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0745]
[0746] To a solution of tert-butyl 8-(6-bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (4.3 g, 8.0 mmol) in DCM (40 mL) was added mCPBA (6.21 g, 25.2 mmol, 3.2 eq.) and stirred at RT for 90 min. The mixture was diluted with DCM and washed with saturated aqueous NaHCO3 and brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified on silica gel eluting with EtOAc / Hex (20-80%) to give the title compound (3.0 g, 66%) as a white solid. MS (ES) m / z = 571 (M+1).
[0747] Preparation Example 235
[0748] 8-(6-bromo-5-chloro-3-ethylsulfonyl-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0749]
[0750] In a manner similar to the method of Preparation Example 114, the title compound (13.5 g, 86%) was obtained using 8-(6-bromo-5-chloro-3-ethylthio-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester. MS (ES) m / z = 587,589 (M+1, Br).
[0751] Preparation Example 302
[0752] 6-Bromo-3-ethylsulfonyl-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline
[0753]
[0754] In a manner similar to that of Preparation Example 114, the title compound (1.00 g, 92%) was obtained using 6-bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline. MS (ES) m / z = 361, 363 (M+1, Br).
[0755] Preparation Example 115
[0756] 8-[6-Bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuran
[0757] [3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0758]
[0759] To a mixture of [(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methanol (2.26 g, 13.8 mmol) in THF (110 mL) under N2 was added LiHMDS (13.7 mL, 13.7 mmol, 1.0 M) in THF and stirred for 20 min. To this solution was added tert-butyl 8-(6-bromo-3-ethylsulfonyl-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (6.54 g, 11.4 mmol) in THF (40 mL) via syringe. After 35 min, the reaction was diluted with EtOAc (250 mL) and washed with brine. The aqueous phase was extracted with EtOAc (2×200 mL), and the combined organic layers were dried over Na2SO4 and concentrated to give a brown solid. The crude material was purified on silica gel using 0-10% MeOH / DCM as eluent to give the title compound (7.0 g, 96%) as a light brown solid. MS (ES) m / z=636 (M+1).
[0760] Preparation Example 236
[0761] 8-[6-Bromo-5-fluoro-3-[(2-methoxy-1,2,3,5,6,7-hexahydropyrrolizin-8-yl)methoxy]-7,9-dihydrofuro[3,4-f]quinazoline
[0762] -1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0763]
[0764] In a manner similar to the method of Preparation Example 115, the title compound (4.5 g, 85%) was obtained using (2-methoxy-1,2,3,5,6,7-hexahydropyrrolizin-8-yl)methanol. MS (ES) m / z = 648,650 (M+1, Br).
[0765] Preparation Example 237
[0766] 8-[6-Bromo-5-chloro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0767]
[0768] In a manner similar to the method of Preparation Example 115, the title compound (12.8 g, 85%) was obtained using 8-(6-bromo-5-chloro-3-ethylsulfonyl-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester. MS (ES) m / z = 652, 654 (M+1, Br).
[0769] Preparation Example 116
[0770] 6-Bromo-1-(3,8-diazabicyclo[3.2.1]octan-8-yl)-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazoline
[0771]
[0772] In a manner similar to the method of Preparation Example 113, 8-[6-bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester was reacted and separated by partitioning between DCM and saturated aqueous NaHCO3 to give the title compound (0.83 g, 99%) as a light yellow foam. MS (ES) m / z = 536 (M+1).
[0773] Preparation Example 117
[0774] 3-[8-[6-Bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octan-3-yl]propoxy-tert-butyl-dimethyl-silane
[0775]
[0776] A solution of 6-bromo-1-(3,8-diazabicyclo[3.2.1]octan-8-yl)-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazoline (0.900 g, 1.68 mmol) in DCM (17 mL) was treated with 3-[(tert-butyldimethylsilyl)oxy]-1-propanal (0.998 g, 5.03 mmol) and NaBH(OAc)3 (1.12 g, 5.02 mmol) and stirred at RT for 2 h. The reaction mixture was treated with saturated aqueous NaHCO3 and stirred for 15 min. H2O was added and the layers were separated. The aqueous layer was extracted twice with DCM. The organic layers were combined, dried over Na2SO4 and concentrated in vacuo. The residue was purified on silica gel using 0% to 4% 7N NH3 / MeOH in DCM to give the title compound (0.844 g, 71%) as an off-white solid. MS (ES) m / z = 708 (M+1).
[0777] The following compounds in Table 6 were prepared using the appropriate aldehyde in a manner similar to that described in Preparation 117. A variety of methods were used to purify the compounds, which methods would be apparent to those skilled in the art.
[0778] Table 6:
[0779]
[0780]
[0781] Preparation Example 122
[0782] 6-[6-Bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxylic acid tert-butyl ester
[0783]
[0784] In a manner similar to the method of Preparation Example 115, the title compound (0.8 g, 84%) was obtained as a light yellow foam using 6-(6-bromo-3-ethylsulfonyl-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,6-diazabicyclo[3.1.1]heptane-3-carboxylic acid tert-butyl ester. MS (ES) m / z = 622 (M+1).
[0785] Preparation Example 303
[0786] 8-[6-Bromo-3-[[(2R)-1,4-dioxan-2-yl]methoxy]-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-
[0787] tert-Butyl diazabicyclo[3.2.1]octane-3-carboxylate
[0788]
[0789] In a manner similar to the method of Preparation Example 115, the title compound (1.72 g, 97%) was obtained as a white solid using [(2S)-1,4-dioxane-2-yl]methanol. MS (ES) m / z = 595, 597 (M+1, Br).
[0790] Preparation Example 304
[0791] 6-Bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazoline diazabicyclo[3.2.1]octane-3-carboxylate
[0792]
[0793] In a manner similar to the method of Preparation Example 115, 6-bromo-3-ethylsulfonyl-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline was used to obtain the title compound (0.11 g, 62%) as an off-white solid. MS (ES) m / z = 426, 428 (M+1, Br).
[0794] Preparation Example 123
[0795] 8-[6-[2-(tert-Butoxycarbonylamino)-5-fluoro-benzothiophen-4-yl]-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline
[0796] -1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0797]
[0798] To a 250 mL 3-necked round bottom flask equipped with a thermocouple, condenser and N2 sparge was added a suspension of 8-(6-bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester (5.00 g, 9.27 mmol) and N-[4-(5,5-dimethyl-1,3,2-dioxaborinane-2-yl)-5-fluoro-benzothiophen-2-yl]carbamic acid tert-butyl ester (5.53 g, 13.9 mmol, 1.5 eq.) in 1,4-dioxane (100 mL) and H2O (31 mL). Heating was set at 70°C and started. At the same time, N2 sparge was started. When the internal temperature reached ~45 ° C, the jet was removed and K3PO4 (2.95 g, 13.9 mmol, 1.5 eq.) and Pd-118 (0.620 g, 0.932 mmol, 0.10 eq.) were added. The reaction temperature was brought to 70 ° C and stirred for 90 min. The reaction was cooled to RT, and the mixture was then diluted with EtOAc, washed with H2O and distributed. The aqueous phase was extracted with EtOAc (100 mL), and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. MTBE (50 mL) was added and the mixture was sonicated for 20 min. The solid was filtered to obtain the product as Batch 1. The filtrate was concentrated and the residue was purified on silica gel, eluting with EtOAc / hexane (0-30%). The fractions containing the product were concentrated to obtain a brown foam, which was dissolved in DCM (20 mL) and treated with hexane (60 mL) dropwise for 1 h while stirring rapidly. The resulting solid was filtered and rinsed with hexanes (50 mL) to give the product as batch 2. The two batches were combined to give the title compound (6.4 g, 88%) as a white solid. MS (ES) m / z = 726 (M+1).
[0799] The following compounds in Table 7 were prepared in a manner similar to that described in Preparation 123. A variety of methods were used to purify the compounds, which methods would be apparent to those skilled in the art.
[0800] Table 7:
[0801]
[0802]
[0803]
[0804] Preparation Example 126
[0805] 8-[6-[2-(tert-Butyloxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5-chloro-3-ethylthio-7,9-dihydrofuro[3,4-f]
[0806] Quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0807]
[0808] To a solution of 8-(6-bromo-5-chloro-3-ethylthio-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester (0.785 g, 1.36 mmol) in THF (10 mL) was added tert-butyl N-[3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)-7-fluoro-benzothiophen-2-yl]carbamate (0.826 g, 2.04 mmol, 1.5 eq.) and Cs2CO3 (1.39 g, 4.27 mmol, 3.15 eq.). The mixture was stirred and purged with N2 for 10 min. Pd-117 (0.202 g, 0.274 mmol, 0.20 eq.) was added and N2 was bubbled through the mixture for another 5 min, then the reaction flask was equipped with a reflux condenser and heated at 70 °C for 6 h. The reaction was cooled to RT, diluted with H2O (1 mL) and stirred for 5 min. The mixture was passed through 3.0 g Column (Biotage, LLC; Charlotte, NC) was filtered and eluted with EtOAc until the effluent became clear and colorless. The filtrate was concentrated and purified on silica gel using 20% EtOAc / Hex to give the title compound (0.743 g, 70%) as a white solid. MS (ES) m / z = 767 (M+1).
[0809] The following compounds in Table 8 were prepared in a manner similar to that described in Preparation 126. A variety of methods were used to purify the compounds, which methods would be apparent to those skilled in the art.
[0810] Table 8:
[0811]
[0812]
[0813]
[0814]
[0815]
[0816] Preparation Example 156
[0817] N-[4-[1-[3-[3-[tert-butyl(dimethyl)silanyl]oxypropyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]-1,3-
[0818] tert-Butyl benzothiazol-2-yl]carbamate
[0819]
[0820] To 3-[8-[6-bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octan-3-yl]propoxy-tert-butyl-dimethyl-silane (0.110 g, 0.155 mmol), [2-(tert-butoxycarbonylamino)- 1,3-Benzothiazol-4-yl]boric acid (US10,968,214B2; Preparation Example 17) (0.064 g, 0.217 mmol) and K2CO3 (0.064 g, 0.466 mmol) in 1,4-dioxane (1.5 mL) and H2O (0.5 mL) were passed through N2 for 5 min, and then Pd(PPh3)4 (0.036 g, 0.310 mmol) was added. The resulting mixture was heated at 100°C for 1.5 h, then cooled to RT and partitioned between DCM and H2O. The layers were separated and the aqueous layer was extracted twice with DCM. The organic layers were combined and filtered through a hydrophobic frit ( Phase separation column) and concentrated in vacuo. The residue was purified on silica gel (gradient, 0 to 4% 7N NH3 / MeOH in DCM) to give the title compound (0.098 g, 55%) as a light yellow solid. MS (ES) m / z = 878 (M+1).
[0821] Preparation Example 157
[0822] 8-[6-[2-(tert-Butyloxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5-chloro-3-ethylthio-7,9-dihydrofuro[3,4-f]
[0823] Quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester, isomer 2
[0824]
[0825] Use SFC( IC, 21x250mm, 35% MeOH (with 0.5% DMEA), 65% CO2, 80mL / min) to purify 8-[6-[2-(tert-butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5-chloro-3-ethylthio-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester (5.30g, 6.94mmol). The second eluting isomer (t R2 =10.77 min), concentrated and lyophilized to give the title compound (1.37 g, 42%) as a white solid with 96% ee. MS (ES) m / z = 767 (M+1).
[0826] Preparation Example 323
[0827] 8-(6-Bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3-azabicyclo[3.2.1]octane-3,8-dicarboxylic acid
[0828] O3-tert-butyl ester O8-methyl ester
[0829]
[0830] Combine 6-bromo-1-chloro-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline (0.10 g, 0.28 mmol), 3-azabicyclo[3.2.1]octane-3,8-dicarboxylic acid O3-tert-butyl ester O8-methyl ester (0.22 g, 0.82 mmol) and bis(tri-tert-butylphosphine)palladium(0) (0.022 g, 0.042 mmol) under nitrogen. Add toluene (4 mL), purge the mixture with nitrogen for 3 min, and cool to 0 °C. Add LiHMDS (0.8 mL, 0.8 mmol, 1 M in THF) dropwise over 1.5 min, and allow the reaction mixture to warm to room temperature. After 3 h, pour the reaction into brine and extract with ethyl acetate (2×). Dry the combined organic layers over MgSO4, filter, and concentrate.
[0831] Combine 6-bromo-1-chloro-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline (0.30 g, 0.83 mmol), 3-azabicyclo[3.2.1]octane-3,8-dicarboxylic acid O3-tert-butyl ester O8-methyl ester (0.67 g, 2.5 mmol) and bis(tri-tert-butylphosphine)palladium(0) (0.065 g, 0.12 mmol) under nitrogen. Add toluene (11 mL), purge the mixture with nitrogen for 3 min, and cool to 0 °C. Add LiHMDS (2.4 mL, 2.4 mmol, 1 M in THF) dropwise over 3 min and allow the reaction mixture to warm to room temperature. After 3 h, pour the reaction into brine and extract with ethyl acetate (2×). Dry the combined organic layers over MgSO4, filter, and concentrate.
[0832] The two residues were combined and purified by silica gel column chromatography, eluting with 0 to 30% ethyl acetate in hexanes to give the product (0.55 g, 83%). MS (ES) m / z = 596, 598 (M+1, Br).
[0833] Preparation Example 324
[0834] 8-(6-Bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3-azabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl
[0835] ester
[0836]
[0837] A mixture of 8-(6-bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3-azabicyclo[3.2.1]octane-3,8-dicarboxylic acid O3-tert-butyl ester O8-methyl ester (0.99 g, 1.7 mmol) and LiCl (1.1 g, 25 mmol) in DMSO (9 mL) was stirred at 150 °C for 10 min under microwave irradiation. The reaction was diluted with water and extracted with ethyl acetate (2×). The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated. The residue was purified by silica gel column chromatography eluting with 0 to 30% ethyl acetate in hexanes to give the product (0.11 g, 12%) as the faster eluting isomer. MS (ES)
[0838] m / z=538,540(M+1,Br).
[0839] Preparation Example 158
[0840] 8-[6-[2-(tert-Butyloxycarbonylamino)-3-cyano-thieno[3,2-c]pyridin-4-yl]-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0841]
[0842] A mixture of tert-butyl 8-[6-bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (0.500 g, 0.786 mmol), KOAc (0.231 g, 2.35 mmol) and bis(neopentyldiol)diboron (0.266 g, 1.18 mmol) in 1,4-dioxane (8 mL) was bubbled with N2 for 10 min. Pd-117 (0.057 g, 0.078 mmol) was added and the resulting mixture was heated at 95° C. for 2 h. The reaction mixture was cooled to RT. H2O (2.6 mL) was added and the mixture was bubbled with N2 for 10 min. Tert-butyl N-(4-chloro-3-cyano-thieno[3,2-c]pyridin-2-yl)carbamate (0.245 g, 0.791 mmol), XPhos Pd G4 (0.071 g, 0.078 mmol) and K3PO4 (0.250 g, 1.18 mmol) were added and the resulting mixture was heated at 85°C for 1 h. The reaction mixture was cooled to RT and partitioned between DCM and H2O. The layers were separated and the aqueous layer was extracted twice with DCM. The organic layers were combined, dried over Na2SO4 and concentrated in vacuo. The residue was purified on silica gel (gradient, 0 to 6% 7N NH3 / MeOH in DCM) to give the title compound (0.404 g, 62%) as a slightly yellow-brown solid. MS (ES) m / z = 831 (M+1).
[0843] Preparation Example 244
[0844] 8-[6-[2-(tert-Butyloxycarbonylamino)-3-cyano-7-fluoro-thieno[3,2-c]pyridin-4-yl]-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]
[0845] Octane-3-carboxylic acid tert-butyl ester
[0846]
[0847] In a manner similar to the method of Preparation Example 158, the title compound (0.667 g, 46%) was obtained using tert-butyl N-(4-chloro-3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamate. MS (ES) m / z = 849 (M+1).
[0848] Preparation Example 245
[0849] 8-[6-[2-(tert-Butyloxycarbonylamino)-3-cyano-7-fluoro-thieno[3,2-c]pyridin-4-yl]-5-fluoro-3-[(2-methoxy-1,2,3,5,6,7-hexahydropyrrolizin-8-yl)methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]
[0850] Octane-3-carboxylic acid tert-butyl ester
[0851]
[0852] In a manner similar to the method of Preparation Example 158, the title compound (0.43 g, 42%) was obtained using 8-[6-bromo-5-fluoro-3-[(2-methoxy-1,2,3,5,6,7-hexahydropyrrolizin-8-yl)methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester and N-(4-chloro-3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamic acid tert-butyl ester. MS (ES) m / z = 861 (M+1).
[0853] Preparation Example 246
[0854] 8-[6-[2-(tert-Butyloxycarbonylamino)-3-cyano-7-methyl-thieno[3,2-c]pyridin-4-yl]-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]
[0855] Octane-3-carboxylic acid tert-butyl ester
[0856]
[0857] In a manner similar to the method of Preparation Example 158, the title compound (0.10 g, 24%) was obtained using tert-butyl N-(4-chloro-3-cyano-7-methyl-thieno[3,2-c]pyridin-2-yl)carbamate. MS (ES) m / z = 845 (M+1).
[0858] Preparation Example 159
[0859] 6-[6-[2-(tert-Butyloxycarbonylamino)-3-cyano-thieno[3,2-c]pyridin-4-yl]-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxylate
[0860] Tert-butyl ester
[0861]
[0862] In a manner similar to the method of Preparation Example 158, the title compound (0.101 g, 42.5%) was obtained as a light yellow solid using 6-[6-bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxylic acid tert-butyl ester. MS (ES) m / z = 617 (M+1).
[0863] Preparation Example 307
[0864] 8-[6-[2-(tert-Butyloxycarbonylamino)-3-cyano-7-fluoro-thieno[3,2-c]pyridin-4-yl]-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0865]
[0866] In a manner similar to the method of Preparation Example 158, 8-(6-bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester and N-(4-chloro-3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamic acid tert-butyl ester were used to obtain the title compound (2.15 g, 61%) as a white solid. MS (ES) m / z = 752 (M+1).
[0867] Preparation Example 308
[0868] N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuran
[0869] tert-Butyl [3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate
[0870]
[0871] In a manner similar to the method of Preparation Example 158, the title compound (0.080 g, 35%) was obtained using 6-bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazoline and tert-butyl N-(4-chloro-3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamate. MS (ES) m / z = 639 (M+1).
[0872] Preparation Example 325
[0873] 6-[6-[2-(tert-Butyloxycarbonylamino)-3-cyano-7-fluoro-thieno[3,2-c]pyridin-4-yl]-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxylic acid tert-butyl ester
[0874]
[0875] In a manner similar to the method of Preparation Example 158, the title compound was obtained using 6-(6-bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,6-diazabicyclo[3.1.1]heptane-3-carboxylic acid tert-butyl ester and N-(4-chloro-3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamic acid tert-butyl ester. MS (ES) m / z = 738 (M+1).
[0876] Preparation Example 326
[0877] N-[3-cyano-4-(3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-7-fluoro-thieno[3,2-c]pyridin-2-yl]
[0878] Tert-Butyl Carbamate
[0879]
[0880] In a manner similar to the method of Preparation Example 158, 6-bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline and tert-butyl N-(4-chloro-3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamate were used to obtain the title compound (43.0 g, 72%) as a brown solid. MS (ES) m / z = 542 (M+1).
[0881] Preparation Example 327
[0882] 8-[6-[2-(tert-Butyloxycarbonylamino)-3-cyano-7-fluoro-thieno[3,2-c]pyridin-4-yl]-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3-azabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0883]
[0884] In a manner similar to the method of Preparation Example 158, the title compound (0.050 g, 9%) was obtained using 8-(6-bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3-azabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester and N-(4-chloro-3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamic acid tert-butyl ester. MS (ES) m / z = 751 (M+1).
[0885] Preparation Example 160
[0886] 8-[6-[3-cyano-2-[dimethylaminomethyleneamino]benzofuran-4-yl]-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-
[0887] Butyl Ester
[0888]
[0889] To a round-bottom flask were added tert-butyl 8-[6-bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (1.10 g, 1.73 mmol), N'-[3-cyano-4-(5,5-dimethyl- 1,3,2-dioxaborinane-2-yl)benzofuran-2-yl]-N,N-dimethyl-formamidine (0.67 g, 2.07 mmol, 1.2 eq.), K3PO4 (0.550 g, 2.59 mmol, 1.5 eq.), Pd-118 (0.11 g, 0.173 mmol, 0.10 eq.), 1,4-dioxane (8.6 mL) and H2O (1.7 mL). The mixture was bubbled with N2 and then heated at 90°C for 3 h. The reaction was cooled, diluted with EtOAc, washed with saturated aqueous NaHCO3 and brine, then dried over MgSO4, filtered and concentrated. The residue was purified on silica gel (0-10% MeOH / DCM) to give the title compound (0.78 g, 58.7%). MS (ES) m / z = 769 (M+1).
[0890] Preparation Example 161
[0891] 8-[6-[2-(tert-Butoxycarbonylamino)-5-fluoro-benzofuran-4-yl]-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline
[0892] -1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0893]
[0894] In a manner similar to the method of Preparation Example 160, the title compound (0.375 g, 95.0%) was obtained using 8-(6-bromo-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester and N-[4-(5,5-dimethyl-1,3,2-dioxaborinane-2-yl)-5-fluoro-benzofuran-2-yl]carbamic acid tert-butyl ester. MS (ES) m / z = 710 (M+1).
[0895] Preparation Example 162
[0896] [4-[2-(tert-Butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5-chloro-7-methylthio-1,3-dihydrofuro[3,4-f]quinolin-9-yl] trifluoromethanesulfonate
[0897]
[0898] To a stirred mixture of tert-butyl N-[4-(5-chloro-9-hydroxy-7-methylthio-1,3-dihydrofurano[3,4-f]quinolin-4-yl)-3-cyano-7-fluoro-benzothiophen-2-yl]carbamate (7.5 g, 13.44 mmol, 1 eq.) and 2,6-lutidine (3.31 g, 30.91 mmol, 2.3 eq.) in DCM (100 mL) at 0°C under N2 was added DMAP (0.25 g, 2.01 mmol, 0.15 eq.) and Tf2O (7.58 g, 26.88 mmol, 2 eq.) dropwise. The resulting mixture was stirred at 0°C for 2 h. The mixture was concentrated under reduced pressure and the residue was purified on silica gel using PE:EtOAc (3:1 to 1:1) as eluent to give the title compound (8.0 g, 86%) as a light yellow solid. MS (ES) m / z = 690 (M+1).
[0899] Preparation Example 163
[0900] tert-Butyl N-[4-(9-bromo-5-chloro-7-methylthio-1,3-dihydrofuro[3,4-f]quinolin-4-yl)-3-cyano-7-fluoro-benzothiophen-2-yl]carbamate
[0901]
[0902] To a stirred solution of [4-[2-(tert-butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5-chloro-7-methylthio-1,3-dihydrofuro[3,4-f]quinolin-9-yl] trifluoromethanesulfonate (8.0 g, 11.5 mmol, 1 eq.) in ACN (100 mL) was added LiBr (20.13 g, 231.8 mmol, 20 eq.). The resulting mixture was stirred at 85 °C for 18 h. The mixture was concentrated under reduced pressure and then poured into H2O (200 mL). After filtration, the filter cake was dried under vacuum at 40°C to give a crude product, which was then suspended in 1,4-dioxane (70 mL) and di-tert-butyl dicarbonate (3.77 g, 17.28 mmol, 1.5 eq.) and DMAP (0.31 g, 2.53 mmol, 0.22 eq.) were added. The resulting mixture was stirred at RT for 2 h and then concentrated under reduced pressure. The residue was purified on silica gel using DCM / EtOAc (15:1 to 10:1) to give the title compound (6.0 g, 84%) as a yellow solid. MS (ES) m / z = 620 (M-1).
[0903] Preparation Example 164
[0904] 8-[6-(2-amino-3-cyano-benzofuran-4-yl)-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0905]
[0906] To a round-bottom flask was added 8-[6-[3-cyano-2-[dimethylaminomethyleneamino]benzofuran-4-yl]-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizine-8-yl]methoxy]-7,9-dihydrofurano[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester (780 mg, 1.02 mmol), MeOH (20 mL) and 1M NaOH (2.5 mL, 2.5 mmol, 2.5 eq.). The mixture was heated to 60° C. and stirred for 5 h. The reaction was cooled to 0° C. and 5N HCl was added to adjust to pH 4. The reaction mixture was placed on a 20 g SCX column, washed with 3 column volumes of MeOH, and then eluted with 3 column volumes of 2N NH3 in MeOH. The basic fraction was concentrated to give the title compound (588 mg, 81.2%) as an oil. MS (ES) m / z = 715 (M+1).
[0907] Preparation Example 165
[0908] N-[2-[4-[2-(tert-Butyloxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5-chloro-7-methylthio-1,3-dihydrofuran
[0909] tert-Butyl [3,4-f]quinolin-9-yl]ethyl]carbamate
[0910]
[0911] A mixture of tert-butyl N-[4-(9-bromo-5-chloro-7-methylthio-1,3-dihydrofuro[3,4-f]quinolin-4-yl)-3-cyano-7-fluoro-benzothiophen-2-yl]carbamate (0.500 g, 0.805 mmol), tert-butyl N-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborinan-2-yl)ethyl]carbamate (0.466 g, 1.65 mmol) and Cs2CO3 (0.787 g, 2.42 mmol) in 1,4-dioxane (8 mL) and water (0.8 mL) was bubbled with N2 for 15 min. Pd(ddpf)Cl2 (0.059 g, 0.081 mmol) was added and the resulting mixture was heated at 70°C for ~18 h. The reaction mixture was cooled to RT and partitioned between DCM and H2O. The layers were separated and the aqueous layer was extracted twice with DCM and twice with CHCl3:IPA (4:1). The organic layers were combined, dried over Na2SO4 and concentrated in vacuo. The residue was purified on silica gel using EtOAc / Hex (10-70%) to give the title compound (0.367 g, 67%) as a white solid. MS (ES) m / z = 685 (M+1).
[0912] Preparation Example 166
[0913] 8-[4-[2-(tert-Butyloxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5-fluoro-7-methylthio-1,3-dihydrofuro[3,4-f]
[0914] Quinolin-9-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0915]
[0916] A suspension of tert-butyl 3,8-diazabicyclo[3.2.1]octane-3-carboxylate (0.416 g, 1.90 mmol, 2.5 eq.), tert-butyl N-[4-(9-bromo-5-fluoro-7-methylsulfanyl-1,3-dihydrofuro[3,4-f]quinolin-4-yl)-3-cyano-7-fluoro-benzothiophen-2-yl]carbamate (0.446 g, 0.70 mmol) and Cs2CO3 (0.481 g, 1.47 mmol, 2 eq.) in DMF (25 mL) was purged with N2 for ~5 min. Pd2(dba)3 (0.085 g, 0.15 mmol, 0.2 eq.) and BrettPhos (0.165 g, 0.292 mmol, 0.4 eq.) were added, the flask was sealed and heated to 100°C for 6 h. The reaction mixture was cooled to RT, diluted with EtOAc and washed with brine. The aqueous layer was extracted with EtOAc, and the combined organic layers were dried over Na2SO4 and concentrated. The residue was purified on silica gel, eluting with EtOAc / Hex (0% to 60%) to give the title compound (0.221 g, 39%) as a yellow solid. MS (ES) m / z = 737 (M+1).
[0917] Preparation Example 167
[0918] (1R,4R)-5-[6-[2-(tert-Butyloxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5-methyl-7,9-dihydrofuro[3,4-f]
[0919] Quinazolin-1-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester
[0920]
[0921] To a stirred mixture of (1R,4R)-5-[6-[2-(tert-butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5-chloro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester (470 mg, 0.68 mmol), K2CO3 (281 mg, 2.03 mmol) and methylboronic acid (406 mg, 6.78 mmol) in 1,4-dioxane (20 mL) was added RuPhos (94.9 mg, 0.20 mmol) and XPhos Palladacycle Gen. 4 (117 mg, 0.14 mmol) portionwise at RT. The resulting mixture was stirred at 100° C. under N2 for 2 h. The mixture was cooled to RT, diluted with H2O (100 mL), and extracted with EtOAc (3×100 mL). The combined organic layers were washed with brine (3×100 mL), dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography using PE / EtOAc (1:1 to 1:2) to give the title compound (350 mg, 69.0%) as a red solid. MS (ES) m / z=673 (M+1).
[0922] Preparation Example 168
[0923] 8-[6-[2-(tert-Butyloxycarbonylamino)-5-fluoro-benzothiophen-4-yl]-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-
[0924] tert-Butyl diazabicyclo[3.2.1]octane-3-carboxylate
[0925]
[0926] To a solution of 8-[6-[2-(tert-butoxycarbonylamino)-5-fluoro-benzothiophene-4-yl]-3-ethylthio-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester (28.6 g, 37.4 mmol) in THF (375 mL) was added TES (24 mL, 150 mmol, 4.00 eq.) and PdCl2 (0.688 g, 3.69 mmol, 0.10 eq.) and stirred at RT for 4 h. H2O (100 mL) was added dropwise and the mixture was stirred at RT for 15 min. The mixture was filtered through celite and rinsed with EtOAc (100 mL). The filtrate was partitioned and the organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified on silica gel using EtOAc / hexane (10-60%) to give the title compound (22.35 g, 90%) as a white foam. MS (ES) m / z = 666 (M+1).
[0927] The following compounds in Table 9 were prepared in a manner similar to Preparation 168. A variety of methods were used to purify the compounds, which methods would be apparent to those skilled in the art.
[0928] Table 9:
[0929]
[0930]
[0931] Preparation Example 172
[0932] 8-[6-[2-(tert-Butoxycarbonylamino)-3-cyano-5-fluoro-benzothiophen-4-yl]-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline-1-yl
[0933] tert-Butyl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylate
[0934]
[0935] In a 250 mL 3-necked round bottom flask equipped with a thermocouple, N2 inlet and dropping funnel, 8-[6-[2-(tert-butoxycarbonylamino)-5-fluoro-benzothiophen-4-yl]-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester (0.640 g, 0.961 mmol) was dissolved in THF (10 mL). The flask was placed in a bath (ACN / dry ice) at -45°C and purged with N2. After the internal temperature reached -45°C, chlorosulfonyl isocyanate (0.42 mL, 4.8 mmol, 5.0 eq.) was added dropwise at a rate such that the internal temperature remained below -30°C. After 90 min, the cold reaction mixture was poured into DMF (15 mL) and stirred at RT for 1 h. The mixture was diluted with EtOAc and then washed with 0.2M LiCl (3×300 mL) and brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified on silica gel using EtOAc / hexane (10% to 100%) to give the title compound (0.553 g, 83%) as a white solid. MS (ES) m / z=691 (M+1).
[0936] The following compounds in Table 10 were prepared in a manner similar to that described in Preparation 172. A variety of methods were used to purify the compounds, which methods would be apparent to those skilled in the art.
[0937] Table 10:
[0938]
[0939]
[0940]
[0941] AD-H,50×250mm,30% EtOH:70% CO2,180mL / min
[0942] AD-H, 30×250mm, 35% IPA (0.2% DEA): 65% CO2, 50mL / min
[0943] Preparation Example 255
[0944] 8-[6-[2-(tert-Butoxycarbonylamino)-3-cyano-5-fluoro-benzothiophen-4-yl]-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline-1-yl
[0945] tert-Butyl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylate, isomer 2
[0946]
[0947] In a manner similar to the method of Preparation Example 168, 8-[6-[2-(tert-butoxycarbonylamino)-3-cyano-5-fluoro-benzothiophen-4-yl]-3-ethylthio-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester was reacted, followed by chiral purification ( AD-H, 30×250 mm, 30% IPA:70% CO2, 100 mL / min) to obtain the title compound (1.02 g, 35%). MS (ES) m / z = 691 (M+1).
[0948] Preparation Example 176
[0949] 8-[6-(2-amino-3-cyano-5-fluoro-benzofuran-4-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0950]
[0951] To a round bottom flask was added 8-[6-[3-cyano-2-[dimethylaminomethyleneamino]-5-fluoro-benzofuran-4-yl]-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester (0.225 g, 0.357 mmol), MeOH (2 mL) and 1 M NaOH (0.9 mL, 0.893 mmol, 2.5 eq.) and heated at 60°C for 90 min. The reaction was cooled to 0°C and 5N HCl was added to adjust to pH 4. The mixture was washed with brine, extracted with EtOAc (3×), dried over MgSO4, filtered and concentrated to give the title compound (0.188 g, 92%). MS (ES) m / z=576 (M+1).
[0952] Preparation Example 177
[0953] 8-[6-[2-(tert-Butyloxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-3-ethylthio-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0954]
[0955] To tert-butyl 8-[6-[2-(tert-butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5-chloro-3-ethylthio-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (0.390 g, 0.498 mmol) in 1,4-dioxane (5 mL) and IPA ( To a solution in 1 mL of 4% paraformaldehyde (0.1 mL) was added Cs2CO3 (0.489 g, 1.50 mmol, 3.0 eq) and chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.041 g, 0.051 mmol, 0.10 eq.) and heated at 100°C for ~18 h. The reaction was cooled to RT. The mixture was diluted with EtOAc, washed with saturated aqueous NH4Cl and brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by silica gel chromatography eluting with EtOAc / Hex (10-50%) to give the title compound (0.289 g, 60%) as an off-white solid with 75% purity, which was used in the subsequent step without further purification. MS (ES) m / z = 733 (M+1).
[0956] Preparation Example 256
[0957] 8-[6-[2-(tert-Butoxycarbonylamino)-3-cyano-benzothiophen-4-yl]-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0958]
[0959] In a manner similar to the method of Preparation Example 177, the title compound (0.57 g, 83%) was obtained using 8-[6-[2-(tert-butoxycarbonylamino)-3-cyano-benzothiophen-4-yl]-5-chloro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester. MS (ES)
[0960] m / z=812(M+1).
[0961] Preparation Example 178
[0962] 8-[6-[2-(tert-Butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-3-ethylsulfonyl-5-fluoro-7,9-dihydrofuran
[0963] [3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[0964]
[0965] To a solution of 8-[6-[2-(tert-butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester (1.13 g, 1.47 mmol) in DCM (15 mL) was added mCPBA (0.842 g, 4.88 mmol, 3.3 eq.) and stirred at RT for 2 h. The mixture was diluted with DCM, washed with saturated aqueous NaHCO3 and brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified on silica gel eluting with 40% EtOAc / Hex to give the title compound (1.15 g, 75%) as a white solid. MS (ES) m / z = 783 (M+1).
[0966] The following compounds in Table 11 were prepared in a manner similar to that described in Preparation 178. A variety of methods were used to purify the compounds, which methods would be apparent to those skilled in the art.
[0967] Table 11:
[0968]
[0969]
[0970]
[0971]
[0972]
[0973]
[0974] 1 Single atropisomer (from the precursor in Preparation 157)
[0975] 2 Single atropisomer (from the precursor in Preparation 248)
[0976] 3Single atropisomer (from the precursor in Preparation 251)
[0977] Preparation Example 190
[0978] 6-[6-[2-(tert-Butoxycarbonylamino)-3-cyano-5-fluoro-benzothiophen-4-yl]-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline-1-yl
[0979] tert-Butyl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxylate
[0980]
[0981] To a solution of 6-[6-[2-(tert-butoxycarbonylamino)-3-cyano-5-fluoro-benzothiophene-4-yl]-3-ethylsulfonyl-5-fluoro-7,9-dihydrofurano[3,4-f]quinazolin-1-yl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxylic acid tert-butyl ester (1.16 g, 1.50 mmol) in DCM (15 mL) and MeOH (15 mL) stirred at RT was added NaBH4 (0.58 g, 15 mmol, 10 eq.). After 15 min, the reaction mixture was diluted with DCM (300 mL), and then saturated NaHCO3 aqueous solution (100 mL) and H2O (500 mL) were added. The reaction mixture was stirred at RT until gas evolution ceased. The organic layer was separated and the aqueous layer was extracted with DCM (300 mL). The organic layers were combined, then dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified on silica gel using MeOH / DCM (0-2%) as eluent to give the title compound (0.80 g, 77%). MS (ES) m / z = 677 (M+1).
[0982] The following compounds in Table 12 were prepared in a manner similar to that described in Preparation 190. A variety of methods were used to purify the compounds, which methods would be apparent to those skilled in the art.
[0983] Table 12:
[0984]
[0985] Preparation Example 193
[0986] (1R,4R)-5-[6-[2-(tert-Butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-9-(cyanomethyl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester
[0987]
[0988] To a sealed flask was added tert-butyl (1R,4R)-5-[6-bromo-9-(cyanomethyl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate (1.00 g, 1.98 mmol) and tert-butyl N-[3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-7-fluoro-benzothiophen-2-yl]carbamate (1.20 g, 2.97 mmol) in THF (20.0 mL). The flask was bubbled with N2 for 15 min, then Pd-117 (430 mg, 0.601 mmol) was added, followed by Cs2CO3 (1.30 g, 3.99 mmol). The flask was sealed and heated in an oil bath at 70°C for 2 h with stirring. The reaction mixture was cooled to RT, diluted with THF and filtered through a pad of celite. The filter cake was washed with 10% MeOH in DCM. The filtrate was concentrated and the residue was purified by silica gel column chromatography using acetone / hexane (0-40%) to give a crude product, which was purified again on silica gel using 1% to 5% 7N NH3 / MeOH in DCM to give the title compound (0.795 g, 56%) as a yellow solid. MS (ES) m / z = 716 (M+1).
[0989] Preparation Example 194
[0990] (1R,4R)-5-[6-[2-(tert-Butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5-chloro-9-(cyanomethyl)-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester
[0991]
[0992] In a manner similar to the method of Preparation Example 193, the title compound (0.25 g, 54.7%) was obtained as a yellow solid using (1R,4R)-5-[6-bromo-5-chloro-9-(cyanomethyl)-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester. MS (ES) m / z = 732 (M+1).
[0993] Preparation Example 333
[0994] 6-Bromo-3-ethylsulfonyl-5-fluoro-N-[[(2S)-1-methylpyrrolidin-2-yl]methyl]-7,9-dihydrofuro[3,4-f]quinazolin-1-amine
[0995]
[0996] In a manner similar to the method of Preparation Example 102, the title compound was obtained using 6-bromo-1-chloro-3-ethylsulfonyl-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline and [(2S)-1-methylpyrrolidin-2-yl]methanamine. MS (ES) m / z = 473, 475 (M+1, Br).
[0997] Preparation Example 195
[0998] 8-[6-[2-(tert-Butyloxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid
[0999] Tert-butyl ester
[1000]
[1001] To [(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methanol (1.15 g, 7.01 mmol) in THF (30 mL) under N2 at RT was added LiHMDS (6.7 mL, 6.7 mmol, 1 M in THF) dropwise and stirred at RT for 20 min. To this solution was added 8-[6-[2-(tert-butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-3-ethylsulfonyl-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester (2.3 g, 2.9 mmol) in THF (20 mL) dropwise via syringe. After 40 min, the reaction was diluted with EtOAc and washed with brine. The aqueous layer was extracted twice with EtOAc, and the combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated to give a brown solid. The material was purified by silica gel (0% to 3.5% 7N NH3 / MeOH in DCM) to give the title compound (2.26 g, 91%) as a yellow solid. MS (ES) m / z = 848 (M+1).
[1002] The following compounds in Table 13 were prepared in a manner similar to that described in Preparation 195. A variety of methods were used to purify the compounds, which methods would be apparent to those skilled in the art.
[1003] Table 13:
[1004]
[1005]
[1006]
[1007]
[1008]
[1009]
[1010]
[1011]
[1012]
[1013]
[1014]
[1015]
[1016]
[1017]
[1018]
[1019]
[1020]
[1021]
[1022]
[1023]
[1024]
[1025]
[1026]
[1027]
[1028]
[1029]
[1030] 1 The reaction was heated at 55 °C for -18 h.
[1031] 2 Single atropisomer (from the precursor in Preparation 157)
[1032] 3 The reaction was heated at 80 °C for 1 h.
[1033] 4 The reaction was heated at 60 °C for -48 h.
[1034] 5 Will AD-H, 21×150mm, 25% IPA (0.5% DMEA): 75% CO2, 70mL / min
[1035] 6 Single atropisomer (from the precursor in Preparation 248)
[1036] 7 Single atropisomer (from the precursor in Preparation 251)
[1037] OD, 20×250mm, 20% EtOH (0.5% DMEA): 80% CO2, 80mL / min
[1038] Preparation Example 223
[1039] 4-Bromo-5-fluoro-7-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-1,3-dihydrofuro[3,4-f]quinoline
[1040]
[1041] A solution of LHMDS (1M in THF, 7.3 mL, 7.3 mmol) and N-methyl-l-prolinol (0.9 mL, 7 mmol) in DMF (15 mL) was stirred for 5 min. A suspension of 4-bromo-7-chloro-5-fluoro-1,3-dihydrofuro[3,4-f]quinoline (1.0 g, 3.3 mmol) in DMF (30 mL) was added and stirred at RT for ~18 h. The reaction solution was added to H2O (150 mL) and the resulting solid was filtered, washed with H2O, and placed under vacuum at 40 °C overnight to give the title compound (1.1 g, 85%) as a white solid. MS (ES) m / z = 381 (M+1).
[1042] Preparation Example 224
[1043] 8-[6-[2-(tert-Butyloxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5-chloro-3-cyano-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[1044]
[1045] A mixture of 8-[6-[2-(tert-butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5-chloro-3-ethylsulfonyl-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester, isomer 2 (Preparation Example 157; 765 mg, 0.957 mmol) and NaCN (93.8 mg, 1.91 mmol) in DMSO (10 mL) was stirred at RT for 1 h. The resulting mixture was diluted with EtOAc (200 mL), washed with H2O (3×200 mL) and brine (200 mL), then dried over anhydrous Na2SO4, concentrated and concentrated under reduced pressure to give the title compound (650 mg, 93%) as a yellow solid. MS (ES) m / z=732 (M+1).
[1046] Preparation Example 225
[1047] 6-[2-(tert-Butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-1-(3-tert-Butoxycarbonyl-3,8-diazabicyclo
[1048] [3.2.1]octan-8-yl)-5-chloro-7,9-dihydrofuro[3,4-f]quinazoline-3-carboxylic acid methyl ester
[1049]
[1050] At RT, to a stirred solution of 8-[6-[2-(tert-butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophene-4-yl]-5-chloro-3-cyano-7,9-dihydrofurano[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester (650 mg, 0.888 mmol) in MeOH (10 mL) was added dropwise a solution of NaOH (71.0 mg, 1.78 mmol) in H2O (10 mL). The resulting mixture was stirred at RT for 2 h. The mixture was cooled to 0 ° C and acidified to pH 2-3 using 1N HCl solution and stirred at RT for 2 h. The resulting mixture was concentrated under reduced pressure and extracted with EtOAc (300 mL). The combined organic layers were washed with H2O (3×200 mL) and brine (200 mL), and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give the title compound (580 mg, 85%) as a yellow solid. MS (ES) m / z = 765 (M+1).
[1051] Preparation Example 226
[1052] 8-[6-[2-(tert-Butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-5-chloro-3-(hydroxymethyl)-7,9-dihydrofuran
[1053] [3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[1054]
[1055] To a mixture of methyl 6-[2-(tert-butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophen-4-yl]-1-(3-tert-butoxycarbonyl-3,8-diazabicyclo[3.2.1]octan-8-yl)-5-chloro-7,9-dihydrofuro[3,4-f]quinazoline-3-carboxylate (200 mg, 0.261 mmol) in EtOH (20 mL) stirred at 0°C was added NaBH4 (19.8 mg, 0.522 mmol) in portions. The resulting mixture was stirred at RT under N2 for 1 h. The reaction was quenched with H2O at 0°C. The resulting mixture was concentrated under reduced pressure and extracted with EtOAc (300 mL). The organic layer was washed with H2O (3×200 mL), brine (200 mL) and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give the title compound (150 mg, 78%) as a yellow solid. MS (ES) m / z = 737 (M+1).
[1056] Preparation Example 296
[1057] 8-[6-(2-amino-3-cyano-5-fluoro-benzofuran-4-yl)-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester, isomer 1
[1058]
[1059] A mixture of 8-[6-[2-(tert-butoxycarbonylamino)-3-cyano-5-fluoro-benzofuran-4-yl]-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester (0.548 g, 0.659 mmol) and hexafluoroisopropanol (3 mL) was stirred at 110° C. for 4 min under microwave irradiation. The mixture was concentrated and purified by reverse phase flash purification using a C18 column, eluting with 0% to 100% ACN in 10 mM NH4HCO3 aqueous solution with 5% MeOH to give the racemate, which was then subjected to chiral purification ( IC, 21×250 mm, 35% EtOH (w / 0.5% DMEA): 65% CO2, 80 mL / min) to give the title compound (0.126 g) as a white solid. MS (ES) m / z = 732 (M+1).
[1060] Preparation Example 297
[1061] 6-[6-(2-amino-3-cyano-5-fluoro-benzofuran-4-yl)-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxylic acid tert-butyl ester
[1062]
[1063] In a manner similar to the method of Preparation Example 296, the title compound (0.28 g) was obtained using 6-[6-[2-(tert-butoxycarbonylamino)-3-cyano-5-fluoro-benzofuran-4-yl]-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxylic acid tert-butyl ester. MS (ES) m / z=718 (M+1).
[1064] Preparation Example 298
[1065] (1R,4R)-5-[6-(2-amino-3-cyano-5-fluoro-benzofuran-4-yl)-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester, isobutyl
[1066] Construct 2
[1067]
[1068] In a manner similar to the method of Preparation Example 296, (1R, 4R)-5-[6-[2-(tert-butoxycarbonylamino)-3-cyano-5-fluoro-benzofuran-4-yl]-5-fluoro-3-[[(2R, 8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizine-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester was reacted, followed by chiral purification ( IC, 21×250mm, 40% MeOH:60% CO2, 70mL / min) to obtain the title compound (0.14g). MS (ES) m / z=718 (M+1).
[1069] Preparation Example 299
[1070] N-[4-[1-[3-[3-[tert-butyl(dimethyl)silanyl]oxypropyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]-5,7-
[1071] tert-Butyl difluoro-1,3-benzothiazol-2-yl]carbamate
[1072]
[1073] In a similar manner to the method of Preparation Example 156, the title compound (0.50 g) was obtained using [2-(tert-butoxycarbonylamino)-5,7-difluoro-1,3-benzothiazol-4-yl]boronic acid. MS (ES) m / z = 914 (M+1).
[1074] Preparation Example 400
[1075] 6-Bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-(2,2,2-trifluoroethoxy)-7,9-dihydrofuro[3,4-f]quinazoline
[1076]
[1077] In a manner similar to the method of Preparation Example 112, 6-bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-ol and trifluoroethanol were used to obtain the title compound (2.2 g, 77%) as a light yellow solid. MS (ES) m / z = 524,526 (M+1, Br).
[1078] Preparation Example 401
[1079] tert-Butyl N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-(2,2,2-trifluoroethoxy)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate
[1080]
[1081] In a manner similar to the method of Preparation Example 158, 6-bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-(2,2,2-trifluoroethoxy)-7,9-dihydrofuro[3,4-f]quinazoline and tert-butyl N-(4-chloro-3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamate were used to obtain the title compound (1.5 g) as a pale yellow solid. MS (ES) m / z = 737 (M+1).
[1082] Preparation Example 402
[1083] tert-N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-[[(2S)-1-methylpyrrolidin-2-yl]methylamino]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamic acid
[1084] Butyl Ester
[1085]
[1086] In a manner similar to the method of Preparation Example 158, the title compound was obtained using 6-bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-N-[[(2S)-1-methylpyrrolidin-2-yl]methyl]-7,9-dihydrofuro[3,4-f]quinazolin-1-amine and tert-butyl N-(4-chloro-3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl)carbamate. MS (ES) m / z = 751 (M+1).
[1087] Preparation Example 403
[1088] tert-Butyl N-[3-cyano-4-[1-(dimethylamino)-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]-7-fluoro-thieno[3,2-c]pyridin-2-yl]carbamate
[1089]
[1090] In a manner similar to the method of Preparation Example 111, the title compound was obtained using tert-butyl N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-(2,2,2-trifluoroethoxy)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate and dimethylamine. MS (ES) m / z = 682 (M+1).
[1091] Preparation Example 404
[1092] N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-(methylamino
[1093] tert-Butyl)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate
[1094]
[1095] In a manner similar to the method of Preparation Example 111, the title compound was obtained using tert-butyl N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-(2,2,2-trifluoroethoxy)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate and methylamine. MS (ES) m / z = 668 (M+1).
[1096] Preparation Example 405
[1097] tert-Butyl N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-(2-hydroxyethylamino)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate
[1098]
[1099] In a manner similar to the method of Preparation Example 111, the title compound was obtained using tert-butyl N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-(2,2,2-trifluoroethoxy)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate and ethanolamine. MS (ES) m / z = 698 (M+1).
[1100] Preparation Example 406
[1101] tert-Butyl N-[4-[1-(azetidin-1-yl)-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]-3-cyano-7-fluoro-thieno[3,2-c]pyridin-2-yl]carbamate
[1102]
[1103] In a manner similar to the method of Preparation Example 111, the title compound was obtained using tert-butyl N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-(2,2,2-trifluoroethoxy)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate and azetidine. MS (ES) m / z=694 (M+1).
[1104] Preparation Example 407
[1105] tert-Butyl N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-(3-methoxyazetidin-1-yl)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate
[1106]
[1107] In a manner similar to the method of Preparation Example 111, the title compound was obtained using tert-butyl N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-(2,2,2-trifluoroethoxy)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate and 3-methoxyazetidine. MS (ES) m / z=724 (M+1).
[1108] Preparation Example 408
[1109] tert-Butyl N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-morpholino-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate
[1110]
[1111] In a manner similar to the method of Preparation Example 111, the title compound was obtained using tert-butyl N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-(2,2,2-trifluoroethoxy)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate and morpholine. MS (ES) m / z = 724 (M+1).
[1112] Preparation Example 409
[1113] tert-Butyl N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-(2-methoxyethoxy)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate
[1114]
[1115] In a manner similar to the method of Preparation Example 195, the title compound was obtained using tert-butyl N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-(2,2,2-trifluoroethoxy)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate and 2-methoxyethanol. MS (ES) m / z = 713 (M+1).
[1116] Preparation Example 410
[1117] tert-Butyl N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-hydroxy-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate
[1118]
[1119] To a solution of tert-butyl N-[3-cyano-7-fluoro-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-(2,2,2-trifluoroethoxy)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]thieno[3,2-c]pyridin-2-yl]carbamate (0.15 g, 0.20 mmol) in THF (2 mL) was added dropwise a solution of NaOH (0.041 g, 1.02 mmol) in H2O (0.2 mL) under nitrogen. After 2 h, the mixture was diluted with H2O (50 mL) and extracted with EtOAc (2×100 mL). The combined organic layers were washed with brine (2×100 mL), dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The residue was diluted with DMF (2 mL) and purified by reverse phase flash purification using a C18 column, eluting with 24% to 37% ACN in a 10 mM NH4HCO3 aqueous solution with 0.05% NH4OH to give the title compound (0.022 g, 16%) as a white solid. MS (ES) m / z=655 (M+1).
[1120] Preparation Example 411
[1121] tert-Butyl N-(4-hydroxythieno[2,3-b]pyridin-2-yl)carbamate
[1122]
[1123] A mixture of 4-hydroxythieno[2,3-b]pyridine-2-carboxylic acid hydrochloride (1.96 g, 8.5 mmol) and triethylamine (4.8 mL, 34 mmol, 4.0 eq) in tert-butyl alcohol (40 mL) was heated to form a solution and then cooled to RT. Diphenylphosphoazidoester (2.5 mL, 11 mmol, 1.3 eq) was added. The reaction mixture was stirred at RT for 10 min and then heated at 85 °C overnight. The mixture was concentrated in vacuo. The residue was purified on silica gel, eluting with 10-100% acetone in hexanes to give the title compound (1.70 g, 76%). MS (ES) m / z = 267 (M+1).
[1124] Preparation Example 412
[1125] (2-Aminothieno[2,3-b]pyridin-4-yl) trifluoromethanesulfonate
[1126]
[1127] To a suspension of tert-butyl N-(4-hydroxythieno[2,3-b]pyridin-2-yl)carbamate (1.45 g, 5.4 mmol) in DCM (110 mL) was added 2,6-lutidine (1.2 mL, 10 mmol, 1.9 eq) and 4-dimethylaminopyridine (0.067 g, 0.54 mmol, 0.10 eq). The reaction mixture was cooled in an ice bath and treated dropwise with trifluoromethanesulfonic anhydride (1.2 mL, 7.0 mmol, 1.3 eq) and stirred in an ice bath for 1 h. Additional 2,6-lutidine (1.2 mL, 10 mmol, 1.9 eq) and trifluoromethanesulfonic anhydride (1.2 mL, 7.0 mmol, 1.3 eq) were added. The reaction mixture was stirred in an ice bath for 30 min and then quenched with saturated aqueous sodium bicarbonate. The layers were separated and the aqueous layer was extracted twice with DCM. The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The residue was purified on silica gel, eluting with 0-75% MTBE in hexanes to give impure fractions. The impure fractions were concentrated in vacuo and further purified on silica gel, eluting with 50-100% DCM in hexanes. The aqueous layer was extracted 4 times with 4:1 CHCl3:isopropanol. The combined organic layers were dried over sodium sulfate and concentrated in vacuo. The residue was purified on silica gel, eluting with 10-50% MTBE in hexanes. The clean fractions from the second and third silica gel purifications were combined and concentrated in vacuo to give the title compound (0.71 g, 44%) as an off-white solid. MS (ES) m / z = 299 (M+1).
[1128] Preparation Example 413
[1129] [2-[Bis(tert-butoxycarbonyl)amino]thieno[2,3-b]pyridin-4-yl] trifluoromethanesulfonate
[1130]
[1131] To a solution of (2-aminothieno[2,3-b]pyridin-4-yl) trifluoromethanesulfonate (0.67 g, 2.26 mmol) in 1,4-dioxane (45 mL) was added di-tert-butyl dicarbonate (1.23 g, 5.64 mmol, 2.5 eq) and 4-dimethylaminopyridine (0.028 g, 0.227 mmol, 0.10 eq). The reaction mixture was stirred at RT for 6 days and concentrated in vacuo. The residue was purified on silica gel, eluting with 0-50% MTBE in hexanes to give the title compound (0.93 g, 82%). MS (ES) m / z = 499 (M+1).
[1132] Preparation Example 414
[1133] [2-(tert-Butoxycarbonylamino)-3-cyano-thieno[2,3-b]pyridin-4-yl]trifluoromethanesulfonate
[1134]
[1135] A solution of [2-[bis(tert-butoxycarbonyl)amino]thieno[2,3-b]pyridin-4-yl]trifluoromethanesulfonate (0.550 g, 1.10 mmol) in acetonitrile (11 mL) was cooled in an ice bath. Chlorosulfonyl isocyanate (0.3 mL, 3 mmol, 3 eq) was added dropwise and the reaction mixture was stirred in an ice bath for 5 h, placed in a -20 °C refrigerator overnight, allowed to warm to RT, and stirred for 3.5 h. The reaction mixture was cooled in an ice bath, added dropwise to N,N-dimethylformamide (8.5 mL, cooled in an ice bath), stirred for 1 h, slowly poured into cold saturated aqueous sodium bicarbonate solution, and diluted with EtOAc. The layers were separated and the aqueous layer was extracted twice with EtOAc. The combined organic layers were washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, and concentrated in vacuo. The residue was purified on silica gel using 0-50% DCM in hexanes to give the title compound (0.118 g, 25%) as an off-white solid. MS (ES) m / z = 424 (M+1).
[1136] Preparation Example 415
[1137] 8-[6-[2-(tert-Butyloxycarbonylamino)-3-cyano-thieno[2,3-b]pyridin-4-yl]-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester
[1138]
[1139] Reaction mixture A: A mixture of tert-butyl 8-[6-bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (0.370 g, 0.581 mmol), KOAc (0.171 g, 1.74 mmol) and bis(neopentyldiol)diboron (0.197 g, 0.872 mmol) in 1,4-dioxane (6 mL) was bubbled with N2 for 10 min. [Bis(2-(diphenylphosphino)phenyl)ether]dichloropalladium(II) (0.043 g, 0.059 mmol) was added and the resulting mixture was sealed and heated at 95° C. for 2.5 h. The reaction mixture was cooled to RT and maintained overnight.
[1140] Reaction mixture B: A mixture of tert-butyl 8-[6-bromo-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (0.370 g, 0.581 mmol), KOAc (0.171 g, 1.74 mmol) and bis(neopentyldiol)diboron (0.197 g, 0.872 mmol) in 1,4-dioxane (6 mL) was bubbled with N2 for 10 min. [Bis(2-(diphenylphosphino)phenyl)ether]dichloropalladium(II) (0.043 g, 0.059 mmol) was added and the resulting mixture was sealed and heated at 95° C. overnight. The reaction mixture was cooled to RT.
[1141] Reaction mixture C: A mixture of [2-(tert-butoxycarbonylamino)-3-cyano-thieno[2,3-b]pyridin-4-yl]trifluoromethanesulfonate (0.162 g, 0.383 mmol), 1,4-dioxane (4 mL) and water (1.2 mL) was bubbled with N2 for 15 min. Potassium phosphate (0.162 g, 0.763 mmol) and XPhos Pd G4 (CAS#1599466-81-5; 0.035 g, 0.039 mmol) were added and the resulting mixture was sealed and heated at 85 °C. Reaction mixture A was added via syringe and heated for 1 h, then cooled to RT. The reaction mixture was heated again at 85 °C. One-third of reaction mixture B was added via syringe and heated for 1 h. The remaining reaction mixture B was added via syringe and heated for 1 h. The reaction mixture was partitioned between DCM and water. The layers were separated and the aqueous layer was extracted twice with DCM. The organic layers were combined, dried over Na2SO4 and concentrated in vacuo. The residue was purified on silica gel using 1-5% 7N ammoniacal methanol / DCM as eluent to give the title compound (0.200 g, 45%). MS (ES) m / z = 831 (M+1).
[1142] Example 1
[1143] 2-Amino-4-[1-(3,8-diazabicyclo[3.2.1]octan-8-yl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]-5-fluoro-benzothiophene-3-carbonitrile, isomer 2
[1144]
[1145] To a solution of tert-butyl 8-[6-[2-(tert-butoxycarbonylamino)-3-cyano-5-fluoro-benzothiophen-4-yl]-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (0.605 g, 0.876 mmol) in DCM (5 mL) was added TFA (4 mL) and stirred at RT for 25 min. The mixture was concentrated, DCM was added, and the mixture was concentrated again three times. The mixture was filtered through an SCX column, eluting with MeOH (4CV) and then eluting with 7N NH3 / MeOH (4CV) to give the crude product, which was purified on silica gel, eluting with a gradient of 1% to 10% 7N NH3 / MeOH in DCM to give the racemate, which was then subjected to chiral purification ( AS-H, 21×250 mm, 35% MeOH (w / 0.5% DMEA): 65% CO2, 80 mL / min) to give the title compound (0.129 g, 30%) as a white solid. MS (ES) m / z = 491 (M+1).
[1146] The example compounds in Table 14 were prepared in a similar manner as described in Preparation 296 or Example 1. A variety of methods were used to purify the compounds, which methods are obvious to those skilled in the art. The chiral purification methods used for the examples in Table 14 (if applicable) are provided in Table 18.
[1147] Table 14:
[1148]
[1149]
[1150]
[1151]
[1152]
[1153]
[1154]
[1155]
[1156]
[1157]
[1158]
[1159]
[1160]
[1161]
[1162]
[1163]
[1164]
[1165]
[1166]
[1167]
[1168]
[1169]
[1170]
[1171]
[1172]
[1173]
[1174]
[1175]
[1176]
[1177]
[1178]
[1179]
[1180] 1 Single diastereomer
[1181] 2 Single atropisomer (from the precursor in Preparation 157)
[1182] 3 Single atropisomer (from the precursor in Preparation 266)
[1183] 4 Single atropisomer (from the precursor in Preparation 248)
[1184] 5 Single atropisomer (from the precursor in Preparation 296)
[1185] 6 Single atropisomer (from the precursor in Preparation 251)
[1186] 7 Single atropisomer (from the precursor in Preparation 255)
[1187] 8 Single atropisomer (from the precursor in Preparation 298)
[1188] a Using MS(ES)-
[1189] Embodiment 46
[1190] 2-Amino-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-[3-(2-hydroxyethyl)-3,8-diazabicyclo[3.2.1]octan-8-yl]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]benzothiophene-3-carbonitrile
[1191]
[1192] A solution of tert-butyl N-[4-[1-[3-[2-[tert-butyl(dimethyl)silanyl]oxyethyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]-3-cyano-benzothiophen-2-yl]carbamate (0.250 g, 0.281 mmol) in THF (2 mL) was treated with 1 M TBAF in THF (0.7 mL, 0.7 mmol) and stirred at RT for 1.5 h. A second portion of 1 M TBAF in THF (0.7 mL, 0.7 mmol) was added and the mixture was stirred for ~18 h. The mixture was concentrated and dried under vacuum. The residue was dissolved in DCM (5 mL), treated with TFA (2 mL) and stirred at RT for ~18 h. The mixture was concentrated. DCM was added and the mixture was concentrated again. The residue was dissolved in DCM / MeOH, loaded onto an SCX, eluted with MeOH and DCM, then eluted with 1:12N NH3 / MeOH:DCM. The ammonia-charged eluent was concentrated in vacuo and purified by reverse phase flash chromatography using a C18 column, eluting with 5-50% ACN in 10 mM NH4HCO3 aqueous solution with 5% MeOH to give the title compound (0.111 g, 59%) as an off-white solid. MS (ES) m / z = 674 (M+1).
[1193] Embodiment 47
[1194] 2-Amino-7-fluoro-4-[5-fluoro-1-[(1S,4S,7S)-7-fluoro-2,5-diazabicyclo[2.2.1]heptane-2-yl]-7,9-dihydrofuro[3,4-f]
[1195] Quinazolin-6-yl]benzothiophene-3-carbonitrile
[1196]
[1197] (1S,4S,7R)-5-[6-[2-(tert-butoxycarbonylamino)-3-cyano-7-fluoro-benzothiophene-4-yl]-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-7-fluoro-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid benzyl ester (280 mg, 0.384 mmol) was stirred in TFA (10.0 mL) at RT. The resulting mixture was then stirred at 70 ° C for 5 h. The mixture was concentrated under reduced pressure and diluted with DMF (3 mL). The mixture was then basified to pH 9 with NH3H2O. The mixture was purified on a C18 column using a gradient elution of 46% to 65% ACN in 10 mM NH4HCO3 aqueous solution to give the title compound (39.5 mg, 20.2%) as a white solid. MS (ES) m / z = 495 (M+1).
[1198] Embodiment 48
[1199] 2-Amino-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-[3-(3-hydroxypropyl)-3,8-diazabicyclo[3.2.1]octan-8-yl]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]benzothiophene-3-carbonitrile
[1200]
[1201] A solution of 2-amino-4-[1-(3,8-diazabicyclo[3.2.1]octan-8-yl)-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]benzothiophene-3-carbonitrile (0.800 g, 1.27 mmol) in DCM (13 mL) and MeOH (2.5 mL) was treated with 3-[(tert-butyldimethylsilyl)oxy]-1-propanal (0.756 g, 3.81 mmol) and NaBH(OAc)3 (0.850 g, 3.81 mmol). After stirring at RT for 1 h, the reaction mixture was poured directly onto an SCX, eluting first with MeOH and DCM, then with 1:1 2N NH3 / MeOH:DCM. The ammoniated fractions were concentrated. The residue was dissolved in DCM / MeOH and passed through the SCX a second time. The concentrate from the ammoniated fractions was purified on silica gel (eluted with 0% to 5% 7N NH3 / MeOH in DCM) and then by reverse phase flash chromatography using a C18 column (eluted with 5% to 51% ACN in 10 mM NH4HCO3 aqueous solution with 5% MeOH) to give the title compound (0.541 g, 62%) as a light beige solid. MS (ES) m / z = 688 (M+1).
[1202] The example compounds in Table 15 were prepared in a similar manner as described in Example 48. A variety of methods were used to purify the compounds, which methods are obvious to those skilled in the art. The chiral purification methods used for the examples in Table 15 (if applicable) are located in Table 18.
[1203] Table 15:
[1204]
[1205]
[1206]
[1207]
[1208]
[1209]
[1210]
[1211]
[1212]
[1213]
[1214]
[1215]
[1216]
[1217]
[1218]
[1219]
[1220]
[1221]
[1222]
[1223]
[1224]
[1225]
[1226]
[1227]
[1228]
[1229]
[1230]
[1231]
[1232]
[1233]
[1234] 1 Single atropisomer (from the precursor in Example 1)
[1235] 2 Prepared using 37 wt% formaldehyde in water, without MeOH co-solvent
[1236] 3 Single atropisomer (from the precursor in Preparation 266)
[1237] 4 Single atropisomer (from the precursor in Preparation 248)
[1238] 5 Single atropisomer (from the precursor in Preparation 296)
[1239] 6 Single atropisomer (from the precursor in Preparation 251)
[1240] 7 Single atropisomer (from the precursor in Preparation 255)
[1241] Embodiment 55
[1242] 2-Amino-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-[3-[(2R)-2-hydroxypropyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]benzothiophene-3-carbonitrile
[1243]
[1244] A solution of 2-amino-4-[1-(3,8-diazabicyclo[3.2.1]octan-8-yl)-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]benzothiophene-3-carbonitrile (0.120 g, 0.191 mmol) in MeOH (4 mL) was treated with (R)-(+)-propylene oxide (0.056 g, 0.945 mmol). The mixture was heated at 70 °C in a sealed tube for 2 h and then concentrated. The residue was purified by reverse phase flash chromatography using a C18 column (eluting with 5% to 64% ACN in 10 mM NH4HCO3 aqueous solution with 5% MeOH) to give the title compound (0.089 g, 62%) as a light beige solid. MS (ES) m / z = 688 (M+1).
[1245] The example compounds in Table 16 were prepared in a similar manner as described in Example 48 or Example 55. A variety of methods were used to purify the compounds, which methods are obvious to those skilled in the art. The chiral purification methods used for the examples in Table 16 (if applicable) are located in Table 18.
[1246] Table 16:
[1247]
[1248]
[1249]
[1250]
[1251]
[1252]
[1253]
[1254]
[1255]
[1256]
[1257]
[1258]
[1259]
[1260]
[1261]
[1262] 1 Single atropisomer (from the precursor in Preparation 296)
[1263] 2 Single atropisomer (from the precursor in Preparation 248)
[1264] 3 Single atropisomer (from the precursor in Preparation 298)
[1265] Examples 56 and 57
[1266] 2-Amino-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-[3-[(2S)-2-hydroxypropyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]benzothiophene-3-carbonitrile
[1267] and
[1268] 2-Amino-4-[5-fluoro-1-[3-[(2S)-2-hydroxypropyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-methoxy-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]benzothiophene-3-carbonitrile
[1269]
[1270] In a manner similar to the method described in Example 55, 2-amino-4-[1-(3,8-diazabicyclo[3.2.1]octan-8-yl)-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]benzothiophene-3-carbonitrile was reacted using (S)-(-)-propylene oxide and heating the reaction at 70° C. for ~18 h. The product was purified by reverse phase flash purification using a C18 column (5% to 50% in 10 mM NH4HCO3 aqueous solution with 5% MeOH). After the residue was purified by elution with ACN (elution with 4% CO 2 ), the two products were separated to give 2-amino-4-[5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-1-[3-[(2S)-2-hydroxypropyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]benzothiophene-3-carbonitrile (0.033 g, 37%), a peach-colored solid, MS (ES) m / z = 688 (M+1), and 2-amino-4-[5-fluoro-1-[3-[(2S)-2-hydroxypropyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-3-methoxy-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]benzothiophene-3-carbonitrile (0.020 g, 26%), an off-white solid. MS (ES) m / z = 561 (M+1).
[1271] Embodiment 189
[1272] 3-[8-[6-(2-amino-3-cyano-5-fluoro-benzothiophen-4-yl)-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octan-3-yl]-N-methyl-propionamide
[1273]
[1274] A mixture of 2-amino-4-[1-(3,8-diazabicyclo[3.2.1]octan-8-yl)-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]-5-fluoro-benzothiophene-3-carbonitrile (single atropisomer from the precursor in Preparation 248, 0.060 g, 0.093 mmol), 3-chloro-N-methylpropanamide (0.056 g, 0.465 mmol), potassium iodide (0.0077 g, 0.046 mmol) and triethylamine (0.019 g, 0.186 mmol) in acetonitrile (3 mL) was heated at 80 °C for -12 h. The mixture was concentrated, diluted with DMF (2 mL), and purified by reverse phase flash purification using a C18 column, eluting with 35% to 51% ACN in 10 mM NH4HCO3 aqueous solution with 0.1% NH4OH to give the title compound (0.021 g, 30%) as a white solid. MS (ES) m / z = 733 (M+1).
[1275] The example compounds in Table 17 were prepared in a similar manner as described in Example 189. A variety of methods were used to purify the compounds, which methods are obvious to those skilled in the art. The chiral purification methods used for the examples in Table 17 (if applicable) are located in Table 18.
[1276] Table 17:
[1277]
[1278]
[1279]
[1280] 1 Single atropisomer (from the precursor in Preparation 248)
[1281] 2 Single atropisomer (from the precursor in Preparation 266)
[1282] Embodiment 194
[1283] 3-[8-[6-(2-amino-5,7-difluoro-1,3-benzothiazol-4-yl)-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-1-yl]-3,8-diazabicyclo[3.2.1]octan-3-yl]propan-1-ol
[1284]
[1285] In a similar manner to the method of Example 1, the title compound (0.028 g, 16%) was obtained using tert-butyl N-[4-[1-[3-[3-[tert-butyl(dimethyl)silanyl]oxypropyl]-3,8-diazabicyclo[3.2.1]octan-8-yl]-5-fluoro-3-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]-7,9-dihydrofuro[3,4-f]quinazolin-6-yl]-5,7-difluoro-1,3-benzothiazol-2-yl]carbamate. MS (ES) m / z = 700 (M+1).
[1286] The chiral purification methods used for the example compounds in Tables 14-17 are in Table 18.
[1287] Table 18: Purification methods
[1288]
[1289]
[1290]
[1291]
[1292] Columns are available from Daicel Chiral Technologies; West Chester, PA.
[1293] b XBridge columns are available from Waters Corp.; Milford, MA.
[1294] c Chiral ART columns are available from YMC America, Inc.; Devens, MA.
[1295] Columns are available from Phenomenex, Inc.; Torrance, CA.
[1296] Biological assays
[1297] The following assays demonstrate that the exemplified compounds are potent KRas G12D inhibitors, inhibiting the growth of certain tumors in vitro and / or in vivo.
[1298] Embodiment 376
[1299] Active RAS GTPase ELISA in PANC-1 cells (KRas G12D mutation)
[1300] The purpose of this assay is to measure the ability of the test compound to inhibit constitutive RAS GTPase activity in human PANC-1 (RRID: CVCL_0480) pancreatic ductal adenocarcinoma cells (supplier: ATCC#CRL-1469). The RAS GTPase ELISA kit (Active Motif catalog number 52097) contains a 96-well glutathione-coated capture plate and a glutathione-S-transferase (GST) fused to the Raf-Ras binding domain (RBD) protein provided by the kit. Activated pan-RAS (GTP-bound) in the cell extract specifically binds to Raf-RBD. The bound RAS is detected using a Ras primary antibody that recognizes human K-Ras (and H-Ras). The HRP-conjugated anti-rat IgG secondary antibody recognizes the primary antibody, and the chromogenic substrate solution promotes chemiluminescent readings.
[1301] PANC-1 cells were plated at 75,000 cells / well in 80 μL complete medium (DMEM, high glucose, L-glutamine, GIBCO; 10% heat-inactivated fetal bovine serum, GIBCO) and incubated overnight at 37°C / 5% CO2. After approximately 24 hours, 20 μL (1:3) serially diluted (in complete medium) test compounds (1 μM-50 μM top concentration) and 20 μL serially diluted (in complete medium) controls (maximum signal wells: 0.5% DMSO, minimum signal wells: 10 μM reference positive control compound) were added to the cell plate and incubated for 2 hours at 37°C / 5% CO2. Complete lysis / binding buffer containing protease inhibitor cocktail (PIC) was prepared and stored on ice. One hour before completing the cell plate incubation, GST-Raf-RBD was diluted in lysis / binding buffer, 50 μL of mixed buffer per well was added to the supplied opaque white ELISA assay plate, and incubated at 4 ° C for at least 1 hour with gentle shaking. After 2 hours, the cells were washed with 100 μL of ice-cold PBS without Ca2+ / Mg2+ and lysed with 100 μL of lysis / binding buffer (AM11) supplied with the kit. After vigorous shaking of the plate for 30-50 minutes at ambient temperature, the cell plate was centrifuged at 410xg (about 1500rpm) for 10 minutes. During the centrifugation step, a wash buffer diluted to 1X with ultrapure H2O and filtered through 0.2 μm was prepared at ambient temperature, and then used to wash the GST-Raf-RBD coated assay plate (3×100 μL). Next, 50 μL of cell lysate was added to the GST-Raf-RBD coated assay plate and incubated at ambient temperature for 1 hour with gentle shaking. During this incubation period, 1X antibody binding buffer was prepared from the thawed concentrate. The assay plate was washed with 1X wash buffer (3×100 μL), followed by the addition of 50 μL of RAS primary antibody (kit supply number 101678) diluted 1:500 in 1x antibody binding buffer. After one hour of ambient incubation with gentle shaking, the assay plate was washed with 1X wash buffer (3×100 μL). Subsequently, 50 μL of anti-rat HRP-conjugated IgG secondary antibody (0.25 μg / μL) (diluted 1:5000 in 1X antibody binding buffer) was added to each well of the assay plate and incubated at ambient temperature for another hour with gentle shaking. Finally, the assay plate was washed with 1X wash buffer (4×100 μL), followed by the addition of 50 μL of mixed ambient temperature chemiluminescent working solution (a combination of reaction buffer and chemiluminescent substrate). Using a luminescence program optimized for the assay plate size, the 2104 EnVision TM A plate reader (Perkin Elmer) recorded the luminescent emission data from each well.
[1302] The signal was converted to percent inhibition using the following equation:
[1303] % inhibition = 100 - [(test compound signal - median of minimum signal) / (median of maximum signal - median of minimum signal) x 100]. Maximum signal is the control well with no inhibitor (DMSO). Minimum signal is the control well containing a reference inhibitor sufficient to completely inhibit activity. v17, IC was determined by fitting the percent inhibition at each inhibitor concentration to a four-parameter nonlinear logistic equation 50 : y = (A + ((BA) / (1 + ((x / C) ^ D)))), where y = % inhibition, A = minimum asymptote, B = maximum asymptote, C = relative IC 50 Or the inhibitor concentration that produces 50% inhibition within the fitted range of the two asymptotes, D = Hill slope.
[1304] In the above assays, the compounds of Examples 1-5, 7-12, 14-18, 20-26, 28-59, 62, 64, 67, 68, 93-192, 194, 206-209, 211-239, 241-250, 279, 323, 327, 328, 331, 332, 334, 336, 340-345, 348, 351, 354-356, 358, 363, 364, 367-372, and 374 all exhibited the ability to inhibit constitutive RAS GTPase activity, thereby demonstrating inhibition of the KRas G12D mutant enzyme relative to the IC . 50 <100 nM. This data shows that compounds of Formula I-VIII (including Ia-VIIa) described herein are potent inhibitors of KRAS-GTP activity in this human pancreatic cancer cell culture, demonstrating their ability to inhibit the KRas G12D mutant.
[1305] Embodiment 377
[1306] Active RAS GTPase ELISA in MKN-45 cells (KRas wild type)
[1307] The purpose of this assay is to measure the ability of the test compound to inhibit constitutive RAS GTPase activity in human MKN-45 gastric adenocarcinoma cells (supplier: JCRB, supplier ID: JCRB 0254, batch number: 05222009). The RAS GTPase ELISA kit (Active Motif catalog number 52097) contains a 96-well glutathione-coated capture plate and a glutathione-S-transferase (GST) fused to the Raf-Ras binding domain (RBD) protein provided by the kit. Activated pan-RAS (GTP-bound) in the cell extract specifically binds to Raf-RBD. Bound RAS is detected with a Ras primary antibody that recognizes human K-Ras (and H-Ras). The HRP-conjugated anti-rat IgG secondary antibody recognizes the primary antibody, and the chromogenic substrate solution facilitates chemiluminescent readings.
[1308] MKN-45 cells were plated at 75,000 cells / well in 80 μL complete medium (DMEM, high glucose, L-glutamine, GIBCO; 10% heat-inactivated fetal bovine serum, GIBCO) and incubated overnight at 37°C / 5% CO2. After approximately 24 hours, 20 μL (1:3) serially diluted (in complete medium) test compounds (1-10 μM top concentration) and 20 μL serially diluted (in complete medium) controls (maximum signal wells: 0.1% DMSO, minimum signal wells: 10 μM reference positive control compound) were added to the cell plate and incubated for 2 hours at 37°C / 5% CO2. Complete lysis / binding buffer containing protease inhibitor cocktail (PIC) was prepared and stored on ice. One hour before completing the cell plate incubation, GST-Raf-RBD was diluted in lysis / binding buffer, 50 μL of the mixed buffer per well was added to the supplied opaque white ELISA assay plate, and incubated at 4 ° C for at least 1 hour with gentle shaking. After 2 hours, the cells were washed with 100 μL of ice-cold PBS without Ca2+ / Mg2+ and lysed with 100 μL of lysis / binding buffer (AM11) supplied with the kit. After vigorous shaking of the plate for 30-50 minutes at ambient temperature, the cell plate was centrifuged at 410xg (about 1500rpm) for 10 minutes. During the centrifugation step, the wash buffer was diluted to 1X with ultrapure H2O and then used to wash the GST-Raf-RBD coated assay plate (3×100 μL). Next, 50 μL of cell lysate was added to the GST-Raf-RBD coated assay plate and incubated at ambient temperature for 1 hour with gentle shaking. During this incubation period, 1X antibody binding buffer was prepared from the thawed concentrate. The assay plate was washed with 1X wash buffer (3×100 μL), followed by the addition of 50 μL of RAS primary antibody (kit supply number 101678) diluted 1:500 in 1x antibody binding buffer. After one hour of ambient incubation with gentle shaking, the assay plate was washed with 1X wash buffer (3×100 μL). Subsequently, 50 μL of anti-rat HRP-conjugated IgG secondary antibody (0.25 μg / μL) (diluted 1:5000 in 1X antibody binding buffer) was added to each well of the assay plate and incubated at ambient temperature for another hour with gentle shaking. Finally, the assay plate was washed with 1X wash buffer (4×100 μL), followed by the addition of 50 μL of mixed ambient temperature chemiluminescent working solution (a combination of reaction buffer and chemiluminescent substrate). Using a luminescence program optimized for the assay plate size, the 2104 EnVision TM A plate reader (Perkin Elmer) recorded the luminescent emission data from each well.
[1309] The signal was converted to percent inhibition using the following equation:
[1310] % inhibition = 100 - [(test compound signal - median of minimum signal) / (median of maximum signal - median of minimum signal) x 100]. Maximum signal is the control well with no inhibitor (DMSO). Minimum signal is the control well containing a reference inhibitor sufficient to completely inhibit activity. v17, IC was determined by fitting the percent inhibition at each inhibitor concentration to a four-parameter nonlinear logistic equation 50 : y = (A + ((BA) / (1 + ((x / C) ^ D)))), where y = % inhibition, A = minimum asymptote, B = maximum asymptote, C = relative IC 50 Or the inhibitor concentration that produces 50% inhibition within the fitted range of the two asymptotes, D = Hill slope.
[1311] Examples 1, 3, 5, 7, 9-11, 13-18, 20, 22-28, 45, 46, 48, 49, 51-58, 62, 64, 68, 95, 96, 98-100, 103, 106-108, 110, 113, 114, 116-127, 130-146, 148-151, 153, 156-158, 161, 162, 170-187, 189-192, 194, 212-214, 216-218, 2 Compounds 20, 224-229, 231, 232, 234-239, 241-243, 247-249, 327, 328, 330-332, 334-338, 340, 341, 343, 344, 348, 349, 351, 354-356, 358, 363, 364, 366, 367 and 372-374, all of which exhibited a significant (i.e., greater than 10-fold) selective inhibition preference for the KRasG12D mutant relative to KRas wild type.
[1312] Embodiment 378
[1313] Phospho-ERK in cells responsive to KRAS inhibition Determination
[1314] The purpose of these assays is to quantify the ability of the test compound to selectively inhibit KRAS signaling in cells with amplified KRAS and expressing activating KRAS G12 mutations (Table 19). The cancer cell lines used in this study were selected based on the presence of homozygous mutations that activate the KRAS gene or KRAS gene amplification. In addition, these assays were performed in a group of RAS-free mouse embryonic fibroblasts (MEFs), which were transformed to express only KRAS wild type, HRAS and NRAS (Table 19), respectively. MEF cells were used to confirm the KRAS selectivity of the test compound.
[1315] Table 19: Cell line information
[1316] Cell line name RAS mutations / characteristics Determine the seeding concentration (cells / well) MKN45 WT KRAS amplification / human gastric cancer 20,000 SW620 KRAS G12V / Human Colorectal Cancer 20,000 HPAC KRAS G12D / Human Pancreatic Cancer 2,500 NCI-1373 KRAS G12C / human lung cancer 5,000 MEF-NRAS RAS-free MEFs, expressing only NRAS 20,000 MEF-HRAS RAS-free MEFs, only expressing HRAS 10,000 MEF-KRAS RAS-free MEFs, only expressing KRAS 2,500
[1317] The activity of the compounds was determined by measuring changes in the phosphorylation levels of the downstream effectors extracellular signal-regulated kinases-1 and 2 (ERK1 / 2). Ultra TM p-ERK 1 / 2 (Thr202 / Tyr204) Assay Kit (#ALSU-PERK-A50K, Waltham, MA) to measure the phosphorylation level of ERK-1 / 2. The assay is a quantitative sandwich immunoassay that can be used to detect phosphorylation of a target protein from cell lysates using bead-based Alpha technology. The assay kit contains two antibodies, one that binds to the phospho-Thr202 / Tyr204 epitope on ERK-1 / 2 and the other that recognizes an additional site on the protein. One of these antibodies is biotinylated and associated with streptavidin-coated Alpha donor beads, and the other antibody is conjugated to Acceptor beads are conjugated. When ERK-1 / 2 is phosphorylated in a cell lysate, the donor and acceptor beads are brought into close proximity. When the donor beads are excited by light of 600nm wavelength, the photosensitizer within the beads converts ambient oxygen into an excited singlet state. When the acceptor beads are within 200nm of the reaction, the singlet oxygen reacts with the acceptor, resulting in chemiluminescent emission. The amount of light measured is proportional to the amount of phosphorylated ERK-1 / 2 in the lysate. Ultra TM p-ERK 1 / 2 (Thr202 / Tyr204) Assay Kit contains Antibody-conjugated donor and acceptor beads, lysis buffer concentrate, and a set of proprietary buffers (activation buffer, reaction buffer 1, reaction buffer 2, and dilution buffer).
[1318] For the assay, a 10-point 3-fold dilution series of test compounds and controls was made in 30 nL DMSO (Labcyte San Jose, CA) were dispensed into white 384-well assay plates (Proxiplate-384, PerkinElmer #6008280). The cells were then added to the assay plates at cell line specific densities (Error! Reference source not found). 8 μL of assay medium (HBSS, Sigma #55021C, 10% FBS, GIBCO #10082-147) was added to each well of the assay plate. The final concentration of compound in each well ranged from 0.5 to 10,000 nM, and the final DMSO concentration was 0.375%. The maximum signal control wells contained only 0.375% DMSO (negative control) and the minimum signal control wells contained 10,000 nM control compound (positive control). The cells in suspension were incubated with the test compounds and reference compounds at 37°C / 5% CO2 for 2 hours. After 2 hours of incubation, the cells were incubated by adding 2 μL of 5% DMSO supplemented with a protease / phosphatase inhibitor cocktail (Thermo Scientific #78442). Lysis buffer concentrate (5X) was used to lyse the cells. The assay plates were covered with opaque lids and shaken at 750 rpm for 30 minutes at room temperature on a multiplate shaker (Heidolph, Schwabach, Germany) to induce cell lysis. During the lysis process, The acceptor beads were mixed with the prepared buffer (1:1 Reaction buffers 1 and 2 and After cell lysis, the plate was centrifuged briefly and 5 μL of the prepared acceptor beads were added to each well. The plate was then covered and incubated at room temperature in the dark for 2 hours. During the acceptor bead incubation period, Prepare donor beads by diluting Alpha Streptavidin Donor Beads 1:50 in Dilution Buffer. After incubation of acceptor beads, add 5 μL of donor bead mixture per well to the plate. Then cover the plate and incubate it in the dark at room temperature for 2 hours. After this incubation period, use a Compatible with optical cubes The AlphaLISA signal was read using an FSX multifunctional plate reader (BMG Labtech, Ortenberg, Germany).
[1319] Using Genedata 17.0.3, analysis from Raw signal obtained in the assay. In the program, the data is normalized using 32 wells treated with the inhibition control (maximum inhibition / positive control) and 32 wells treated with 0.375% DMSO alone (minimum inhibition / negative control) to calculate the % activity of the compound:
[1320]
[1321] Using Genedata 17.0.3 Fit the % activity values to a four-parameter nonlinear logistic equation to determine the IC50 value:
[1322]
[1323] Where y = % activity, bottom value = minimum asymptote, top value = maximum asymptote, x = compound concentration, IC 50 = concentration of compound achieving half maximal activity, h = Hill coefficient.
[1324] In the above assays, the compounds of the Examples specified herein demonstrated the ability to reduce the levels of phosphorylated ERK-1 / 2 in cells expressing KRAS and KRAS variants, suggesting that G12C (Examples 2, 24, 29, 32, 35, 37, 40, 42-45, 48, 55, 56, 59, 68, 93, 95-97, 101, 103, 106-109, 113, 114, 116, 129, 152, 159, 161, 162, 164-166, 168, 169, 172, 190-192, 206, 208, 211-213, 218, 219, 243, 244, 280-289, 292-318, 320, 321, 343, 346, 347, 370, and 375), KRAS G12D (Examples 2, 14, 24, 29, 35, 37, 42-45, 48, 55, 56, 59, 68, 93, 95-97, 101, 103, 106-109, 113, 114, 116, 129, 152, 159, 161, 162, 164-166, 168, 169, 175, 188, 190-193, 212, 213, 218-220, 229, 231, 233, 243, 244, 280-289, 292-313, 316, 318, 343, 346, 347, 370 and 375), KRAS G12V (Examples 29, 30, 32, 35, 37-40, 42-45, 59, 93, 97, 108, 109, 165, 166, 168, 209, 211, 219, 280-289, 292-318, 320, 321, 346, 347, 370 and 375) or KRAS WT (Examples 2, 29, 30, 32, 35, 37-40, 42-45, 48, 56, 59, 62, 93, 95-97, 101, 103, 107-109, 113, 114, 116, 129, 159, 161, 162, 164-166, 168, 169, 190-192, 209, 211, 218, 219, 244, 280-289, 292-314, 316-318, 320, 321346, 347, 370 and 375) cells inhibit constitutive RAS activity, relative to IC 50<500 nM. Examples 2, 14, 24, 45, 48, 49, 55, 56, 59, 68, 95-97, 101, 103, 106-109, 113, 114, 116, 121-124, 126, 129, 130, 142, 152, 159, 161, 162, 164- Compounds 166, 168, 169, 172, 175, 188, 190-193, 211-213, 218-220, 229, 231, 233, 243, 244, 280-289, 293, 295-302, 305-311, 314-322, 343, 346, 347, 370, and 375, all of which showed relative IC values > 2 μM 50 .
[1325] The data show that the compounds of Formulas I-VIII (including Ia-VIIa) described herein are potent inhibitors of KRAS human cancer cells expressing KRAS, demonstrating their ability to inhibit KRAS G12C, G12D or G12V mutants, and have a significant selective inhibition preference for KRAS mutants relative to HRAS or NRAS.
[1326] Table 10: Abbreviations
[1327] KRAS Kirsten rat sarcoma virus NRAS Neuroblastoma RAS viral oncogene homolog HRAS Harvey rat sarcoma virus MEF Mouse embryonic fibroblast ERK Extracellular signal-regulated kinase AlphaLISA α-Linkage Immunosorbent Assay DMSO Dimethyl sulfone HBSS Hank's Balanced Salt Solution FBS Fetal bovine serum <![CDATA[CO2]]> carbon dioxide
Claims
1. A compound of the following formula or a pharmaceutically acceptable salt thereof: in: A is -C(H)- or -N-; B is -C(R4)- or -N-; D1 is -CH2-, -CH2CH2- or -CH(CH2CN)-; X is -O- or -S-; Y is -C(CN)- or -N-; Z is -C(R 3c )-or-N-; G is -C(R 3b )-or-N-; R1 is H, hydroxyl, methoxy, C 1-4 Alkyl, C 2-4 heteroalkyl, azetidine, N-linked piperazine, piperidine, morpholine, or a group selected from the following formulas: Wherein C 1-4 Alkyl, C 2-4 The heteroalkyl, azetidine, piperidine or N-linked piperazine is optionally substituted with one or more of the following groups: amino, hydroxy, methyl, trideuteromethyl, methoxy, oxetane or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methyl, hydroxymethyl, methoxy, trifluoromethoxy, difluoromethoxy, -O-trideuterated methyl, cyclopropyl, oxetane, pyrazole, imidazole, amino, -CONR7R7, -O-(CH2) p -OC 1-3 Alkyl, -O-(CH2) p -OH or -O-CO-C 1-3 alkyl, wherein the piperidine or the N-linked piperazine is optionally 1-3 alkyl bridge, and wherein the cyclopropyl, imidazole or pyrazole are each optionally substituted by a hydroxyl group or a C 1-3 alkyl; E1 is –(CR7R7–) n , E2 is -CR7R7-, -NR7- or -O-, and E3 is –(CR7R7–) m , where m+n is 1, 2, 3 or 4; p is 1, 2, or 3; R2 is H, halogen or methyl; R 3a , R 3b and R 3c are each independently H, methyl or halogen; R4 is H, methyl, -CH2-OH, -O-R5-R6, -O-R6 or azetidine optionally substituted with NR7R7, wherein R5 is -CH2-, -CH(CH3)- or -CH2-CH2-, wherein R6 is H, C 1-3 Alkyl, C 2-3 Heteroalkyl, C 3-6 Cycloalkyl, C 4-6 heterocycloalkyl, 2-oxo-1,3-dihydrobenzimidazole, imidazole or pyrazole, wherein the C 1-3 Alkyl, C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally substituted by one or more of the following groups: oxo, halogen, hydroxy, methoxy, difluoromethoxy, NR7R7, C 1-4 Alkyl, C 1-4 alkenyl, -CN or -CO-CH2OH, wherein the C 1-4 The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methoxy or NR7R7, wherein the C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-4 Alkyl groups are fused to form a bicyclic ring, or the C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-3 The alkyl group is bridged and wherein if R4 is H, then R1 is not H; and Each R7 is independently H or C 1-3 alkyl.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein G is -N-.
3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein G is -N-, and Z is -C(R 3c )-.
4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein G is -C(R 3b )-.
5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein G is -C(R 3b )-, and Z is -N-.
6. The compound according to claim 4 or 5, or a pharmaceutically acceptable salt thereof, wherein R 3b It's F.
7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein G is -C(R 3b )-;R 3a , R 3b and R 3c are independently H or halogen; R1 is H, methoxy, C 1-4 Alkyl, C 2-4 heteroalkyl, N-linked piperazine, piperidine or a group of the formula: Wherein C 1-4 Alkyl, C 2-4 The heteroalkyl, piperidine or N-linked piperazine is optionally substituted with one or more of the following groups: amino, hydroxy, methyl, trideuteromethyl, oxetane or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methyl, hydroxymethyl, methoxy, trifluoromethoxy, cyclopropyl, oxetane, pyrazole, imidazole, amino, -CONR7R7, -O-(CH2) p -OC 1-3 Alkyl, -O-(CH2) p -OH or -O-CO-C 1-3 alkyl, wherein the piperidine or N-linked piperazine is optionally 1-3 alkyl bridge, and wherein the cyclopropyl, imidazole or pyrazole are each optionally substituted by: C substituted by one or more hydroxyl groups 1-3 Alkyl; and R4 is H, methyl, -CH2-OH, -O-R5-R6, -O-R6 or azetidine optionally substituted with NR7R7, wherein R5 is -CH2-, -CH(CH3)- or -CH2-CH2-, wherein R6 is H, C 1-3 Alkyl, C 2-3 Heteroalkyl, C 3-6 Cycloalkyl, C 4-6 Heterocycloalkyl or 2-oxo-1,3-dihydrobenzimidazole, wherein the C 1-3 Alkyl, C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally substituted by one or more of the following groups: halogen, hydroxy, methoxy, NR7R7, C 1-4 Alkyl or C 1-4 alkenyl, wherein the C 1-4 The alkyl group is optionally substituted with one or more of the following groups: halogen or hydroxy, wherein the C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-4 Alkyl groups are fused to form a bicyclic ring, or the C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-3 The alkyl groups are bridged, and wherein if R4 is H, then R1 is not H.
8. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein G is -C(R 3b )-;R 3a , R 3b and R 3c are each independently H or halogen; and R1 is H, methoxy, C 1-4 Alkyl, C 2-4 heteroalkyl, N-linked piperazine, piperidine or a group of the formula: Wherein C 1-4 Alkyl, C 2-4 The heteroalkyl, piperidine or N-linked piperazine is optionally substituted with one or more of the following groups: amino, hydroxy, methyl, trideuteromethyl, oxetane or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methyl, hydroxymethyl, methoxy, trifluoromethoxy, cyclopropyl, oxetane, pyrazole, imidazole, amino or -CONR7R7, wherein the piperidine or N-linked piperazine is optionally substituted by C 1-3 alkyl bridge, and wherein the cyclopropyl, imidazole or pyrazole are each optionally substituted by: C substituted by one or more hydroxyl groups 1-3 and R4 is H, methyl, -CH2-OH, -O-R5-R6, -O-R6 or an azetidine optionally substituted with NR7R7, wherein R5 is -CH2-, -CH(CH3)- or -CH2-CH2-, wherein R6 is H, C 1-3 Alkyl, C 2-3 Heteroalkyl, C 3-6 Cycloalkyl, C 4-6 Heterocycloalkyl or 2-oxo-1,3-dihydrobenzimidazole, wherein the C 1-3 Alkyl, C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally substituted by one or more of the following groups: halogen, hydroxy, methoxy, NR7R7, C 1-4 Alkyl or C 1-4 alkenyl, wherein the C 1-4 The alkyl group is optionally substituted with one or more of the following groups: halogen or hydroxy, wherein the C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-4 Alkyl groups are fused to form a bicyclic ring, or the C 3-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-3 The alkyl groups are bridged, and wherein if R4 is H, then R1 is not H.
9. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein G is -C(R 3b )-;R 3a , R 3b and R 3c are independently H or halogen; R1 is H, C 1-4 Alkyl, C 2-4 heteroalkyl or N-linked piperazine, wherein the C 1-4 Alkyl, C 2-4 The heteroalkyl or N-linked piperazine is optionally substituted with one or more of the following groups: amino, hydroxy, methyl, oxetane or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methyl, hydroxymethyl, methoxy, cyclopropyl, oxetane or amino, and wherein the N-linked piperazine is optionally substituted with one or more of the following groups: 1-3 The alkyl groups are bridged; and R4 is H, methyl, -CH2-OH, -O-R5-R6 or -O-R6, wherein R5 is -CH2-, -CH2(CH3)- or -CH2-CH2-, wherein R6 is H, C 1-3 Alkyl, C 2-3 Heteroalkyl, C 4-6 Cycloalkyl or C 4-6 Heterocycloalkyl, wherein the C 1-3 Alkyl, C 4-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally substituted by one or more of the following groups: halogen, hydroxy, methoxy, C 1-4 Alkyl or C 1-4 alkenyl, wherein the C 1-4 The alkyl group is optionally substituted with one or more of the following groups: halogen or hydroxy, wherein the C 4-6 Cycloalkyl or C 4-6 The heterocycloalkyl group is optionally 1-4 The alkyl groups are fused to form a bicyclic ring, and wherein if R4 is H, then R1 is not H.
10. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein X is -S-.
11. The compound according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein Y is -C(CN)-.
12. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein X is -O-, and Y is -C(CN)-.
13. A compound according to any one of claims 1-4, 6-12 or a pharmaceutically acceptable salt thereof, wherein Z is -C(R 3c )-.
14. The compound according to claim 13 or a pharmaceutically acceptable salt thereof, wherein R 3a and R 3c are each independently H or F.
15. A compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, wherein R 3a It's H.
16. The compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein Z is -N-.
17. The compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein A is -N-.
18. The compound according to any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein A is -C(H)-.
19. The compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein B is -C(R4)-.
20. The compound according to any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof, wherein B is -C(H)-.
21. The compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, wherein D1 is -CH2-.
22. The compound according to any one of claims 1 to 21, or a pharmaceutically acceptable salt thereof, wherein R1 is N-linked piperazine.
23. A compound according to any one of claims 1-8, 10-21, or a pharmaceutically acceptable salt thereof, wherein R1 is an N-linked piperazine, wherein the N-linked piperazine is optionally substituted with one or more of the following groups: amino, hydroxy, methyl, trideuteromethyl, oxetane or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methyl, hydroxymethyl, methoxy, trifluoromethoxy, cyclopropyl, oxetane, pyrazole, imidazole, amino or -CONR7R7, and the N-linked piperazine is optionally substituted with C 1-3 alkyl bridge, and wherein the cyclopropyl, imidazole or pyrazole are each optionally substituted by: C substituted by one or more hydroxyl groups 1-3 alkyl.
24. A compound according to any one of claims 1-8, 10-21 or a pharmaceutically acceptable salt thereof, wherein R1 is H, methoxy, C 1-4 Alkyl, C 2-4 heteroalkyl, N-linked piperazine, piperidine or a group of the formula: Wherein C 1-4 Alkyl, C 2-4 The heteroalkyl, piperidine or N-linked piperazine is optionally substituted with one or more of the following groups: amino, hydroxy, methyl, trideuteromethyl, oxetane or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methyl, hydroxymethyl, methoxy, trifluoromethoxy, cyclopropyl, oxetane, pyrazole, imidazole, amino or -CONR7R7, wherein the piperidine or the N-attached piperazine is optionally substituted with one or more of the following groups: 1-3 alkyl bridge, and wherein the cyclopropyl, imidazole or pyrazole are each optionally substituted by: C substituted by one or more hydroxyl groups 1-3 alkyl.
25. A compound according to any one of claims 1-6, 10-21, or a pharmaceutically acceptable salt thereof, wherein R1 is H, methoxy, -CH2-CH2-NH2, or a group of the formula:
26. A compound according to any one of claims 1-8, 10-21 or a pharmaceutically acceptable salt thereof, wherein R1 is 27. A compound according to any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, wherein R1 is 28. The compound according to any one of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein R1 is H.
29. A compound according to any one of claims 1-6, 10-21, or a pharmaceutically acceptable salt thereof, wherein R1 is an N-linked piperazine substituted with one or more of the following groups: methyl, trideuterated methyl or C 1-3 Alkyl, wherein the C 1-3 The alkyl group is optionally substituted with one or more of the following groups: halogen, hydroxy, methyl, hydroxymethyl, methoxy, trifluoromethoxy, difluoromethoxy, -O-trideuterated methyl, cyclopropyl, oxetane, pyrazole, imidazole, -CONR7R7, -O-(CH2) p -OC 1-3 Alkyl, -O-(CH2) p -OH or -O-CO-C 1-3 alkyl, and wherein the cyclopropyl, imidazole or pyrazole are each optionally substituted by a hydroxyl group or a C 1-3 alkyl, and wherein the N-attached piperazine is connected via a C 1-3 Alkyl groups form bridges.
30. A compound according to any one of claims 1-6, 10-21 or a pharmaceutically acceptable salt thereof, wherein R1 is selected from:
31. A compound according to any one of claims 1-19 or 21-30, or a pharmaceutically acceptable salt thereof, wherein R4 is -O-CH2-R6.
32. The compound according to claim 31, or a pharmaceutically acceptable salt thereof, wherein R6 is azetidine, pyrrolidine, piperidine, oxetane, tetrahydrofuran, morpholine, cyclobutane or 1,4-dioxane.
33. A compound according to any one of claims 1-6, 10-19 or 21-30, or a pharmaceutically acceptable salt thereof, wherein R4 is methyl, methoxy, -CH2-OH or a group of the formula 34. A compound according to any one of claims 1-8, 10-19 or 21-31, or a pharmaceutically acceptable salt thereof, wherein R4 is 35. A compound according to any one of claims 1-19 or 21-31, or a pharmaceutically acceptable salt thereof, wherein R4 is 36. A compound according to any one of claims 1-6, 10-19 or 21-31, or a pharmaceutically acceptable salt thereof, wherein R4 is selected from:
37. A compound according to any one of claims 1 to 36, or a pharmaceutically acceptable salt thereof, wherein R2 is F or Cl.
38. A compound according to any one of claims 1-37, or a pharmaceutically acceptable salt thereof, wherein R2 is F.
39. A compound according to any one of claims 1-37, or a pharmaceutically acceptable salt thereof, wherein R2 is Cl.
40. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein X is S, Y is -C(CN)-, and Z is -C(R 3c )-, R2 is F or Cl, R 3a Yes H, R 3b Yes H, R 3c is F, and D1 is -CH2-.
41. A pharmaceutical composition comprising a compound according to any one of claims 1 to 40 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.
42. A method for treating cancer in a patient, the method comprising administering to a patient in need thereof an effective amount of the pharmaceutical composition of claim 41, wherein the cancer is selected from the group consisting of lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, bile duct cancer, and colorectal cancer.
43. A method of treating cancer in a patient, the method comprising administering to a patient in need thereof an effective amount of a compound of any one of claims 1-40, or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, bile duct cancer, and colorectal cancer.
44. The method of claim 42 or 43, wherein the cancer is non-small cell lung cancer, and wherein one or more cells express KRas G12D mutant protein.
45. The method of claim 42 or 43, wherein the cancer is colorectal cancer and wherein one or more cells express KRas G12D mutant protein.
46. The method of claim 42 or 43, wherein the cancer is pancreatic cancer and wherein one or more cells express KRas G12D mutant protein.
47. The method of claim 42 or 43, wherein prior to administration of the compound or a pharmaceutically acceptable salt thereof, the patient has a cancer determined to have one or more cells expressing a KRas G12D mutant protein.
48. The method of claim 42 or 43, wherein the cancer is non-small cell lung cancer, and wherein one or more cells express KRas G12C, G12D and / or G12V mutant proteins.
49. The method of claim 42 or 43, wherein the cancer is colorectal cancer and wherein one or more cells express KRas G12C, G12D and / or G12V mutant proteins.
50. The method of claim 42 or 43, wherein the cancer is pancreatic cancer, and wherein one or more cells express KRas G12C, G12D and / or G12V mutant proteins.
51. The method of claim 42 or 43, wherein prior to administration of the compound or a pharmaceutically acceptable salt thereof, the patient has a cancer identified as having one or more cells expressing KRas G12C, G12D and / or G12V mutant proteins.
52. A method of treating a cancer having a KRas G12D mutation in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of any one of claims 1-40, or a pharmaceutically acceptable salt thereof.
53. The method of claim 52, wherein the cancer is selected from KRas G12D mutant lung cancer, KRas G12D mutant pancreatic cancer, KRas G12D mutant cervical cancer, KRas G12D mutant esophageal cancer, KRas G12D mutant endometrial cancer, KRas G12D mutant ovarian cancer, KRas G12D mutant bile duct cancer, and KRas G12D mutant colorectal cancer.
54. The method of claim 53, wherein the cancer is KRas G12D mutant non-small cell lung cancer.
55. The method of claim 53, wherein the cancer is KRas G12D mutant colorectal cancer.
56. The method of claim 53, wherein the cancer is KRas G12D mutant pancreatic cancer.
57. A method of treating a cancer having a KRas G12C, G12D and / or G12V mutation in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of any one of claims 1-40, or a pharmaceutically acceptable salt thereof.
58. The method of claim 57, wherein the cancer is selected from KRas G12C, G12D and / or G12V mutant lung cancer, KRas G12C, G12D and / or G12V mutant pancreatic cancer, KRas G12C, G12D and / or G12V mutant cervical cancer, KRas G12C, G12D and / or G12V mutant esophageal cancer, KRas G12C, G12D and / or G12V mutant endometrial cancer, KRas G12C, G12D and / or G12V mutant ovarian cancer, KRas G12D mutant cholangiocarcinoma, and KRas G12C, G12D and / or G12V mutant colorectal cancer.
59. The method of claim 58, wherein the cancer is KRas G12C, G12D and / or G12V mutant non-small cell lung cancer.
60. The method of claim 58, wherein the cancer is KRas G12C, G12D and / or G12V mutant colorectal cancer.
61. The method of claim 58, wherein the cancer is KRas G12C, G12D and / or G12V mutant pancreatic cancer.
62. The method according to any one of claims 42-61, wherein the patient is also administered an effective amount of one or more of the following substances: a PD-1 inhibitor, a PD-L1 inhibitor, a CDK4 / CDK6 inhibitor, an EGFR inhibitor, an ERK inhibitor, an Aurora A inhibitor, a SHP2 inhibitor, a platinum drug and pemetrexed, or a pharmaceutically acceptable salt thereof.
63. A compound according to any one of claims 1-40, or a pharmaceutically acceptable salt thereof, for use in therapy.
64. A compound according to any one of claims 1-40, or a pharmaceutically acceptable salt thereof, for use in treating cancer.
65. The compound for use according to claim 64, or a pharmaceutically acceptable salt thereof, wherein the cancer has a KRas G12D mutation.
66. The compound for use according to claim 64, or a pharmaceutically acceptable salt thereof, wherein the cancer has a KRas G12C, G12D and / or G12V mutation.
67. The compound for use according to any one of claims 64-66, or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from lung cancer, pancreatic cancer, cervical cancer, esophageal cancer, endometrial cancer, ovarian cancer, bile duct cancer, and colorectal cancer.
68. A compound according to any one of claims 1-40, or a pharmaceutically acceptable salt thereof, for use in cancer treatment in combination with one or more of the following substances simultaneously, separately or sequentially: PD-1 or PD-L1 inhibitors, CDK4 / CDK6 inhibitors, EGFR inhibitors, ERK inhibitors, Aurora A inhibitors, SHP2 inhibitors, platinum drugs and pemetrexed, or pharmaceutically acceptable salts thereof.
